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ABSTRACT
Cancer is the most common genetic disease in humans. It has been estimated that more 
than 10 million new cancer patients are detected worldwide each year. In the last decades, 
many efforts have been made by the research community to contribute to the fight against 
cancer. These works greatly expanded our understanding of the disease. However, the 
exact mechanisms of cancer initiation and progression remain elusive. The research on 
cancer genomes has focused on the identification of DNA sequence mutations and 
chromosomal rearrangements. Some of these somatic alterations can confer a growth 
advantage to cancer cells and promote cancer development. Mutated genes in cancer 
genomes can be potential new drug targets or serve as biomarkers for the improvement of 
diagnostics and therapy.
Today, high-throughput genome-wide profiling technologies allow us to characterize the 
molecular profiles of cancer samples on various levels, including copy number alterations, 
gene expression, point mutations and epigenetic marks. Cancer research has gradually 
shifted from single experiments to large-scale “omics” data analysis approaches. It is an 
exciting, but challenging work. Our group aims to develop  reliable and robust methods to 
characterize cancer genomes by analyzing large-scale oncogenomic datasets.
During the last 4 years, I have focused my efforts on using systems biology  and statistical 
methods to model and annotate genomic array data in human cancer. My research is 
based on a data collection and re-analysis project that generates very large amounts of 
microarray data. Computational biology approaches were applied on this dataset for data 
mining. We collected more than 40000 arrays, including comparative genomic 
hybridization (CGH) and SNP (single nucleotide polymorphism) arrays, from several public 
databases. A pipeline was developed to process raw data and determine copy number 
aberrations (CNAs). All data was converted to a unified and structured format, and stored 
in our arrayMap  database, together with available clinical information. We also set up an 
online website for providing this resource to the research community.
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Based on the large-scale CNA data in our database, the second project aimed to explore 
the correlation between CNAs and local gene density  across cancer genomes. Through a 
genome binning method, I found that focal CNAs are significantly enriched in gene-rich 
regions. In addition, this positive correlation is not only driven by cancer genes. Since this 
result is derived from more than 16000 cancer samples, it provides a global insight into the 
relationship  between cancer genome instability  and structure from a new perspective. The 
enrichment reveals that there may be a non-neutral selection pressure for CNA regions 
across the genome. The observed significant positive correlation in this project may enable 
a better elucidation of mechanisms by which CNAs contribute to tumor development, and 
promote a more systematic understanding of cancer.
The third project presented here is related to a new phenomenon, termed “chromothripsis”, 
found in cancer development. In this type of events, contiguous chromosomal regions are 
fragmented into many pieces, and the cell’s DNA repair machinery randomly fuses these 
segments together to rescue the genome. This is quite different from the classical step-by-
step model of cancer development. We developed an algorithm based on scan statistics to 
automatically detect chromothripsis-like patterns, and identify both size and location of the 
involved regions. From our input of 22,347 high quality arrays, we identified 918 
chromothripsis cases, representing 132 cancer types. The results from this dataset provide 
several new insights regarding the distribution of chromothripsis-like patterns and a 
comprehensive estimation of chromothripsis incidence in a large range of cancer entities. 
Importantly, our work partly  overcomes the limitation of individual research projects 
resulting from the relatively low incidence of chromothripsis in cancer samples available. 
An investigation into the affected chromosomal regions supports breakage-fusion-bridge 
cycles as one of the potential underlying mechanisms. Finally, we evaluated the clinical 
associations of chromothripsis and found that this event may be associated with a poor 
outcome. The observed chromothripsis events in our project may reflect on heterogenous 
biological phenomena, and probably vary in their specific impact on oncogenesis.
Taken together, the results presented in this thesis characterize the cancer genome by 
large-scale oncogenomic array data, and further elucidate the potential mechanisms 
underlying cancer development.
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ZUSAMMENFASSUNG
Krebs ist die häufigste auf genomische Veränderungen zurückzuführende Erkrankung. 
Weltweit wird in jedem Jahr bei geschätzt 10 Millionen Menschen eine Krebserkrankung 
diagnostiziert. In den letzten Jahrzehnten wurden grosse Anstrengungen unternommen, 
um Krebs unter Einsatz wissenschaftlicher Methoden zu bekämpfen. Obwohl dies unser 
Verständnis bösartiger Erkrankungen massiv erweitert hat, sind trotzdem viele 
Mechanismen der Krebsentstehung und Ausbreitung noch immer unvollständig 
charakterisiert.
Bisher wurde im Genom von Krebszellen hauptsächlich nach Mutationen in der DNA-
Sequenz sowie nach chromosomalen Veränderungen gesucht. Einige dieser 
Veränderungen führen bekanntermassen zu einem Wachstumsvorteil von Krebszellen und 
begünstigen die Krebsentwicklung. Die am häufigsten mutierten Gene in Krebszellen 
stellen potenzielle Angriffspunkte für neue Medikamente dar oder könnten als Biomarker 
zur verbesserten Diagnose und Therapie dienen.
Heutzutage können die molekularen Profile von Krebszellproben auf unterschiedlichen 
Ebenen durch genomweite Hochdurchsatztechnologien untersucht werden – von 
chromosomalen Aberrationen und Punktmutationen, über Modulation der Genexpression 
bis hin zu epigenetischen Veränderungen. Die molekulare Krebsforschung hat sich dabei 
von der Beurteilung einzelner Experimente hin zur umfassenden “omics”-Analyse 
entwickelt. Diese Untersuchungen sind sowohl hochinteressant von ihrer Thematik, als 
auch anspruchsvoll in der Durchführung. Unsere Forschungsgruppe beteiligt sich hier 
durch die Entwicklung von verlässlichen und robusten Methoden zur umfassenden 
Analyse von Krebsgenomen.
Während der letzten vier Jahre habe ich mich hauptsächlich mit systematischer und 
statistischer Analyse zur Modellierung und Annotation genomischer Array-Daten von 
menschlichen Krebszellen beschäftigt. Meine Forschung basiert auf einem 
Datenkollektions-und Wiederanalyse-Projekt, das eine grosse Menge Microarray-Daten 
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produziert hat. Zum “data mining” wurden computer-gestützte Methoden auf diesen 
Datensatz angewendet. Wir haben hierzu Daten von mehr als 40'000 Genomanalysen aus 
öffentlich zugänglichen Datenbanken gesammelt, einschliesslich Daten von komparativer 
Genomhybridisierung (CGH) und Einzelnukleotidvariationen (SNP). Ich entwickelte einen 
definierten Arbeitsablauf um Rohdaten zu prozessieren und Veränderungen der regionalen 
DNA-Kopienanzahl (CNAs) zu analysieren. Alle Daten wurden in ein einheitlich 
strukturiertes Format gebracht und zusammen mit verfügbaren klinischen Informationen in 
unserer “arrayMap”-Datenbank gespeichert. Zusätzlich haben wir eine Online-Resource 
entwickelt, um diese Daten der Forschungsgemeinschaft zugänglich zu machen.
Basierend auf der umfassenden CNA-Datensammlung in unserer Datenbank wurde in 
einem zweiten Projekt der Zusammenhang zwischen CNAs und lokaler Gendichte 
analysiert. Durch “genome binning” habe ich herausgefunden, dass fokale CNAs in 
genreichen Regionen signifikant angereichert sind. Zusätzlich konnte ich zeigen, dass 
diese Korrelation nicht nur durch Krebsgene verursacht wird. Da diese Erkenntnis auf 
mehr als 16'000 Proben basiert, erlaubt sie einen globaleren Einblick ins Verhältnis 
zwischen Instabilität und Struktur von Krebsgenomen. Diese Anreicherung zeigt, dass ein 
nicht-neutraler Selektionsdruck für CNA-Regionen über das ganze Genom bestehen 
könnte. Die in diesem Projekt beobachtete signifikant-positive Korrelation könnte einen 
besseren Einblick in die Mechanismen ermöglichen, durch die CNAs zur 
Tumorentwicklung beitragen und für ein systematischeres Verständnis von Krebs sorgen.
Im dritten Projekt wurde ein neues Phänomen namens Chromothripsis untersucht, das 
kürzlich für den Prozess der Krebsentwicklung beschrieben wurde. Hierbei werden 
zusammenhängende chromosomale Regionen in viele Teile fragmentiert, worauf die 
zelluläre DNA-Reparaturmaschinerie diese Stücke zur Rettung des Genoms zufällig 
wieder zusammensetzt. Dies stellt einen fundamentalen Unterschied zum klassischen 
schrittweisen Modell der Krebsentstehung dar. Unter Verwendung einer “Scan-Statistcs” 
basierten Methodik haben wir einen Algorithmus entwickelt, der automatisch 
Chromothripsis-artige Muster detektiert und sowohl Grösse als auch Lokalisation der 
beteiligten Regionen identifiziert. In den 22'347 untersuchten Array-datensätzen konnten 
wir 918 Fälle von Chromothripsis -artigen Mustern  aus 132 unterschiedlichen Krebsarten 
beschreiben. Die Ergebnisse dieser Analyse erlauben neue Einblicke in die Verteilung von 
Chromothripsis-artigen Mustern und eine umfassende Einschätzung der Chromothripsis-
Häufigkeit in einer grossen Anzahl von Krebsfällen. Unsere Arbeit konnte dabei teilweise 
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die Grenzen überwinden, die sich aus der relativ kleinen Anzahl der verfügbaren 
Chromothripsis-Fälle in individuellen Forschungsprojekten ergeben. Die Analyse der 
betroffenen Chromosomenregionen unterstützt “breakage-fusion-bridge-cycles” als einen 
der möglicherweise zugrunde liegenden Mechanismen. Untersuchungen der Assoziatione 
klinischer Daten mit Chromothripsis-artigen Genommustern und zeigte ein häufiges 
Zusammenfallen dieser Ereignisse mit einer schlechten klinischen Prognose. Aus unseren 
Daten ergeben sich aber auch Hinweise, dass die beobachteten Chromothripsis-artigen 
Fälle möglicherweise ein heterogenes biologisches Phänomen darstellen, und damit in 
ihrem spezifischen Einfluss auf die Onkogenese variieren könnten.
Zusammenfassend charakterisieren die in dieser Arbeit präsentierten Resultate das 
Krebsgenom durch umfassende Analysen onkogenomische Array-Daten und bringen neue 
Einblicke der Krebsentwicklung potenziell zugrunde liegende Mechanismen.
xi
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Part 퐈
INTRODUCTION AND CONTEXT

1  INTRODUCTION
Cancer is a class of diseases that are responsible for the overall leading cause of death 
worldwide1. There are over 200 different types of cancer, although this number depends 
on the various classification systems. The overall defining feature of cancer is an out-of-
control cell growth that may form tumors and harm the body2,3. Tumors with un-invasive 
growth and without metastasis are considered to be benign. Malignant tumors can spread 
to other organs in the body through the blood and lymphatic systems, and finally cause the 
death of cancer patients4.
The field of cancer research had begun by the end of the 19th century. David von 
Hansemann5 and Theodor Boveri6 first reported the role of the “genome” in cancer 
development at the turn of the 20th century. They observed the aberration of 
chromosomes under the microscope, and proposed the hypothesis that cancers are 
abnormal clones of cells, and caused by change of hereditary material. Almost 50 years 
later, the discovery of DNA as the hereditary material was made7. Furthermore, Watson 
and Crick described the structure of DNA8. Thus, the idea that damage DNA and genome 
mutations cause cancer was accepted.
The next spectacular success in cancer research came from the discovery  of Philadelphia 
(Ph) chromosome, which is a karyotypic marker in chronic myeloid leukemia9,10. This 
chromosome is caused by a translocation between chromosome 9 and chromosome 22. 
At the beginning, the translocation occurs in a single bone marrow cell. After the process 
of clonal expansion, it finally  gives rise to the leukemia. This was the first consistent 
chromosome alteration in human cancer and provided an evidence for chromosomal 
abnormality as the direct cause of neoplasia9,10.
The discovery of Philadelphia chromosome greatly stimulated interest in cancer research. 
At the same time, new technologies had been developed to identify genetic alterations in 
whole cancer genomes, and provided new insights into the mechanisms of human tumors 
at the molecular level. For example, comparative genomic hybridization (CGH) is a 
molecular cytogenetic method for genome-wide screening of DNA copy number 
3
aberrations11,12,13. With the successive developments of cancer research tools, focuses of 
studies have expanded from single genes to pathways, and from classical genetics to 
systems biology. It is clear that, in the future, systematic functional approaches will be 
employed to integrate genome-scale information, and obtain a comprehensive molecular 
understanding of cancer. In clinical practice, the products of decades of research have 
greatly contributed to the development of novel diagnostic methods and therapeutic 
strategies3,14. Today, cancer biology has become one of the most exciting fields in life 
sciences, and continuously provides us with new insights into our most common genetic 
disease.
The work presented in this thesis represents an effort to analyze large-scale data sets 
derived mainly from array comparative genomic hybridization experiments for different 
cancer types, through bioinformatics and statistical methodology. Our studies focus on 
elucidating and modeling mechanisms for cancer development. Through the data 
collection project, we also provide the research community  a valuable resource for 
oncogenomic data. It is an in silico systems biology platform for the comprehensive study 
of cancer.
4
2  THE CANCER GENOME
2.1 CANCER AND COPY NUMBER ABERRATION
Cancer as a leading cause of disease is responsible for approximately 12% of deaths 
around the world1. Millions of people die from cancer each year. Although there are many 
types of cancer, they have some common characteristics. Cancer cells grow out of control 
and form solid masses (tumors) or diffusely invasive cells with expansive growth 
characteristics (e.g. bone marrow replicate in leukemias)1. In the beginning, these cells 
usually suffer from DNA damage. These damages are neither repaired nor induce cell 
death. These tumor cells continue to generate new abnormal cells. Malignant tumors may 
invade, and subsequently destroy, the healthy tissues adjacent to them. The invasion of 
essential organs, such as the liver, brain, kidneys or lungs, may eventually cause loss of 
organ function and ultimately death. Moreover, metastasis may occur if cancer cells 
spread from their original location, i.e. the primary tumor, to a distant organ15. A recent 
review summarized six hallmarks of cancer2:
• Sustaining of proliferative signaling
• Evading growth suppressors
• Resisting cell death
• Enabling replicative immortality
• Inducing angiogenesis
• Activating invasion and metastasis
These hallmarks represent six biological capabilities acquired during cancer progression, 
indicating the complexity of the cancer genome. Treatments modalities in cancer include 
radiation therapy16, chemotherapy17, surgery, immunotherapy18, targeted agents19. Which 
treatment or combination of treatments should be chosen depends on the type, size and 
location of cancer, as well as the patient’s age and physical condition.
Cancer can affect every organ and cell type in the human body, though some organs are 
more frequently affected than others. Even in one organ, there are usually many potential 
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cellular types that cancer can develop. For example, there are several types of cells in the 
lung, which correspond to different cancer types. If the cancer develops from squamous 
cells (i.e. bronchial lining), it is called squamous-cell lung carcinoma, that developing from 
gland cells is lung adenocarcinoma20,21, that from neuroendocrine cells in the bronchus 
called small-cell lung carcinoma. In general, more than 200 different types of cancer may 
arise in the human body. There are many ways for cancer classification, and some 
examples are listed in Table 1. The commonly used methods based on site of origin or 
histological types of cancer cells1. The treatment will be different depending on the type of 
cancer. Therefore, the accurate categorization of tumors and subtypes is important for 
both therapy and prognostic assessment.
When based on the site of origin, cancers can be classified by  the affected organs. In this 
case, the main types of cancer would include brain cancer, breast cancer, lung cancer, 
liver cancer, kidney cancer, colorectal cancer, etc. Figure 1 shows the proportion of 
different cancer types based on the GLOBOCAN22 estimates in 2008. This figure also 
compares the incidences with ratios of cancers that are derived from our collection of 
oncogenomic microarrays23. The genomic array data collection and processing procedures 
are presented in Chapter 4.
Table 1. Several cancer classification systems
Classification system Description Approximate number of types
ICD-O-3 morphology Used principally in tumor or cancer registries for coding the 
histology of neoplasms, usually obtained from a pathology report 873
ICD-O-3 topography Used principally in tumor or cancer registries for coding the site of 
neoplasms 98
SEER Surveillance, Epidemiology and End Results 70
Clinico-pathological entities Combination of morphology and topography 83
At the moment, the international standard for cancer classification is ICD-O-3 (International 
Classification of Diseases for Oncology, 3rd Edition)24. It is a coding system developed by 
the World Health Organization (WHO), that integrates tumor site (topography) and the 
histology (morphology)24. The code is composed of five digits ranging from 8000/0 to 
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9989/3. The first four digi ts 
represent the histological term of 
the neoplasm. The separate one-
digit code after the slash is the 
behavior code, which indicates 
whether the tumor is malignant, 
benign, in situ, or uncertain. As an 
example of the ICD-O coding 
system on the central nervous 
tumors, Table 2 lists the names and 
codes of all cranial and paraspinal 
nerves tumors based on the 2007 
WHO classification of tumors. In my 
following works, I mainly use the 
ICD-O-3 system to annotate 
oncogenomic data.
Clinical information is particularly  important in cancer research. Besides morphology and 
topography, other clinical data that I collected including patient age, stage, grade, sample 
source, follow up  and information on death. Cancer stage describes the extent to which a 
cancer has developed by spreading. It is essential in choosing a treatment method and 
assessing prognosis. Several staging systems are used by the research community to 
classify tumors. In general, they take into account the size and location of the tumor, and 
the spread in reference to nearby lymph nodes1. The two most commonly used staging 
methods are TNM and the four-stage rating scale. The TNM system evaluates tumors for 
size (T), presence or absence of regional lymph node involvement (N), and distant 
metastasis (M)25. Specifically, “T” ranges from 0 to 4, where higher values represent 
increasing tumor size and involvement. Similarly, “N” ranges from 0 to 3, to indicate the 
degrees of lymph node involvement, with 0 being the lowest and 3 being the highest 
degrees. “M” can be 0 or 1, and provides the information if there is evidence of distant 
spread. The four-stage rating system assigns a number from I to IV  to a tumor, with I 
represents an isolated cancer and IV means the cancer has spread to other organs, i.e. 
from early stage to advanced stage. In short, stage is one of the important tumor 
characteristics, and helps in cancer treatment. The two staging systems can be converted 
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Table 2. Tumors of cranial and paraspinal nerves
Tumors ICD-O code
Schwannoma (neurilemoma, neurinoma) 9560/0
    Cellular 9560/0
    Plexiform 9560/0
    Melanotic
 
9560/0
Neurofibroma 9540/0
    Plexiform
 
9550/0
Perineurioma
    Perineurioma, NOS 9571/0
    Malignant perineurioma
 
9571/3
Malignant peripheral nerve sheath tumour (MPNST)
    Epithelioid MPNST 9540/3
    MPNST with mesenchymal differentiation 9540/3
    Melanotic MPNST 9540/3
    MPNST with glandular differentiation 9540/3
to each other by transformation of parameters, as is shown in Table 3. For the data 
annotation work in Chapter 4, I used this table to unify cancer stages.
Figure 1. Incidence of different cancer types obtained from GLOBOCAN 2008 and arrayMap. 
Red and blue bars represent data from GLOBOCAN and arrayMap, respectively. The cancer type 
data is derived from GLOBOCAN.
Our understanding of the cancer genome has been improved significantly in recent 
decades, through the rapid advances in molecular biology  technology  and cytogenetics. 
These achievements provide a promise for further exploration of the causes of tumor, and 
allow the development of methods for early detection and cure of cancer. In the last five 
years, thousands of high resolution genomic or expression microarray experiments have 
been performed, hundreds of cancer genomes have been sequenced, and even more will 
follow. These studies generated global profiles of genomic rearrangements, gene 
expression and somatic mutations in cancer. It will be exciting to perform large-scale data 
analysis with this wealth of data and results. Actually, numerous cancer genes, candidate 
biomarkers and therapeutic targets have been discovered. In a more comprehensive level, 
analyses of pathways, regulatory and functional networks in human cancer have been 
carried out. In order to systematically store and retrieve these valuable cancer genome 
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data, many efforts have been devoted to create various repositories, such as GEO26, 
ArrayExpress27, TCGA28,29 and the UCSC Cancer Genomics Browser30. These public 
databases promote meta-analysis, which will help  to elucidate the molecular 
underpinnings of cancer.
It is now clear that cancer is a genetic 
disease, caused by a series of acquired or 
inherited mutations. Cancer patients can 
inherit abnormal DNA from their parents. 
However, most DNA damage is caused by 
replication errors resulting from normal cell 
proliferation or induced by carcinogenic 
factors present in our environment. Some 
human behaviors may lead to higher 
cancer incidence rates. For example, there 
is a strong correlation between lung cancer 
and smoking31, and between liver cancer 
and over-consumption of alcohol32, and 
a l s o b e t w e e n s k i n c a n c e r a n d 
overexposure to sunlight33, and so on. In 
general, common genetic mutations in 
cancer may be broadly classified as genomic rearrangements and sequence mutations4. 
This thesis focuses on the study of genomic rearrangements in large-scale.
Genomic rearrangements involve changes to a whole chromosome or large chromosomal 
regions. The related genomic fragments may be constituted by gains, losses, 
amplifications, insertions, inversions or translocations34. Both classical cytogenetic and 
molecular biological techniques have been employed to study genomic rearrangements. At 
least three underlying mechanisms of genomic recombination events have been well 
described by previous publications.
• Non-homologous end joining (NHEJ). NHEJ is the most comprehensive DNA repair 
mechanism in higher eukaryotes35. It involves ligation of any two broken ends 
independently  of DNA homology. Two sub-pathways involved into NHEJ: classical and 
non-classical.
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Table 3. Cancer stage grouping
Stage Primary Tumor (T)
Lymph 
Nodes (N)
Metastasis 
(M)
Stage I T1 N0 M0
Stage II T1 N1 M0
T2 N0 M0
T2 N1 M0
Stage III T1 N2 M0
T2 N2 M0
T3 N0 M0
T3 N1 M0
T3 N2 M0
Stage IV T4 Any N M0
Any T N3 M0
Any T Any N M1
• Homologous recombination. It occurs during the repair of DNA double-strand breaks. 
DNA sequences which show extensive homology can cause chromosomal mis-pairing35. 
Four pathways are implicated in homologous recombination: non-allelic homologous 
recombination35,36 (NAHR), break-induced replication37 (BIR), single-strand annealing36,38 
(SSA) and gene conversion37.
• Microhomology-mediated replication-dependent recombination (MMRDR). They are 
DNA replication-based models and have been used to explain the occurrence of strand 
misaligning by microhomology36. It is a general term, including several models, such as 
microhomology-mediated break-induced replication36,39 (MMBIR), break-induced serial 
replication slippage40 (BISRS), fork stalling and template switching41,42 (FoSTes).
Genomic rearrangements can be further subdivided into copy number neutral 
rearrangements, including inversions and translocations, and copy number alterations, 
including duplications, deletions and amplifications43,44. DNA copy number aberrations are 
a hallmark of solid tumors3. They may localize and disturb  oncogenes or tumor 
suppressors and contribute to cancer progression45. Furthermore, genomic imbalances 
exhibit distinct landscapes in many tumor entities, and have been used for tumor 
subclassification, and to aid diagnosis and prognosis46,47,48.
Various types and sizes of genomic imbalances can be discerned. Usually, high-level 
amplifications can be as small as 100 kb  in length, and genomic gains and losses are 
ranging from small focal regions to the whole chromosome49. Focal changes are useful for 
screening novel cancer gene candidates50. The mechanism by which CNAs contribute to 
cancer development is still poorly  understood. One hypothesis is that genomic changes 
increase or decrease gene expression levels of one or more cancer genes51,52. Therefore, 
integrating CNAs with gene expression data would provide more meaningful results by 
helping to identify driver mutations. Another hypothesis is correlated with breakpoints, 
which often lead to the formation of oncogenic fusion genes53,54.
CNAs can be detected by array CGH technology55, which is described in detail in the next 
chapter. By definition, array CGH is not able to detect copy number neutral 
rearrangements. However, other genome-wide molecular screening methods, such as 
massively parallel paired-end sequencing, allow the detection of such genomic 
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alterations56. Since CNAs are a valuable resource for cancer research, we launched the 
arrayMap project to collect and annotate genomic arrays. It provides an overview of copy 
number abnormalities in human cancer from CGH experiments23. The database is 
continuously  updated by extracting data from associated resources. The results of this 
study are presented in Chapter 4.
2.2 CANCER GENES
Genome sequence mutations, together with DNA copy number alterations, represent the 
basis for cancer development4. These mutations may result in altered cancer genes. Two 
types of cancer genes are responsible for the initiation and progression of cancers: 
oncogenes and tumor suppressor genes45. In most cases, the presence of a mutation in a 
single gene is not sufficient in itself to cause cancer, because of the existence of protective 
mechanisms of the body. Cancer is likely to occur when several genes are defective.
Oncogenes are a kind of abnormal genes that when they are activated, they predispose 
cells to develop into cancers57,58,59,60. They help  to drive the rampant cell growth that 
underlies tumors. Fox example, when DNA damage occurs, the abnormal cells normally 
undergo a programmed form of death, know as apoptosis61. However, activated 
oncogenes may disturb  the apoptosis procedure on these cells and trigger those cells to 
proliferate. Oncogenes are usually turned on by chromosomal translocations, copy number 
alterations or DNA damage, such as UV light, viruses or hazardous chemicals, and 
sometimes even by a missense point mutation in a gene57,59. Many oncogenes found in 
cancers are expressed at high levels or under focal amplifications62. Until now, hundreds 
of oncogenes have been identified in human cancer and the number continues to grow63. 
Some of these oncogene sequences or their products are considered as potential 
therapeutic targets for cancer drug development64.
One of the well-documented oncogenes is MYC, which is frequently activated by  missense 
mutations in many types of cancers65,66. It is located on the long arm of chromosome 8 
near the telomere region. The discovery  of MYC as a oncogene was first reported in a 
study of Burkitt’s lymphoma in 198267,68,69. In the following research, it was found to be 
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activated in many cancer types, including breast cancer, liver cancer, lung cancer, stomach 
cancer. MYC belongs to a family of transcription factors, which include L-myc 70,71 and N-
myc 72,73 genes. The product of MYC is a hub protein that is at the center of a complex 
protein-protein interaction network, and participates in many growth promoting signal 
transduction pathways74,75. MYC is directly or indirectly  involved in multiple cellular 
functions, including cell proliferation, growth, differentiation and apoptosis. MYC is also 
known to affect chromosomal stability, regulates a number of components of the mitotic 
checkpoint, and triggers metastasis76. Several mechanisms can regulate the level of 
expression of MYC by controlling its proximal promoter region77.
On the other hand, tumor suppressor genes generally inhibit abnormal cell proliferation, 
which work the opposite way to oncogenes78. Loss or dysfunction of these genes will 
contribute to the development of cancer. Particularly, this kind of genes are usually 
involved in cell cycle checkpoint control, apoptosis promotion and DNA repair processes79. 
They help  to prevent the accumulation of mutations in normal cells. In most cases, one 
copy of a tumor suppressor is sufficient to control cell proliferation. Thus, both alleles of a 
tumor suppressor gene must be lost or inactivated to contribute cancer development. This 
model is known as the two-hit hypothesis, and was first proposed in 1971 from the genetic 
mechanism analysis of retinoblastoma80. Today, this hypothesis serves as the basis for 
understanding the role of tumor suppressor genes in cancer development81,82. The 
inactivations may arise from point mutations, deletions or epigenetic silencing. Note that, 
there is an event, called “loss of heterozygosity” (LOH), that often leads to the inactivation 
of tumor suppressor gene83,84. During this process, in a heterozygous cell, one copy of the 
tumor suppressor gene is inactivated by loss-of-function mutations, which are usually point 
mutations or focal deletions. Subsequently, chromosomal deletions or somatic 
recombinations occur and replace the normal gene copy with a mutant copy. Furthermore, 
inherited tumor suppressor gene mutations are extremely useful in diagnostic applications. 
Tumor suppressor gene therapy was developed to treat cancer by restoring the function of 
a tumor suppressor gene lost or functionally  inactivated in cancer cells85,86. The increasing 
knowledge of tumor suppressor genes will continue to enhance our ability  to more 
successfully treat tumors at the molecular level.
The most representative tumor suppressor gene probably is TP5387,88. This gene is 
located on the short arm of chromosome 17. The involvement of TP53 in neoplasia is 
more common than any other known tumor suppressors or oncogenes89,90. Therefore, 
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TP53 may have become the most striking tumor suppressor gene, which is believed to 
mutate in up to 50% of all human cancers88. The protein encoded by TP53 is a highly 
linked node in the human protein-protein interaction network. TP53 is involved in many 
cellular pathways, including DNA repair procedure, promote metastasis, trigger apoptosis 
and differentiation91,92,93. Loss of p53 function is responsible for a number of human 
cancers. The dysfunction procedure can be caused by mutations of p53 or perturbations in 
p53 signaling pathways. Furthermore, the inherited germline mutations of a TP53 allele will 
cause Li-Fraumeni syndrome (LFS)94,95. It is a disorder that significantly  increases the risk 
of several types of cancer, e.g. leukemias, sarcomas, breast cancers and brain tumors96. 
In a number of clinical studies, a poor outcome has consistently been associated with 
mutated TP53. The growing understanding of the novel functions of TP53 has already led 
to the identification of potential targets for new drugs effectively  against cancer97. Table 4 
is a list of important databases contain information about known cancer genes.
The correlation between cancer genes and CNAs is well defined, as discussed before. 
However, the relationship of CNAs to the gene density in the human genome is not 
determined yet. Our efforts of genomic array data collection enable us to perform a 
systematic study about this issue. The results of this study are presented in Chapter 5.
Table 4. Public databases that provide information on genes implicated in human cancer
Database Description Website
CancerGenes A gene selection resource for cancer genome projects cbio.mskcc.org
CancerResource Cancer-relevant proteins and compound interactions bioinf-data.charite.de/
cancerresource/
CCDB Cervical cancer gene database crdd.osdd.net/raghava/ccdb/
CGED Cancer gene expression database lifesciencedb.jp/cged/
COLT-Cancer Essential gene profiles in human cancer cell lines colt.ccbr.utoronto.ca/cancer/
COSMIC Catalogue Of Somatic Mutations In Cancer cancer.sanger.ac.uk/
cancergenome/projects/cosmic/
dbDEPC Differentially Expressed Proteins in Human Cancer lifecenter.sgst.cn/dbdepc
DDOC Functional context of genes implicated in ovarian 
cancer
apps.sanbi.ac.za/ddoc/
DDPC Database of Genes Associated with Prostate Cancer apps.sanbi.ac.za/ddpc/
Network of Cancer Genes Network properties of cancer genes bio.ieo.eu/ncg/
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2.3 EVOLUTION OF CANCER
Cancer is an evolutionary process3. The development of each tumor in different patients is 
a unique series of mutational events. It demonstrates the heterogeneity of cancer genome 
evolution. The occurrence of somatic mutations and natural selection are the underlying 
power of the evolutionary process. In the last decade, the application of high resolution 
microarray and massively parallel sequencing technologies provided new insights into the 
mutational landscape of cancer98,99,100. Through sequencing, the genomic sequence of 
tumor genome was compared to the sequence of corresponding germline DNA. This 
method generates comprehensive catalogues of somatic mutations in a single individual 
cancer genome.
Based on these valuable data, the classic model of carcinogenesis was proposed and 
comprehensively accepted3,101. In this model, random and heritable genomic mutations are 
accumulated in individual cells, which undergo natural selection. In the tumor 
microenvironment, cells with deleterious mutations are weeded out, whereas cells that 
have acquired specific alterations that promote proliferation will be preserved3. This 
competition process selects cells that survive more effectively than others. Over time and 
after many cell cycles, if a cell acquires a series of advantageous mutations that allow it to 
grow uncontrollably, to invade normal tissues, and to enable metastasis, it may gradually 
progress to invasive tumor. In this way, cancer is a multi-step  procedure, and is the 
outcome of the Darwinian evolution process, like the events occur in species3,102. Getting a 
clear understanding of all the fundamental mutation events and their order during tumor 
evolution is important to elaborate the underlying mechanisms of cancer.
Since cancer evolution is a step-by-step process, it is believed that single mutations are 
not sufficient to cause cancer, but these alterations may initiate malignant growth or 
promote the cell’s malignant transformation2,3. Although a large number of somatic 
abnormalities may occur in a cell’s life cycle, it is not necessary that all these changes 
contribute to development of the cancer. Many, even most alterations have made no 
contribution at all. Given this situation, the concepts of “driver” and “passenger” mutations 
have been proposed50,103.
Driver mutation is a kind of somatic mutations that disturb cancer genes and confer growth 
advantage on the cancer cell. They are positively selected in the environment of cancer 
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tissue during cancer evolution. Generally, driver mutations are required for maintenance of 
the tumor. In contrast with driver mutations, passenger mutations make no contribution to 
clonal growth and are not selected during cancer evolution3,103. These mutations are 
carried along with the driver mutation events and clonal expansion, and may be observed 
in the final tumor cells.
Obviously, it is important, also a challenge, to distinguish driver from passenger mutations 
in cancer research50,104. Although passenger mutations are likely to be randomly 
distributed in the genome, recurrent somatic mutation hotspots usually contain hundreds of 
genes. It again exhibits the heterogeneous nature of cancer genome.
Although the classic model of cancer progression has been comprehensively  accepted, a 
phenomenon termed “chromothripsis” was recently characterized in cancer genomes, 
defined by the occurrence of tens to hundreds of clustered genomic rearrangements, 
supposedly having arisen in a single catastrophic event105. In this model, contiguous 
chromosomal regions are fragmented into many pieces, via presently unknown 
mechanisms106,107. Supposedly, these segments are then randomly fused together by the 
cell’s DNA repair machinery. Obviously, these somatically acquired genomic 
rearrangements may result in complex patterns of regional copy number changes. They 
have the potential to interrupt or activate multiple genes, and are consequently  implicated 
in cancer development. It has been proposed that this “shattering” and aberrant repair of a 
multitude of DNA fragments may provide an alternative oncogenetic route, in contrast to 
the step-by-step paradigm of cancer development105. Figure 2 is a schema of 
chromothripsis that occurs in a single catastrophic chromosome shattering event. The 
initial study reported some evidence of a high prevalence in bone tumors105. The following 
studies of chromothripsis revealed that these events are also observed in multiple 
myeloma108, colorectal cancer109,110, acute lymphoblastic leukaemia111, hepatocellular 
carcinoma112, neuroblastoma113, breast cancer114,115 and medulloblastoma116,117. Besides 
human cancers, recent research have also reported chromothripsis events in 
germline118,119 and non-human genomes120.
The discovery  of chromothripsis reveals a possible new paradigm in cancer development 
and stimulates great interest in the study of this phenomenon121-132. However, although 
several hypotheses have been proposed105,107,125,133-136, the underlying mechanisms are 
still unknown. We launched a project that aims to integrate as much data as possible to 
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provide the most comprehensive overview of chromothripsis events, and eventually 
elucidating the potential mechanisms underlying chromothripsis. Since the chromosome-
shattering was observed in a wide variety of tumors, the underlying mechanism is likely to 
reflect unknown general features of human cancer. The methods and results of this project 
are presented in Chapter 6.
Figure 2. Schema of the process of chromothripsis in a single chromosome. The 
chromosome is shattered into many pieces. Then these fragments, or some of the fragments, are 
pieced together to generate a derivative chromosome. The other segments lost to cell. 
Chromothripsis can involve several chromosomes.
Original chromosome
Catastrophic chromosome breakage
Stitched chromosome
Pieces lost to cell
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3  GENOMIC ARRAYS
3.1 EVOLUTION OF CYTOGENETICS AND MOLECULAR METHODS
The observed correlation between cancer initiation and/or progression and chromosome 
structural aberration has led to the development of several screening techniques capable 
of detecting DNA copy number changes. The conventional methods employed in cancer 
cytogenetics including chromosome banding and karyotyping137,138,139. These early 
techniques uncovered many genetic disorders caused by genome structural variation. The 
last two decade have witnessed substantial progress towards precise and genome-scale 
detection of copy number aberrations by molecular cytogenetic techniques116,140,141. By 
taking advantage of the unprecedented high resolution of these recently  developed 
methods, nowadays we are able to extensively characterize chromosome rearrangements 
in tumor samples and reveal their functions in cancer development. The techniques 
applied in clinical diagnosis and research include fluorescence in situ hybridization142,143,144 
(FISH), chromosome- and array-based comparative genomic hybridization11,55,145 (cCGH 
and aCGH), single-nucleotide polymorphisms146,147 (SNP) arrays and next-generation 
sequencing148,149 (NGS) methods. They completely revolutionized cytogenetic analyses 
and greatly  stimulated interest in molecular cancer research. Figure 3 shows the evolution 
and the timeline of cytogenetic approaches.
In 1960, the Philadelphia (Ph) chromosome was identified as a prognostic marker among 
chronic myeloid leukemia (CML) patients150. It was the first time to successfully correlate a 
specific chromosomal abnormality with a particular malignant disease. Starting from this 
point, cytogenetics has become a powerful and promising tool in cancer research, 
especially  after the invention of chromosome banding in 1970s151,152. In this technique, the 
metaphase chromosomes are stained with special dyes and then examined through a light 
or fluorescence microscope. In the metaphase stage of the cell cycle, chromatin is highly 
condensed and displays characteristic patterns of dark and bright bands. According to 
different staining methods, the resulting pattern can be classified according to the Q-, G- 
and R-banding nomenclature153-156. For example, the most commonly  used Q- and G-
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banding methods stain the chromosomes with quinacrine mustard and Giemsa staining, 
respectively. The dark G bands and bright Q bands are AT rich or gene-poor regions157. To 
the contrary, the G light and Q dark bands are GC  rich or gene-rich sequences157. Based 
on the resolution of the technique, morphological regions can be divided into sub-bands. 
The regular banding produces about 550 light and dark bands, while the most high 
resolution banding produces 800 or more bands. With these bands, it is easy to ascertain 
chromosomal abnormalities in single cell, both numerical and structural, unbalanced and 
balanced. However, through limits in the spatial resolution when using these highly 
condensed chromosomes, metaphase banding is not sensitive enough to determine subtle 
aberrations (less than ~5 Mb). Also, due to the unspecific DNA staining chromosome 
banding is ineffective in characterizing complex rearrangements (those with more than 2 
breakpoints). Even if it has these limitations, chromosome banding is very  informative, and 
is still commonly used in diagnosis and as a prognostic marker158,159.
Figure 3. The evolution and timeline of cytogenetic methodologies. The “Chromosome 
banding” is the conventional cytogenetic method. The remaining approaches are molecular 
cytogenetic techniques, i.e. involve segment specific DNA labeling techniques.
1970 1992 1997 2005
aCGH (Array comparative 
genomic hybridization)
cCGH (Chromosome comparative 
genomic hybridization)
Chromosome banding
NGS (Next-generation sequencing)
1982 1996
FISH (Fluorescence in situ hybridization)
SKY (Spectral karyotyping)
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Fluorescence in situ hybridization (FISH), introduced in the early 1980s, overcame the 
limitations of chromosome banding and became a significant diagnostic tool142,144. In brief, 
chromosome region specific DNA probes are labeled by fluorophores that can be directly 
detected by fluorescence microscopy. These probes are subsequently hybridized to their 
complementary DNA sequences in interphase cells or metaphase chromosomes. 
Fluorescent signal of interrogated specific genomic segments can be detected against a 
chromosomal background staining. The locations and number of these segments may 
reveal numerical or structural aberrations. Moreover, several DNA sequence targets can 
be concurrently detected in the same hybridization experiment by using probes labeled 
with different fluorescent dyes. FISH probes can even be manufactured with gene-level 
coverage, by using big plasmids such as cosmids/fosmids, or large bacterial artificial 
chromosomes160,161,162 (BAC) or yeast artificial chromosome163 (YAC). Furthermore, FISH 
is highly useful in mapping chromosome breakpoints, since chromosomes investigated at 
the metaphase or interphase stage of cell division may display split signals or aberrant 
fusion of differently labeled probes. As FISH analysis is considerably less affected by 
tissue processing artifacts, the results are widely accepted as the most reliable data and 
therefore generally  regarded as “gold standard” for detecting specific chromosomal 
aberrations. However, a major disadvantage to perform FISH analysis is that prior 
knowledge of sequences to be examined is required. Although multicolor karyotyping can 
be applied to simultaneously analyzing several chromosomal loci at one time, the number 
of colors available for FISH is quite limited, and consequently it cannot be used for 
genome-wide screening of copy  number alterations. Additionally, the probe preparation, 
labeling and signal evaluation are labor intensive and time consuming.
In 1992, a technique called comparative genomic hybridization (CGH) was introduced as a 
molecular tool in tumor cytogenetics11. It answers many deficiencies of conventional 
cytogenetics and FISH. This genome-wide technique allows the scanning of the whole 
genome for DNA deletions, duplications and amplifications in a single experiment. In this 
approach, genomic DNA is extracted from the cancer tissue sample and a normal 
reference sample, and differentially  labeled with individual dyes, typically  Cyanine 5 (red) 
and Cyanine 3 (green), respectively. The DNAs are mixed (1:1) and hybridized to normal 
human metaphase preparations on a microscope slide11. The red and green labelled DNA 
fragments compete for their complementary target sequences along each chromosome. 
The images of both fluorescent signals are captured, and the ratio of test to reference 
fluorescence along the chromosomes is quantified using digital image analysis. The red to 
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green fluorescence intensity  ratios measured represent alterations of genetic material in 
the tumor at that specific locus11. For example, due to their equal coverage with hybridized 
DNA fragments from both samples, normal chromosomal regions would have a normalized 
ratio of one and a yellow coloration (pseudo-color) would be observed. Areas with 
deletions in the tumor genome would have fewer (or no) tumor DNA fragments competing 
for the respective template region and result in a ratio below one and an increased green 
signal from the reference DNA;  amplified regions have a ratio above one, and would be 
revealed by  relative increases in the red signal from the patient DNA. In this way, all over- 
and under-represented regions of each chromosome can be identified, and an overview of 
copy number changes throughout the whole tumor genome is obtained. The important 
advantages of this technique have enabled tremendous progress in the field of cancer 
research. First, chromosome-based CGH analysis can be performed without metaphase 
chromosomes from the tumor sample and therefore no cell culture is required. Second, it 
is a fast screening method and only  relatively small amounts of DNA from the tumors are 
needed. Third, it enables analysis of the whole genome in a single experiment, and is 
more efficient in detecting the copy-number related result of complex structural 
aberrations.
Despite all these advantages, chromosome CGH does have some limitations that need to 
be taken into account. A main disadvantage is its inability  to detect balanced 
abnormalities, such as translocations, inversions and polyploid changes. Moreover, the 
repetitive sequences in the probe have to be suppressed with Cot1 DNA (unlabeled 
repetitive DNA)11,164 to reduce non-specific hybridization, or to be omitted in the 
subsequent interpretation process. Finally, the resolution of chromosome CGH is limited to 
5-15 Mb, since the highly condensed metaphase chromosomes are used as the readout. 
Therefore, CNAs smaller than 10 Mb  can not reliably be detected, which may limit the 
widespread clinical application of chromosome CGH. For the detection of such small 
CNAs, a high resolution technique, microarray-based CGH was developed with first 
applications reported in 1997 55.
Like chromosome CGH, array CGH is a technique for genome-wide screening of copy 
number change events55,145. The difference is that the metaphase chromosomes are 
substituted by cloned DNA fragments spotted and immobilized onto glass microscope 
slides, or alternatively by oligonucleotide DNA sequences grown in situ on the array 
substrate. These fragments are microarray probes of which the exact genomic positions 
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are known, and are designed in various sizes for the different platforms. Similar to the 
chromosome CGH procedure, equal amounts of patient and reference DNAs are extracted 
and differentially labeled with distinctive fluorochromes55,145. DNAs from both sources are 
co-hybridized to a glass slide containing the array probes. A microarray  scanner is used to 
scan the slide and convert image files into fluorescent intensity signals. For each single 
clone, the test to control fluorescence signal ratio is proportional to the ratio of the copy 
numbers of related location in the patient and reference genomes. The output of 
thousands of spots with different ratios of the signals provide a high resolution overview of 
CNAs throughout the whole genome. The schematic overview of the array CGH technique 
is shown in Figure 4. The reference sample can be the normal tissue of the same patient 
or pooled genomic DNA. In array CGH, the genomic resolution of different platforms is 
determined by the distance and size of the DNA probes. These interrogating probes can 
be prepared by bacterial artificial chromosomes (BAC) or P1 (PAC) clones165, cosmids and 
fosmids, or based on single-stranded oligonucleotides166. Regardless of the many types of 
probes, the significant advantage of array CGH over chromosome CGH is the high 
resolution and accordingly, the ability  to precisely map copy  number aberrations. It has 
been proven that the use of array CGH has revealed a number of new recurring genomic 
abnormalities that can not be identified by chromosome CGH. The highly improved 
resolution achieved by array CGH enables this technique to detect the precise boundaries 
of CNAs, which may disturb oncogenes or tumor suppressors, and provide insights into 
the mechanisms underlying CNA formation. Moreover, array CGH is sensitive enough for 
studying complex rearrangements generated by more than two chromosome 
breakpoints167. Thus, it quickly  replaced chromosome CGH in the last decade, becoming 
ubiquitous tools in cancer research as well as human genetic disorder studies168.
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Figure 4. Overview of array CGH technology. Genomic DNAs from cancer samples and 
references are differentially  labeled with green (Cy3) and red (Cy5) fluorescence dyes, respectively 
(Other fluorochromes can also be used, like fluorescein isothiocyanate). The two samples are 
mixed and competitively  co-hybridized to an array  containing DNA sequence targets that have 
been spotted on a glass slide. The schema of the slide depicts hundreds of spots with different 
ratios of the fluorescence intensities. These values are proportional to the ratio of the copy 
numbers of genomic DNA in the tumor samples and reference genomes. The yellow  spots on the 
slide indicate the presence of equal amounts of tumor and normal DNA. The spots that appear 
green indicate extra chromosomal material in the tumor sample at that specific location. The red 
spots indicate loss of tumor DNA in the sample. The Cy3/Cy5 fluorescent ratio on each spot is 
captured and normalized to Log2 values, and the median ratio is 0. In the ideogram of signal 
intensity  plot, each dot represents a single probe that spotted on the array, and the ratio for each 
probe is plotted in genome order. The five red probes have a ratio near -1, indicating a genomic 
loss. The six green probes have a ratio near 1, indicating a genomic gain. These results can be 
converted to a high resolution overview of copy number changes throughout the whole genome.
Normal tissueCancer tissue
Cy5 Cy3
Position on Sequence
Mix
Dye
Hybridize
Analysis
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As with other cytogenetic methodologies, array CGH technology also has a number of 
limitations. It is not able to identify  balanced rearrangements. Like in chromosome CGH, 
only copy number imbalances can be detected. Furthermore, it reflects an average pattern 
of all sub-populations in a tumor sample, so that intercellular variabilities are not easily 
assessed.
Figure 5 shows the publication statistics for studies performed chromosome-based and 
array-based CGH169. In the last decade, there has been a significant gradual shift of 
interest from cCGH to aCGH. Array CGH data analysis and interpretation is the major 
focus of this thesis. Since there are so many different types of platforms in aCGH 
technique, and each type has its unique advantages and disadvantages, in the following, 
different platforms will be introduced in detail.
Figure  5. The statistics for published chromosome CGH data and oncogenomic arrays. The 
y-axis represents the number of individual tumors reported in the literature. The data shows a 
growing interest in applying array  CGH techniques for feature detection in cancer samples. The 
shaded bars correspond to the total number of cases discussed in the articles, and the solid bars 
show raw or annotated data that can be collected. Data is obtained from Progenetix database and 
up to February 2013.
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case publication statistics
Links
Case
Numbers (in
Progenetix)
Publication Details
aCGH: 13
Yoshida N, Umino A, Liu F, Arita K, Karube K, Tsuzuki S, Ohshima K and Seto M.
Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic
aberrations.
Cancer Med (2012) 1: 289-294. (PMID 23342278)
aCGH: 48
Grossmann V, Haferlach C, Weissmann S, Roller A, Schindela S, Poetzinger F, et al.
The molecular profile of adult T-cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are
associated with poor prognosis in T-ALL.
Genes Chromosomes Cancer (2013) 52: 410-422. (PMID 23341344)
aCGH: 35
Sarhadi VK, Lahti L, Scheinin I, Tyybakinoja A, Savola S, Usvasalo A, Raty R, et al.
Targeted resequencing of 9p in acute lymphoblastic leukemia yields concordant results with array CGH and reveals
novel genomic alterations.
Genomics (2013) (PMID 23333812)
aCGH: 73
Italiano A, Lagarde P, Brulard C, Terrier P, Lae M, Marques B, Ranchere-Vince D, et al.
Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics.
Clin Cancer Res (2013) (PMID 23329812)
cCGH: 141 (140)
Mesquita B, Lopes P, Rodrigues A, Pereira D, Afonso M, Leal C, Henrique R, Lind GE, et al.
Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors
ETV3 and ELF3 in breast cancer irrespective of molecular . . .
Breast Cancer Res Treat (2013) (PMID 23329352)
aCGH: 47
Wang ZC, Birkbak NJ, Culhane A, Drapkin RI, Fatima A, Tian R, Schwede M, Alsop K, et al.
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome.
Clin Cancer Res (2012) (PMID 22912389)
aCGH: 2
Chen CH, Chuang SM, Yang MF, Liao JW, Yu SL and Chen JJ.
A Novel Function of Ywhaz/Beta-Catenin Axis in Promoting Epithelial-Mesenchymal Transition and Lung Cancer
Metastasis.
Mol Cancer Res (2012) (PMID 22912335)
aCGH: 18
Traina F, Visconte V, Jankowska AM, Makishima H, OKeefe CL, Elson P, Han Y, Hsieh FH, et al.
Single Nucleotide Polymorphism Array Lesions, Tet2, Dnmt3A, Asxl1 and Cbl Mutations Are Present in Systemic
Mastocytosis.
PLoS One 7, 8 (2012): e43090. (PMID 22905207)
aCGH: 1 (1)
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, et al.
Fgf3/Fgf4 Amplification and Multiple Lung Metastases in Responders to Sorafenib in Hepatocellular Carcinoma.
Hepatology (2012) (PMID 22890726)
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3.2 LARGE CLONE ARRAYS
The first array CGH platform was introduced in 1997 with the purpose of enhancing the 
resolution and simplifying the analysis procedure of chromosome CGH55. In these arrays, 
in place of normal metaphase chromosomes thousands of target DNA sequences, i.e. 
array probes, were immobilized on glass slides. These sequences were largely cloned in 
bacterial artificial chromosome or P1-derived artificial chromosome vectors, of typically 
75-130 kb in length. Other clone types used include cosmids and fosmids.
The resolution of platforms is mainly determined by  the length of probe and the density  of 
genome coverage by the clones on the array. Initially, BAC arrays are comprised of ~3000 
large insert clones spaced at ~1 Mb intervals throughout the genome170. They can reliably 
detect larger copy number aberrations, but genomic changes that occur in the gaps 
between the probes will not be identified. Tiling path BAC arrays comprised of 32 000 or 
more clones covering the entire genome were designed later and have allowed for a 
dramatic increase in resolution171. In this way, the theoretical resolution is only limited by 
the size of the probes used.
Besides their resolution, another important parameter of array  platforms, is their sensitivity. 
It is partly  influenced by the inherent biological variability of the samples used in each 
study. For example, due to the lack of non-cancer cells (e.g. stroma cells, blood vessels 
etc.), cell lines offer a more homogeneous cell source than primary samples. Primary 
tissues are frequently contaminated by normal cells, which will reduce the hybridization 
ratio of CNAs. Furthermore, sub-clones of cells that arise during tumor evolution will affect 
the magnitude of specific changes in the profile generated by arrays. Therefore, the 
primary tumors give the overall view of multiple heterogeneous subclones, and the 
contribution of minor variant tumor cells may not reliably be observed.
Among all the oncogenomic platforms, large clone arrays provide the best signal to noise 
ratios. They allow highly sensitive and reproducible detection of a wide range of copy 
number changes including single copy number gains/losses and high-level 
amplifications164. Moreover, since their probes are long enough to minimize non-specific 
hybridization across the array, a CNA that involves only  a single probe can be considered 
as a real genetic event in the tumor instead of an artifact of the technique, if concerning a 
well-defined target. However, one major drawback of large clone arrays, as well as most 
24
array CGH platforms, is the inability to detect rearrangements without change in DNA 
content, such as loss of heterozygosity (LOH) and translocations. Thus, they will have 
limited use in diagnosis of, for instance, hematologic malignancies, for which copy-neutral 
aberrations (e.g. fusion gene generation) known as one of the important mechanisms.
For large clone arrays, there are not a wide variety  of commercial alternatives available. 
The most commonly used are in-house printed arrays, typically UCSF HumArray, VU 
University  Medical Center Microarray Core Facility BAC array, DKFZ (The German Cancer 
Research Center) Human BAC/P1 array, etc. These arrays are generally cheaper than 
commercial arrays.
3.3 CDNA ARRAYS
Soon after the development of BAC/P1 arrays, ~30 000 accurately  mapped cDNAs were 
also used as genomic resource for mapping DNA copy number aberrations across a whole 
genome172,173. Although cDNA arrays were originally designed for analysis of gene 
expression levels, they in principle provided a further increase in resolution of aCGH 
compared to then available BAC/P1 platforms.
In this technique, DNA copy number changes can be measured in a gene specific manner. 
Disease-related genes, such as oncogenes and tumor suppressor genes, can be 
selectively spotted on the array to provide important information. Moreover, the potential 
advantage of using cDNA arrays is that expression analysis of a given sample can be 
carried out in parallel with DNA copy number characterization, on the same platform. The 
combination of copy number and gene expression patterns should prove useful for 
identifying pathogenically important genes in amplicons, in that it can confirm the copy 
number induced expression change in the genes under consideration. In cancer research, 
this feature may facilitate to distinguish cancer “driver” genes from co-amplified 
“passenger” genes. Following the completion and annotation of human genome sequence, 
this platform was thought to greatly accelerate the discovery of genes that play roles in 
tumor progression.
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However, cDNA arrays have unique disadvantages compared to other platforms170,172,173. 
First, they  are not possible to pre-select sequences of cDNAs, and therefore the 
opportunity for discovery novel aberrations is limited. Second, since genes are not 
uniformly distributed throughout the genome, it is difficult to define the resolution of cDNA 
arrays. The resolution can be variable across the gene-rich and gene-poor regions. This 
may increase the uncertainty in the identification of the exact location of breakpoints. 
Third, cDNAs may contain repetitive sequences or short sequences which share extensive 
homology. This phenomenon may influence the signal intensity of specific probe and lead 
to mis-detection of abnormal regions.
The cDNA arrays were first introduced by Stanford University, and oligonucleotides are 
printed on glass slides using a robotic applicator with multiple capillary needles173. These 
arrays have been widely  used in clinical applications because of their relative affordability 
in terms of cost. Beyond this, no specific equipment is required for carrying out 
hybridization and data capture. The most common platforms are SMD 40k cDNA arrays.
3.4 OLIGONUCLEOTIDE ARRAYS
Oligonucleotide-based arrays hold the potential of enhanced design flexibility and to 
overcome some of the drawbacks of the aforementioned techniques174,175,176. Unlike 
cDNA platforms, oligonucleotide arrays are able to distinguish between highly  homologous 
sequences by careful design, as the sequence of probes can be predetermined. A  high 
dense coverage of the genome and relatively high resolution can be obtained by the large 
number of probes.
Oligonucleotide probes can be roughly  classified into the “short” and “long” categories. 
Short oligonucleotide arrays (21-25 mers) were originally designed to characterize single 
nucleotide polymorphisms (SNPs) in the genome as represented e.g. by  the Affymetrix 
platforms177. These arrays have been recruited for assessing copy number aberrations in 
CGH experiments, and will be described in detail in the following section. The long 
oligonucleotide probes are typically 60-70 mers, resulting in a higher probability of non-
repetitive sequences and improved hybridization specificity174. The fluorescence intensities 
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detected on a genome-wide scale are comparable to BAC/P1 arrays in the magnitude of 
signal and background noise.
As a special example, ROMA (representational oligonucleotide microarray  analysis)178 is a 
kind of platform that reduces sample genome complexity and hybridize to long 
oligonucleotide probe sets. Before hybridization, DNA samples have to be cleaved with 
restriction enzyme, and followed by linker-mediated PCR that converts the genomic DNA 
into a predictable sample of reduced complexity. In this way, about 2.5% genome is 
covered, which improves the signal to noise ratio. After amplifications and with sufficient 
probe density, single copy number aberrations can be observed. However, although 
ROMA allows a genome-wide identification of CNAs, the low coverage of the genome may 
lead to large gaps where no genomic information is available. The whole-genome tiling 
path arrays should avoid this problem and provide a higher resolution.
Today a great variety of commercial oligonucleotide platforms are available. The Agilent 
arrays carry 60 mers probes and have been successfully used for clinical cytogenetic 
diagnosis177,179,180. The most popular platforms here are 4x44K, 4x180K and 244K. 
NimbleGen arrays carry 45-85 mers probes and provide flexible design. NimbleGen 2.1M 
arrays contain more probes that allow the researchers to examine focal CNAs at high 
resolution, and other platforms including 85K, 385K, 720K CGH arrays etc. Illumina has 
developed a novel bead array technology which is utilized for a broad range of DNA and 
RNA analysis applications. The common CGH platforms are BeadChip 317K, 610Quad 
and 660Quad. The Affymetrix arrays use photolithography to build 25 mers 
oligonucleotides directly on the array slides. Their outstanding sensitivity  and accuracy  is 
achieved by the high density  of short oligo probes, and will be discussed in the following 
part.
3.5 SNP ARRAYS
Single nucleotide polymorphism arrays are one type of oligonucleotide arrays, which were 
originally designed to detect common SNPs and were mainly  used in genotyping 
studies181,182,183. In addition, these platforms are also used to perform copy number 
27
abnormality identification. Unlike the above-mentioned arrays, which rely  on co-
hybridization of patient and reference DNA, only a single hybridization is performed for 
patient samples184,185. The observed tumor sample intensities are compared to expected 
reference intensities, which can be generated by the same laboratory or from other archive 
sources such as the HapMap Project186,187 (The International HapMap  Consortium). 
However, the reference dataset used may influence the quality control procedure or the 
sensitivity of detecting CNAs. According to previous studies, a large in-house reference 
dataset is more likely to produce improved quality  of results in comparison with the 
external reference datasets. With the normalized Log2 intensity ratios, genomic gains and 
losses can then be called. The relative short probes, usually 25 mers oligonucleotides, 
used for SNP detection provide the lower noise-to-signal ratios than longer probes. 
Therefore, several probes are required to define a copy  number alteration event. In 
general, the design of the original SNP arrays focused on specific loci in order to detect 
SNPs, instead of providing an even coverage of the genome.
Besides genomic gains and losses that can be detected by both CGH and SNP arrays, 
SNP platforms offer the unique possibility to simultaneously analyze loss of heterozygosity 
using the same array183. The signals from individual alleles can be detected to calculate an 
allelic ratio (AR). The AR patterns may reveal particular classes of CNAs. Thus, it is 
possible to distinguish copy number loss from copy neutral genetic events underlying LOH. 
This may be of significance for cancer research, since LOH regions may also correlate 
with increased expression of oncogenes or inactivation of tumor suppressors. For 
instance, the characterization of haplotype structures could facilitate the analysis of cancer 
predisposition.
One important capability  of SNP arrays is to discovery CNVs. To improve the efficiency of 
CNV detection, non-genotyping probes are also included in recent SNP arrays versions, 
and the overall probe density  is also increasing183,188,189. For example, in the Affymetrix 
SNP6 platform which includes 1.8 million probes, both polymorphic or nonpolymorphic 
probes are combined to detect CNVs, copy number aberrations and SNPs.
Another potential function of SNP platforms is to detect polyploidy. This phenomenon is 
observed in most cancer types and supposed to be an important mechanism in tumor 
development183,189. In some cases, the polyploid tumor samples are not possible to be 
identified by the overall hybridization signal on arrays due to experimental and 
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computational normalization to a virtual diploid state, and only relative copy number 
changes against the baseline are able to be detected. The integration of allele specific 
signals and Log2 intensity  ratios allows us to assign absolute copy numbers to 
investigated genomic regions and determine if samples are polyploidy190,191.
With the unique advantages of being able to detect copy neutral LOH, uniparental disomy 
and regions identical by descent, SNP arrays have undergone huge developments over 
the last decade. So far, commercial SNP arrays have achieved remarkable success. 
Affymetrix Microarrays provides robust  precise platforms with various resolutions for 
detecting CNAs and SNPs throughout the whole genome. Affymetrix 100K Mapping arrays 
have a mean marker distance of 24kb, and 500K Mapping arrays have an average inter-
probe distance of 5.8 kb. Recently, Agilent provided “CGH + SNP” arrays that are also 
designed both for capture of copy number changes and for detection of LOH. The 
available platforms including Agilent SurePrint G3 Human Genome CGH+SNP 2x400K 
and 4x180K Microarray. Currently available “SNP” platforms with the highest density  can 
analyze more than 2 million loci using a single array.
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RESULTS

4  CURATED DATABASE FOR COPY NUMBER PROFILING DATA 
IN HUMAN CANCER
4.1 PREFACE
Genomic copy number aberrations are a hallmark of almost all forms of human 
malignancies3. The recurrent genomic imbalances may reveal mutations in oncogenes or 
tumor suppressors45. CNA hot spots identification has proven to be efficient to reveal novel 
cancer-causing genes98. Besides genes, on a systems-level, CNA data is used to detect 
pathways altered in cancers and to deduce functional relevance of pathway members98. 
Since specific CNAs may be attributed to certain tumor types, in some studies copy 
number profiling is employed to differentiate biological as well as clinical subtypes. 
Subtype-associated CNA regions facilitate to understand biological differences and lead to 
discovery of new therapeutic targets. Moreover, gene expression or somatic mutation data 
offer complementary perspectives on the same cancer genome. Thus, CNAs can be 
integrated with these data to provide a more comprehensive model of cancer 
development3.
In the last two decades, molecular-cytogenetic techniques have been applied to screen 
DNA copy number profiles in human cancer98,131. Among these techniques, chromosomal 
and array  comparative genomic hybridization were comprehensively employed for 
genome-wide analysis. While chromosomal CGH has a limited spatial resolution of several 
megabases, the resolution of array based technologies is mainly limited due to cost/benefit 
evaluations instead of technical obstacles. The flood of high resolution aCGH data have 
led to an increased interest in genetic and cancer research, also offer new challenges and 
opportunities for large-scale genomic data mining, modeling and integration. As a result, a 
more complete understanding of functional effect of CNAs in the context of cancer can be 
obtained.
Several online oncogenomic resources have been launched, focusing on different aspects 
of data content as well as representation. In principle, these databases facilitate access 
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and visualization of CNA data. However, they are limited to specific aCGH platforms or 
single institutions as well as limited disease categories. Several commonly used genomic 
array databases are listed below.
• National Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO)
GEO is the largest international public repository  for raw high-throughput microarray 
data26. At the moment, there are more than 32000 series, comprising 800000 samples 
derived from ~1600 organisms included in GEO database. These data sets were 
submitted by the research community. Although GEO provides several web-based tools 
and strategies to assist users to query and analyze data, the main principle of this 
database is to archive raw data. It is not able to allow users to intuitively visualize array 
data.
• European Bioinformatics Institute (EBI) ArrayExpress
ArrayExpress is another major international repository for functional genomics data mainly 
from microarray27. The database supports data query and download. Data sets were either 
submitted directly by the research community or were imported from the NCBI GEO. It 
currently contains data from about one million entities and over 30000 experiments. 
Although ArryExpress provides several pre-analyzed data formats, such as R objects for 
array data, this database also aims to archive raw array data. Thus, it is not easy for users 
to perform custom data analysis and visualization.
• The Cancer Genome Atlas (TCGA)
TCGA dedicates efforts to understand the molecular basis of cancer through large-scale 
genomic data28. Immense amounts of array data were integrated into the database. In 
addition, it provides informatics tools to the research community to make use of these 
data. At the moment, about 7000 arrays from 26 cancer types are stored in TCGA. 
However, only segmented data is publicly available, while the raw data is protected.
• CaSNP
CaSNP database focuses on the collection of CNA information from single-nucleotide 
polymorphism arrays192. It contains ~11500 SNP array data in 104 series. All the data were 
obtained from GEO. CaSNP allows users to input region or gene of interest, and the 
34
summarized frequencies of genomic gain and loss will be returned. It also displays the 
heatmap of copy numbers estimated at each SNP maker. CaSNP is a useful tool for 
cancer CNA research. However, it is limited to SNP arrays with single data source.
• CanGem
CanGem is a public web-based database for storing genomic array data193. Additionally, it 
collects clinical information whenever it is available. CanGem provides custom datasets 
download by querying for specific clinical sample information or copy number changes of 
individual genes. It provides more than 1000 arrays from different data sources.
Although the above-mentioned data sources provide large amount of array data, no single 
data source does yet provide an extensive collection of oncogenomic CNA data, which 
readily could be used for genomic feature mining, across a representative range of cancer 
entities. A comprehensive reference database for copy number profiling data in human 
tumor is needed to promote more effective cancer research.
4.2 arrayMap
For this research project, I collected array CGH data from 4 main data sources, including 
GEO, ArrayExpress, TCGA and publication supplements, and created arrayMap  database 
for providing genomic copy number data sets in human cancer23 (Figure 6). I set up a 
pipeline to accumulate and process oncogenomic array data into a unified and structured 
format. Associated histopathological and clinical information were incorporated into the 
database. So far, arrayMap  contains more than 40,000 arrays on 197 cancer types. Figure 
7 shows the summary of CNA data stored in arrayMap. Samples of interest can be 
browsed, visualized and analyzed via an intuitive interface. Computational tools are 
provided for biostatistical data analysis, such as CNA clustering for case specific or for 
subset data and basic clinical correlations. So far as I know, arrayMap provides the largest 
annotated data for whole genome CNA profiles. arrayMap is publicly available at 
www.arraymap.org.
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Figure 6. An overview of data sources included in arrayMap. The core data of arrayMap is 
obtained from GEO and ArrayExpress. According to our data collection efforts, there are totally 
about 65000 published aCGH cases in literatures. In arrayMap, there are many arrays that are 
submitted into GEO/ArrayExpress or TCGA, but are not published yet.
Figure 7. Summary of oncogenomic data stored in arrayMap. The numbers represent tumor 
samples. AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia.
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arrayMap: A Reference Resource for Genomic Copy
Number Imbalances in Human Malignancies
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Abstract
Background: The delineation of genomic copy number abnormalities (CNAs) from cancer samples has been instrumental
for identification of tumor suppressor genes and oncogenes and proven useful for clinical marker detection. An increasing
number of projects have mapped CNAs using high-resolution microarray based techniques. So far, no single resource does
provide a global collection of readily accessible oncogenomic array data.
Methodology/Principal Findings: We here present arrayMap, a curated reference database and bioinformatics resource
targeting copy number profiling data in human cancer. The arrayMap database provides a platform for meta-analysis and
systems level data integration of high-resolution oncogenomic CNA data. To date, the resource incorporates more than
40,000 arrays in 224 cancer types extracted from several resources, including the NCBI’s Gene Expression Omnibus (GEO),
EBI’s ArrayExpress (AE), The Cancer Genome Atlas (TCGA), publication supplements and direct submissions. For the majority
of the included datasets, probe level and integrated visualization facilitate gene level and genome wide data review. Results
from multi-case selections can be connected to downstream data analysis and visualization tools.
Conclusions/Significance: To our knowledge, currently no data source provides an extensive collection of high resolution
oncogenomic CNA data which readily could be used for genomic feature mining, across a representative range of cancer
entities. arrayMap represents our effort for providing a long term platform for oncogenomic CNA data independent of
specific platform considerations or specific project dependence. The online database can be accessed at http//www.
arraymap.org.
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Introduction
Genomic copy number abnormalities (CNAs) are a relevant
feature in the development of basically all forms of human
malignancies [1]. Many genomic imbalances are recurrent and
display tumor-specific patterns [2,3]. It is believed that these
genomic instabilities reveal mutations in tumor suppressor genes
and oncogenes which eventually result in a clone of fully malignant
cells. Investigation of CNA hot spots (chromosomal loci frequently
involved in CNA) has proven to be an effective methodology to
identify novel cancer-causing genes [4,5]. On a systems level, CNA
data along with expression or somatic mutation data is used to
detect pathways altered in cancers and to deduce functional
relevance of pathway members [6,7]. Since many CNAs have
been attributed to specific tumor types or clinical risk profiles, in
some entities copy number profiling is employed to characterize
different biological as well as clinical subtypes with implications for
treatment and individual prognosis. Subtype-associated CNA
regions are used to predict causative genes, furthering under-
standing of biological differences and leading to discovery of new
therapeutic targets [8,9].
Throughout the last two decades, molecular-cytogenetic tech-
niques have been applied to scan genomic copy number profiles in
virtually all types of human neoplasias. For whole genome analysis,
these techniques predominantly consist of chromosomal and array
comparative genomic hybridization (CGH), including CNA
detection by cDNA and single nucleotide polymorphism (SNP)
arrays [10–12]. While chromosomal CGH has a limited spatial
resolution of several megabases, the resolution of recent array
based technologies (aCGH) is mainly limited due to cost/benefit
evaluations instead of technical obstacles. In this article, we use the
terms ‘‘array CGH’’ and ‘‘aCGH’’ for all technical variants of
whole genome copy number arrays. This includes e.g. single color
arrays for which regional copy number normalization is performed
through bioinformatics procedures applied to external references
and internal data distribution.
The flood of new insights into structural genomic changes in
health and disease has led to an increased interest in genomic data
sets in genetic and cancer research. Several systematic studies of
CNAs across many cancer types have been performed [13,14].
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These efforts attempt a more complete understanding of
functional effect of CNAs in the context of cancer.
The exponential increase of high resolution CNA datasets offers
new challenges and opportunities for large-scale genomic data
mining, data modeling and functional data integration. Several
online resources have been developed, focusing on different
aspects of data content as well as representation [6,15–19]. An
overview of some of the prominent examples is given in Table 1.
In principle, these databases facilitate access and utilization of
CNA data. However, they are limited to specific aCGH platforms
and/or single institutions as well as limited disease categories, or,
as in the cases of GEO [15] and Ensembl ArrayExpress [16],
mainly serve as raw data repositories. To the best of our
knowledge, no single data source does yet provide an extensive
collection of high resolution oncogenomic CNA data which readily
could be used for genomic feature mining, across a representative
range of cancer entities.
Here we present ‘‘arrayMap’’, a web-based reference database
for genomic copy number data sets in cancer. We have generated
a pipeline to accumulate and process oncogenomic array data into
a unified and structured format. The resource incorporates
associated histopathological and clinical information where
accessible.
So far, arrayMap contains more than 40,000 arrays on 224
cancer types from five main data sources: NCBI GEO, EBI
ArrayExpress, The Cancer Genome Atlas, publication supple-
ments and user submitted data. Samples of interest can be
browsed, visualized and analyzed via an intuitive interface.
Computational tools are provided for biostatistical data analysis
such as CNA clustering for case specific or for subset data and
basic clinical correlations. arrayMap is publicly available at www.
arraymap.org.
Results
Data Content
Our combination of both ‘‘top-down’’ (publication driven) as
well as ‘‘bottom-up’’ (array data driven) approaches allowed us to
identify a comprehensive set of accessible aCGH based cancer
CNA data sets and to estimate the ratio of accessible data of the
overall published/deposited data.
As main result of the array data driven approach, we extracted
495 series comprising of 32002 arrays, generated on 237 platforms
from NCBI’s GEO. Among those, raw data files of approximately
29000 whole genome arrays were suitable for inclusion into our
data processing pipeline. When reviewing the content of AE, we
found that the majority of AE cancer genome data sets were also
submitted to GEO. At the time of writing, 11 datasets including
712 arrays not present in GEO had been processed based on AE
specific series. Detailed information on the GEO/AE data sets is
provided in Table S1.
The top-down procedure was based on our group’s continuous
monitoring of cancer related articles utilizing genome copy
number screening approaches, as established for our ‘‘Progenetix’’
project (www.progenetix.org; [19]). The census date for the
literature based data collection was August 15 2011. At this point,
we had identified 931 articles discussing a total of 53213 genomic
cancer CNA profiles based on aCGH techniques. Of these, 8728
cases out of 199 articles so far had been extracted from publication
related sources (e.g. supplementary data tables) and annotated and
made been accessible through Progenetix. This data included
cases for which only supervised information but no probe data was
available (e.g. author annotated Golden Path or cytogenetic CNA
regions). Literature based data sets containing probe specific data
or with the respective data presented to us by the authors (640
samples) were included into our arrayMap data processing
pipeline.
The data content of arrayMap is summarized in Table 2.
Current numbers on the website will include changes based on
ongoing annotation efforts (i.e. addition of data sets, removal of
low quality arrays).
As a by-product of our data collection and annotation efforts,
we are able to provide estimates of content and trends for the
platform usage and cancer entity coverage for the majority of
published data. According to the assigned ICD-O 3 (International
Classification of Diseases for Oncology, 3rd Edition) code and
descriptive diagnostic text, breast carcinoma predominates as
single largest clinical entity with 6459 arrays. Table S2 presents
sample sets in arrayMap classified by ICD-O code.
The most widely available array CGH platforms are either
based on large insert clones (BAC/P1 arrays) or based on shorter
single-stranded DNA molecules (oligonucleotide arrays), which
may or may not include single-nucleotide polymorphism specific
probe sequences (SNP arrays). Also, although designed for gene
expression profiling, cDNA arrays were used by several labora-
tories for measuring genomic copy number changes. Although all
these platforms are considered suitable for whole genome CNA
analysis, their probe densities and other parameters can affect
specific features of the analysis results [20–23]. Table S3 lists the
general platform types and corresponding overall numbers of the
data registered in arrayMap.
Table 1. Prominent online resources of genomic data.
Name Address Platform(s) Data format Comment
GEO [15] www.ncbi.nlm.nih.gov/geo 263 raw & normalized probe signal intensity largest microarray data repository
ArrayExpress* [16] www.ebi.ac.uk/arrayexpress 16 raw & normalized probe signal intensity many duplicate data in GEO
TCGA [6] cancergenome.nih.gov 1 segmentation data raw probe data is limited to download
CanGEM** [17] www.cangem.org 38 normalized probe signal intensity including many types of microarray data
CaSNP [18] cistrome.dfci.harvard.edu/CaSNP 8 average copy number & graphic focus on SNP array data
Progenetix [19] www.progenetix.org 235 ISCN*** & golden path data from publications
Data up to 29 April, 2011.
*excluding data both in GEO and ArrayExpress.
**statistical information only including CGH, SNP and cDNA data.
***International system for human cytogenetic nomenclature.
doi:10.1371/journal.pone.0036944.t001
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In reviewing the technical platform composition, two related
trends become apparent (Figure 1). Originally developed in groups
with expertise in molecular cytogenetics and cancer genome
analysis, printed large insert clone arrays (BAC/P1) were the first
whole genome CNA screening tools with a spatial resolution
surpassing that of chromosomal CGH. Other groups re-employed
cDNA arrays, developed for expression screening, for genomic
hybridizations. However, over the last years one can observe the
overwhelming use of various industrially produced oligonucleotide
array platforms, which compensate their low single probe fidelity
through a probe density at 1–3 orders of magnitude higher than
common for BAC/P1 arrays. Another reason for the success of
oligonucleotide arrays is the integration of SNP specific probes,
which in principle allows to use of the same experiments for
genetic association studies and the evaluation of copy number
neutral loss of heterozygosity regions [12,24,25].
Data Access and Usage Scenarios
Based on our experience from the Progenetix project, a strong
emphasis was put on a user friendly data interface. Here, we
followed a ‘‘dual user type’’ scenario: Users without bioinformatics
background should be able to intuitively visualize core data
features as well as to perform standard analysis procedures, while
for bioinformaticians the formatted database content should be
accessible to use with their analysis tools of choice.
Query interface. Data browsing in arrayMap is based on
two types of query methods: search by experimental series
metadata and search by sample features.
In the series query form, users can perform various search
options by specifying (i) descriptive diagnosis text; (ii) disease
classification (ICD-O 3 code(s)); (iii) disease locus (ICD topography
code(s)); (iv) PubMed ID; (v) technique(s); (vi) series ID. For sample
specific queries, additional features are available: sample ID;
platform ID or description; and single or combined regional
CNAs. Users can input gene name(s) in ‘‘regional CAN’’ search
field. When at least two characters are entered into the field,
suggestions based on a HUGO gene list are displayed for selection.
Gene selections will be converted to genomic locations.
In the results table, associated array information is displayed. A
number of links to additional and/or outside data is provided,
according to the information available: the corresponding
PubMed entries; the original GEO/AE accession display page
for more complete information; the case and publication entries on
the Progenetix website for further analysis; and importantly the
array specific data visualization page.
Data download options. On pages resulting from sample
queries or sample data processing, users are presented with options
to download sample data based on the current queryO˜s return.
Currently, three different file types are offered: JSON files, tab
separated feature files and segments list files. These files enable
bioinformaticians to perform further analyses based on their tools
of choice. Particularly, the JSON format can be used for direct
database import (e.g. MongoDB) or can be deparsed by common
libraries (e.g. JSON.pm), or being read into web applications.
Array probe data visualization. In the array plot interface,
original plots of genomic array data sets can be searched and
visualized (Figure S1). Default threshold parameters which were
either provided with the data or assigned during the initial
visualization will be loaded. In single array visualization, the
general view of probe distribution and post-thresholding segmen-
tation results are displayed for the whole genome as well as for
each individual chromosome. If multiple arrays are retrieved, users
can select sample data for downstream analysis procedures. Figure
S2 shows the screenshot of single array visualization.
Users can segment the raw data values and re-plot the results
after revising the following parameters:
N Golden path edition, default HG18/NCBI Build 36. This is
still the commonly used version of the human reference
genome assembly. At the moment, coordinates of probes from
all platforms were remapped to HG18. For the near future, we
intend to allow for a selection of updated genome editions.
N Chromosomes to plot, default 1 to 22. Single or all
chromosomes can be selected for re-plotting. To avoid gender
bias, most platforms do not contain probes in chromosome X
and Y during the design.
N Loss/gain thresholds. Cut-offs from which a segment is
considered a genomic loss or gain. The optimum thresholds
may vary between platforms.
N Region size in kb. Sets a filter to remove CNA below (e.g.
probable noise) or above (e.g. exclude non-focal CNA) a
certain size range.
N Minimal probe numbers for segments. This parameter can be
used to limit the minimal number of probes required for a
segment to be considered (e.g. to remove aberrant segmenta-
tion due to probe level noise). Empirical examples would be
values of 2–3 for high quality BAC arrays and 6–10 for
Affymetrix SNP 6 arrays.
N Plot region. Single genomic region to be plotted, overriding the
chromosome selection above. When selected, plots with this
region will be generated for all current arrays. This is valuable
to e.g. display the CNA status and copy number transition
points for specific genes of interest (Figure S3).
Zoom-in visualization of focal CNA. Figure 2 shows the
visualization of focal genomic imbalances, e.g. to identify genes of
interest targeted by focal CNA. The whole genome view of
GSM535547 (human high grade glioma sample analyzed by
Agilent Human Genome CGH Microarray 244A) shows a small
regional deletion in chromosome 9p21. When plotting the
approximate locus of the deletion (specified as chr9:21600000-
22400000), genes, probes and chromosome bands in this zoomed
in region are shown. Two genes, MTAP and CDKN2A can be
seen as being localized in a potential homozygously deleted region.
The focal deletion of these known tumor suppressor genes [26,27]
points to their specific involvement in the glioblastoma sample
analyzed here.
Querying compound CNA. The concept of focal CNA
detection can be integrated with a global search for arrays
Table 2. aCGH data integrated in arrayMap.
Data Source Arrays Cases Series Platforms Publications
GEO 32002 25728 495 237 490
ArrayExpress 712 11 16 11
TCGA 7249 3594 19 1 *
Publication
Supplements
.4578** 4578 137
Author Submission 556 539 8 7
Data up to 29 April, 2011.
*Due to lack of publication information, there may be a small amount of
duplicate data in GEO.
**Array number may be higher than case number since reported results per
case occasionally may be based on more than one array. The number does not
include data presented both in publication supplements as well as GEO.
doi:10.1371/journal.pone.0036944.t002
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containing gene specific regional imbalances. As an example, we
demonstrate the search for arrays displaying imbalances in 4 gene
loci associated with glioblastoma: EGFR, a transmembrane
receptor and proto-oncogene [28]; PTEN, a tumor suppressor
gene [29]; ASPM, frequently overexpressed in glioblastoma
relative to normal brain tissue [30]; and CDKN2A (see above).
In the ‘‘Search Samples’’ form, the ‘‘Match (Multiptle) Regions &
Types’’ can be used to specify the genomic regions of those four
genes including the expected CNA type: for EGFR
(chr7:55054219-55242524:1), PTEN (chr10:89613175-
89718511:-1), ASPM (chr1:195319885-195382287:1) and
CDKN2A (chr9:21957751-21984490:-1), respectively. When ex-
ecuting the query, these regions were matched with the whole
database and returned cases which have imbalances overlapping
all these regions. When excluding controls and ‘‘worst quality’’
datasets, 303 out of 42421 arrays could be identified matching all
four CNA regions. In addition to glioblastoma, several other types
of cancer cases were among the results, including e.g. neuroblas-
tomas, breast carcinomas, melanomas and lung carcinomas, which
is in accordance with some previous observations [31–34]. CNA
and associated data of those cases can be processed by online tools
for further analysis and visualization (Figure S4) or downloaded for
offline processing.
Copy number profiling of selected cancer entities. One
aim of arrayMap is to allow researchers to conveniently perform
aCGH meta-analysis across different platforms. By selecting a
single or several cancer entities e.g. based on their ICD entity
codes or diagnostic keywords, users are able to generate disease
specific CNA frequency profiles or to compare profiles of different
cancer types.
As an example, we used ICD-O code 9440/3 (glioblastoma,
NOS) to query the database. 1478 arrays from 25 publications
were returned and passed to our suite of online analysis tools.
Chromosomal ideograms and histograms were generated repre-
senting the frequency of copy number aberrations identified over
the whole dataset (Figure 3A). In the overall aberration profile, the
most common genomic imbalances included whole chromosome 7
gain and chromosome 10 loss, as well as focal gains e.g. on bands
1q21 and 17q21. In our example dataset, a prominent focal
deletion hot-spot was centered around 9p21.3 (921 of 1478 arrays,
62.31%) which had been discussed previously [35]. The distribu-
tion of CNAs over the individual arrays was visualized through a
matrix plot (Figure 3B). As additional information to the frequency
histograms, this form of visualization facilitates e.g. the detection of
CNA patterns among individual arrays as well as the concordance
of individual CNAs (e.g. here the arm-level changes in chromo-
some 7 and 10).
In the matrix plot, clicking on a certain segment would open
the related view in the UCSC genome browser [36], for
detailed information related to this genomic region (SVG plot
only). The plot order of arrays can be re-sorted according to
ICD morphology, ICD topography, clinical group or PubMed
ID, which can be helpful in associating CNA patterns to
external classification categories. For the selected classification
criterium (default: ICD morphology), regional CNA frequencies
for cases matching the different values will be visualized through
a heatmap (Figure 3C); this feature is especially useful when
comparing a number of different primary classification criteria.
An Overall Genomic Copy Number Profile of Cancer
Our high quality core dataset in arrayMap was used to generate
an overall cancer copy number aberration profile based on 29,137
arrays (Figure 4). This data represented 177 cancer types
according to ICD-O 3 code, with 59 types among them contained
Figure 1. Distribution of resolutions and techniques of GEO platforms. Each point represents a genomic array. The Y axis is labeled with
probe number in log scale. The X axis denotes the time sequence of array data generation. From left to right are years from 2001 to 2011.
doi:10.1371/journal.pone.0036944.g001
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more than 50 arrays. Overall, one of the most common genomic
alteration is copy-number gain of chromosome band 8q24, which
is found in 30% of total samples. According to the COSMIC [37]
database, the most significant cancer gene in this region is MYC. It
is a well-documented oncogene codes for a transcription factor
that is believed to regulate the expression of 15% of all genes,
including genes involved in cell division, growth, and apoptosis
[38,39]. Other common imbalances observed in at least 25% of
oncogenomic arrays included gains of regions on e.g. 17q21 (29%),
1q21 (33%) and loss of regions on e.g. 8p23 (32%) and 9p21
(25%), including focal deletions of the CDKN2A/B locus
(Figure 2).
While the overall CNA frequency distribution points towards
DNA features targeted in multiple entities, this information is
insufficient for deriving molecular mechanisms associated with
specific cancer types. The genomic heterogeneity of different
neoplasias is reflected in the varying patterns of regional CNA
frequencies. Based on our core dataset, we have generated a
heatmap-style visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays (Figure S5). The striking
Figure 2. Zoom-in visualization of focal CNA. (A) GSM535547 (human high grade glioma, Agilent CGH 244A) shows high quality of probe
hybridization signal. CNAs are easy to distinguish. (B) When zoom-in the whole chromosome 9, an approximately 80 MB deletion is displayed, with
two breakpoints located in p and q arm respectively. In addition, a small regional deletion in 9p21 is quite clear. Color bars in lower region of the
panel represent 848 genes located in chromosome 9. (C) Zoom in the potential homozygously deleted region in 9p21 by specifying the exact region:
chr9:21600000-22400000. The zoomed-in plot shows probes, chromosome band and two tumor suppressor genes, MTAP and CDKN2A. Gene name
and location will be given while mouse hover. They link to UCSC genome browser with additional information.
doi:10.1371/journal.pone.0036944.g002
Figure 3. Copy number profiling of glioblastoma. (A) Chromosomal ideogram and histogram showing frequency of copy number aberrations.
Percentage values corresponding to gains (yellow) and losses (blue) identified over the whole dataset. The most frequent imbalances include gain of
chromosome 7 and loss of chromosome 10, 9p21.3. (B) Matrix plot of 1478 glioblastoma cases. The Y axis represents individual samples. The
distribution of genomic copy number imbalances reveals the individual aberration patterns of glioblastoma. (C) Heatmap of regional CNA frequencies
for 1478 arrays. The intensity of green and red color components correlates to the relative gain and loss frequencies, respectively. If dataset contains
cancer subtypes, cancers with similar CNA frequency profiles will be clustered together, such that differences between subtypes will be revealed (e.g.
see Figure S4H).
doi:10.1371/journal.pone.0036944.g003
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patterning of the CNA profiles indicates the non-random
occurrence of CNAs, and should be seen as an invitation to
explore e.g. CNA similarities shared by separate histopathological
entities, as a way to transpose knowledge about pathophysiological
mechanisms.
Discussion
arrayMap was developed to facilitate the progress of oncoge-
nomic research. Our aim is to provide high-quality genomic copy
number profiles of human tumors, along with a set of tools for
accessing and analyzing CNA data. The service has been
implemented with a straightforward web interface, including
search options for CNA features and clinical annotation data. All
assembled datasets are processed into platform independent
segmentation and, for the vast majority of arrays, probe level
data files, and are presented in consistent formats. Importantly, the
direct access to precomputed probe level data plots supports a
rapid evaluation of experiments for features of interest. As a
curated database using standardized annotation schemes (e.g. ICD
classification), arrayMap facilitates the exploration of cancer type
specific CNA data, as well as the statistical association of genomic
features to clinical parameters.
arrayMap is a dynamic database that is being continuously
expanded and improved. We will review the existing and newly
published articles to update the database periodically. Over the
past decade, we have witnessed a rapidly increasing number of
aCGH publications, which gives us sufficient evidences to
anticipate that cases in our database will continue to be deposited
at a high rate. Although arrayMap is not a user driven repository,
we welcome and support users interested in using the site for yet
undisclosed data, if they agree on data sharing upon publication.
Although, in contrast to the continuous data from expression
analysis, copy number analysis explores discrete value spaces
(countable number of DNA copies, for segments defined by
genomic base positions), interpretation of the data can vary due to
different low level (e.g. signal/background correction) and higher
level (e.g. segmentation algorithms, regional or size based filtering)
procedures. In that respect, we have to emphasize that the results
of our data processing and annotation procedures are open to
scrutiny. We encourage a critical review of individual results, and
are open for suggestions regarding improved processing proce-
dures for specific platforms.
In this paper, we have provided example scenarios of using
arrayMapondifferent levels, i.e. locus centric and for entityprofiling.
We believe that systematic analyses will help researchers to discover
features which are indiscernible in individual studies, and thus bring
new insights for understanding of disease pathology and the
development of new therapeutic approaches [40–43]. We expect
that researchers will integrate arrayMap datawith their own analysis
efforts, e.g. to increase sample size or for result verification purposes.
We hope that this database will promote further evolution of
microarray data meta-analysis. ArrayMap provides access to more
than 200 tumor types, which makes it suitable for research across
cancer entities. Furthermore, normal sample controls are of vital
importance for genomic imbalances studies. ArrayMap includes
more than 3000 normal samples from healthy individuals or from
normal tissues of cancer patients. These data could be integrated as
reference dataset e.g. to account for copy number variation data
superimposed on the tumor profiling results.
In the near future, with the continuous accumulation of very
high resolution CNA data from genomic arrays and next-
generation sequencing experiments, it will become possible to
integrate these data into systems biology methods to elucidate
effects of genomic instability, and describe the results from more
perspectives. Envisioned examples would be e.g. the identification
of genes that are involved in metastasis and treatment response;
identification of chromosomal breakpoints distribution in cancer;
and modeling functional networks in cancer by systems biology
approaches.
Methods
Dataset Collection
Raw experimental data from a variety of platforms and
repositories were extracted. They were converted to an uniform
format which is suited to our reanalysis and visualization system.
After a series of parsing procedures, the called copy number data is
stored in arrayMap. The flowchart of arrayMap data collection
and analysis is as shown in Figure 5. Five main data sources are
integrated into arrayMap:
GEO/AE. For extracting appropriate data Series from GEO/
AE, two basic criteria have to be fulfilled. First, the raw data has to
be from human malignancies analyzed by BAC, cDNA, aCGH or
oligonucleotide arrays. Second, the array platform must be
genome wide, with the optional omission of the sex chromosomes.
Figure 4. The overall cancer copy number aberration profile consisted of 29137 arrays. This plot represents 177 cancer types according to
ICD-O 3 code. Percentage values in Y axis corresponding to numbers of gains (green) and losses (red) account for the whole dataset.
doi:10.1371/journal.pone.0036944.g004
arrayMap: Genomic Copy Number Imbalances Cancer
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36944
Chromosome or region specific arrays were excluded because they
were not able to reveal the whole genomic profile of the respective
cancer. Associated clinical data was extracted if available.
TCGA. Segmentation data with available clinical information
was extracted and incorporated into the database. Due to data
sharing restrictions, TCGA data is an exception in that, so far no
probe level data is incorporated into arrayMap. This exception
Figure 5. The flowchart of arrayMap data collection and analysis procedures. Publicly available raw data or segmented data was collected
from the respective data sources. Files were re-processed by distinct procedures, according to the different data types. Probe coordinates were
remapped to the most commonly encountered human reference genome assembly (NCBI Build 36/hg18). All probe specific ratios were converted to
log2 values. Thresholds for genomic gain and loss were obtained from the original publications or series annotations; if not available, empirical
thresholds were assigned. A minimum of 2 probes was required for calling a CNA segment, with higher values used on high-density arrays and/or in
cases of excessive probe level noise. Processed probe and segment information was converted to uniform formats and stored in per-sample text files,
which are accessed through the arrayMap web applications.
doi:10.1371/journal.pone.0036944.g005
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was accepted since users will be able to access individual TCGA
datasets through the projects web portal at http://tcga-data.nci.
nih.gov/tcga/.
Publications. Many aCGH datasets can be found in the text
or supplementary files of publications. In order to collect data from
publications, we relied on our Progenetix projectO˜s setup. Data in
Progenetix is manually curated. The collection strategies are:
N literature mining using complex search parameters through
PubMed
N identification of called aCGH data, in GP annotation or
tabular format (article, supplementary tables)
N evaluation of supplementary files for probe specific data tables
N follow-up on article links outs, to repository entries or
referenced datasets
User submission. User submitted data was provided in a
number of formats which were converted to the standard format as
described. Although we accept and support private datasets, we
insist on integration of at least the genomic and core clinical data
(e.g. disease classifiers) upon publication of the datasets analysis
results.
Dataset Analysis
Probe remapping. A pipeline has been generated for
determining the genomic positions for the tens to hundreds of
thousands array probes with reference to a common genome
Golden Path edition. For each array platform, the genome
positions of probes were remapped to the current commonly used
version of the human reference genome assembly (NCBI Build
36.1/hg18). Specific mapping procedures were employed for
different types of probes. BAC clones were firstly remapped
according to the clone sets information of Sanger/DECIPHER
database [44]. If the probe position was not available, the UCSC
Genome annotation database [36] (release hg18) was used for
compensation. After these two steps, a mean of 98% of the BAC
clones were remapped. For IMAGE clone sets, only the UCSC
Genome annotation database was used. The average remapping
rate of IMAGE clones was 91%. Affymetrix raw CEL data files
were analyzed based on hg18 library files, namely the output
segments have hg18 coordinates. The summary of the percentage
of mapped probes is given in Table 3. The mapping details for
each platform can be found in the (Table S4).
Probe signal normalization. The array data available was
given in a variety of formats, most frequently as log2 ratio of probe
hybridization intensity. In order to make data from different
platforms directly comparable, all other types of normalized values
were converted to log2. For dye swap experiments, reference/
tumor intensity ratios data was ‘‘reversed’’ representing a tumor/
reference value. For some two-color arrays for which only raw
signal intensity were provided, the normalized log2 ratio for each
probe was calculated by.
r~ log 2 Ts{Tbð Þ=Rs{Rbð Þ:
where Ts and Tb represent tumor sample intensity and tumor
channel background intensity respectively, and Rs and Rb
represent reference sample intensity and reference channel
background intensity respectively. If multiple instances of the
same clone exist, the average signal intensity of the certain clone
was considered.
To call gains and losses according to normalized log2 ratio is an
important step to identify copy number imbalances. For each re-
analyzable dataset, related publications were explored to obtain
original threshold descriptions. If this information was not
available, empirical thresholds were assigned and resulting CNA
calls were visually compared with probe value plots. Processing
method and threshold information for each array are provided in
the Table S5.
Affymetrix genotyping arrays. For the widely used Affy-
metrix GenomeWide SNP arrays, raw CEL files were downloaded
and underwent a massive re-analysis using the R package
aroma.affymetrix [45] with the CRMAv.2 method [46]. During
the processing step, approximately 50 normal sample arrays were
employed as a reference set for each array type to reduce the noise
level. Normal tissue arrays from different labs were extracted and
used to build the reference dataset. In order to obtain high quality
arrays, we excluded arrays which contain segments greater than 3
mega-bases, since copy number variations are always smaller than
3 mega-bases. The list of normal tissue reference arrays is giving in
Table S6.
Quality control. In our review of array data deposited in
GEO or collected from publication supplements we encountered a
large number of individual data sets with insufficient or limited
probe quality. Also, for samples of unprocessed raw data (e.g.
Affymetrix CEL files), we found that QC measures reported
previously (e.g. call rate [47], NUSE [48], RLE [48]) only had a
limited accuracy for detection of arrays with inadequate probe
level data. Currently, the most viable strategy for quality
assessment of processed, heterogeneous copy number arrays is
the visual inspection of probe plotting and segmentation results
through an experienced researcher. For the first arrayMap edition
we generated a quality classification system, which contains a total
of 4 categories based on inspections of genome-wide array plots:
N Excellent. Probe signal distribution is significantly different
between normal regions and imbalance regions. Signal
baseline is distinct and unique, making segmentation threshold
realistic appearing. Chromosomal changes are pretty clear.
N Good. In general good quality. Probe signal may contain some
noise, but tolerable. Chromosomal changes are distinguish-
able.
Table 3. Percentage of remapped probes according to platform types.
Platform type Average mapping rate Number of arrays Number of GPLs
Original HG18 (Build 36) NA 1583 40
in situ oligonucleotide 99% 21678 55
BAC/P1 98% 5464 55
spotted DNA/cDNA 91% 2365 82
doi:10.1371/journal.pone.0036944.t003
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N Hypersegmented. Serrated distribution of probe signal inten-
sities, causing dozens of separate peaks and discontinuous
segments. Chromosomal changes are always up to several
hundreds and smaller than 5 mega-bases.
N Noisy. Probe signal intensities are highly scattered, but well-
distributed, with high standard deviation, resulting in the
inability to differentiate copy number changes.
Depending on the intended research purpose this basic
classification system can be used for a pre-analysis triage of copy
number data. Applying stringent review criteria we identified a
core dataset with ‘‘excellent’’ quality arrays accounting for
approximately 60 percent of total arrays. We are currently
working on a platform independent quality assessment system for
genomic arrays, which will be implemented in future versions of
the arrayMap resource.
Associated data. For arrayMap, data is stored with separate
datasets for each array. This is in contrast to the Progenetix
database, for which technical replicates where available are
combined into case specific CNA profiles. In arrayMap, technical
replicates are assigned an identical case identifier to facilitate
downstream statistical procedures including e.g. clinical data
correlations. The assignment of the correct diagnostic entity to
each sample is an essential step in generating a binding between
genomic and associated data points. At the same time, to ensure
annotation consistency and make the retrieval process more
efficient, for all CNA profiles the following data points were
manually collected from GEO/ArrayExpress and published
papers if available.
N Descriptive diagnostic text, as available through the original
source
N Diagnostic classification according to the International Clas-
sification of Diseases in Oncology (ICDO 3, morphology with
code)
N Tumor locus according to ICD (ICD topography with code)
N Source of material (e.g. primary tumor, cell line, metastasis)
N Clinical parameters where available, including age, gender,
grade, clinical stage (TNM coded), recurrence/progression,
time to recurrence/progression, death and followup
Web Server. An online interface of arrayMap database was
created using Perl common gateway interface (CGI) and R scripts
running on Mac OS X Server. Sample and series data is stored
using a MongoDB database eingine (http://www.mongodb.org).
Precomputed array plots are stored as flat files, mostly in both
SVG and PNG versions. The online release of the service has been
optimized to be compatible with major browsers supporting
current web standards (CSS2, HTML5, XML with inline SVG;
e.g. Safari .=3.0, Firefox .=3.0, InternetExplorer .=9,
Google Chrome) with limited fallback support. Dynamic graphics
provided in the array plot module were implemented as server side
services by technologies including XML/XHTML, JavaScript,
SVG and HTML5 Canvas.
For the future, we intend a quarterly database content revision
to ensure inclusion of newly published articles and GEO/AE
entries. Archived versions of the sample annotations will be made
available upon special request. Additional feature and small data
updates will be performed as seen necessary. The ‘‘News’’ page of
Progenetix/arrayMap will be used for feature and content
announcements.
Supporting Information
Figure S1 Array data sets visualization. Original plots and
optimized parameters for GSE21530 which contains 8 intimal
sarcoma samples hybridized on Agilent CGH Microarray 244A
platform. The normalized probe signal log2 ratios and post-
thresholding segmentation results for each array are intuitively
displayed. Genomic alterations are represented by horizontal
green (gain) and red (loss) lines. Alterations defined here as regions
with log2 ratio .0.15 or ,20.15. Simplified schemas of CNAs
link to UCSC genome browser for further review.
(PDF)
Figure S2 Screenshot of single array visualization.
ArrayMap plots for GSM630977 (acute myelogenous leukemia).
Besides the whole genome view, subviews of each chromosome are
displayed as well. From these plots, different kinds of genetic
variation events are clearly revealed, e.g. massive genomic
rearrangement in chromosome 6; arm-level gain of chromosome
8q and 3MB focal change around 1p31.3. Through the ‘‘Plot
Array Data’’ interface, users can segment the raw data values and
re-plot the results with customized parameters.
(PDF)
Figure S3 Plot single genomic region. In the ‘‘Plot Array
Data’’ interface, input the precise location (chr5:1100000-
1400000) in ‘‘Plot Region’’ field. Plots with this region were
generated for all 8 arrays in the current series (GSE21530). In this
region, there are 5 genes which are shown schematically as colored
boxes. CNA status and copy number transition points for these
genes are displayed.
(PDF)
Figure S4 Compound CNA query. (A) Four gene loci
associated with glioblastoma (EGFR, PTEN, ASPM and
CDKN2A) were inserted into ‘‘Match (Multiple) Regions &
Types’’ field. 303 out of 42421 arrays were returned. (B)
Classification information of these 303 arrays were displayed
and can be selected for the following analysis. (C) Statistical and
plot parameters can be customized. Associated data was processed
by online tools, and returned results included: (D) Chromosomal
ideogram and (E) histogram, show frequency of copy number
aberrations; (F) Matrix plot reveals the aberration pattern of
selected arrays; (G) Array classification tree generated by
hierarchical Ward clustering, arrays with similar frequency of
CNA are part of the tree branch. (H) Heatmap of CNA
frequencies clustered by clinical group.
(PDF)
Figure S5 Heatmap of frequency profiles for 59 cancer
types. Heatmap visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays in our core dataset. Region
specific gain/loss frequencies were mapped to 1MB intervals. The
intensity of colors (green: gains; losses: red) corresponds to the
relative frequency of CNAs for each interval.
(PDF)
Table S1 Entities extracted from NCBI GEO and EBI
ArrayExpress.
(XLS)
Table S2 Cancer entities grouped by ICD-O code.
(XLS)
Table S3 Platform type distribution in arrayMap.
(XLS)
Table S4 Probe remapping rate for platforms.
(XLS)
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Table S5 Processing method and threshold for calling
genomic gains and losses.
(XLS)
Table S6 Normal tissue reference arrays for Affymetrix
platforms.
(XLS)
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5 THE RELATIONSHIP BETWEEN COPY NUMBER 
ABERRATIONS AND FUNDAMENTAL GENOME STRUCTURE
5.1 PREFACE
DNA copy number aberrations are found in almost all solid tumors and contribute to tumor 
progression3. The segment size may range from the entire chromosome arm to less than 
100 kb. Recent cytogenetic studies revealed the heterogeneity  of neoplasia-associated 
chromosomal aberrations3. There is a hypothesis that the variable extent of CNA would 
tend to indicate different pathways taken by  individual tumors during the course of their 
genetic evolution45. In this way, the profiling of copy number alterations is likely to reflect a 
series of non-neutral selection procedures in cancer genome. Several studies have 
performed large-scale aCGH data analyses on a wide range of cancer types, focused on 
detecting “driver” mutations from recurrent CNAs, which may point to tumor suppressors 
and oncogenes82. However, little is known about specific gene defects that give rise to 
chromosomal alterations in tumors. CNA hotspots encompass hundreds of gene loci, far 
beyond the involvement of a limited set of strong “cancer driver” genes. Moreover, even 
such “regions of interest” are usually highly discordant in different studies of the same 
tumor type. Apart from recurrent CNAs, sporadic gains and losses can occur throughout 
the genome. As a result of genomic instability, these changes may also have an effect on 
tumor progression, rather than just “byproducts”.
As we know, human genome has a complex structure, and it is exemplified by the non-
uniform distribution of genes, both within and between chromosomes194. The clustering of 
genes in the genome, known as gene-rich region, has been taken into account in the array 
probe design. The fundamental aspects of human genome organization are likely to have 
important implications for understanding the non-neutral selection of CNA regions. 
However, the relationship  between CNAs and the pattern of gene distribution has so far 
not been systematically  investigated. The rapid accumulation of oncogenomic data in our 
arrayMap database enables me to examine this question in detail.
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5.2 CNA ENRICHED IN GENE-RICH REGIONS
For this research project, to explore the possible correlation between CNAs and local gene 
density across the genome, I collected 16,264 copy number profiles of 62 diagnostic 
groups from arrayMap. These data represent 19,471 high quality arrays, and were 
collected from 3 public resources, including GEO, ArrayExpress and supplemental 
materials of publications. Among the arrays, 14,837 samples came from 28 diagnostic 
groups, each represented by more than 100 specimens. There are a total of 298,904 gains 
and 307,414 losses, for an average of 18 gains and 19 losses per sample.
In my strategy to investigate the possible non-neutral selection for CNAs in cancer, the 
genome was firstly divided into 10 Mb  non-overlapping intervals, then the number of genes 
within each interval was counted. The definition of gene-rich region here is the genomic 
intervals that contain twice as many as the average 73 genes in 10 Mb  intervals. 
Subsequently, I determined the number of samples that exhibit CNAs in each interval, and 
considered genomic gains and losses respectively. Since many CNAs encompass 
thousands of gene loci, far beyond the size of interval, only focal CNAs were considered, 
which were defined here as being smaller than 5 Mb. I found that focal genomic gains 
were significantly positively correlated with gene-rich regions. To evaluate whether the 
observed correlation could be obtained by chance, I randomly shuffled the number of 
genes in intervals across the genome, and calculated the correlation coefficient. I repeated 
this permutation 10,000 times and the p-value is significant. I also observed a positive 
correlation between focal genomic losses and gene-rich regions.
To determine the correlation at different interval sizes (5 Mb  and 15 Mb) and CNA sizes 
(smaller than 2 Mb  and 10 Mb), I followed the method described above, i.e. I identified 5 
Mb (or 15 Mb) non-overlapping intervals tiling the genome. For each such interval, I 
counted the number of genes and samples present focal CNAs (smaller than 2 Mb or 10 
Mb). For each combination of these parameters, I found that focal CNAs were significantly 
enriched in gene-rich regions. To explore whether this positive correlation was only driven 
by cancer genes, I downloaded the catalogue of cancer gene from COSMIC database and 
excluded all intervals that contain cancer genes. After this step, the positive correlation 
was still observed. This suggests that the correlation is probably genuine.
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For the correlation between CNA breakpoints and gene density, I again divided the 
genome into 1 Mb non-overlapping intervals and counted the number of breakpoints within 
each interval. The breakpoints, like CNAs, were also organized in hotspots across the 
genome. I found that breakpoints were positively  correlated with gene-rich regions. 
Furthermore, this observation was independent of the size of intervals. These data 
indicated that the highly variable genomic regions were largely correlated with gene 
density across the entire genome.
In order to control the robustness of these results, several robustness checks were 
performed. For example, centromeres and telomeres are often substrates for 
rearrangements that are associated with structural genomic alterations in cancer and were 
excluded. Moreover, centromeres and telomeres are also common outliers of CNA 
breakpoints. For breakpoint analysis, I excluded all 1 Mb  intervals that extended to 
centromeres and telomeres of each chromosome. As expected, CNA breakpoints were 
enriched in gene-rich regions after robustness control steps. Since the input data set is 
composed of genomic profiles from 180 array platforms, I divided these platforms into 3 
groups according to their probe numbers and techniques (BAC/P1 and DNA/cDNA, 
oligonucleotide ≧ 200K and oligonucleotide < 200K). I repeated the correlation analysis on 
each of these platform groups, and found the same trend: the focal CNAs were 
significantly enriched in gene-rich regions. Therefore, the conclusions are not biased by 
the resolution of platforms. As for cancer types, cancer type specific analysis were 
performed. Six clinical groups that each has more than 650 samples were selected and all 
indicated a similar positive correlation between focal CNAs and gene-rich region. Thus, 
these observations were free of bias by using data from multiple cancer types. The non-
neutral selection of small CNAs may be a recurring feature of cancer genome evolution. 
Overall, these results present the landscape of copy number changes in cancer, as well as 
its correlation with the fundamental genome structure, promote a basic understanding of 
human cancer.
The manuscript is included below.
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Abstract
Copy number aberrations (CNAs) are a hallmark of cancer genomes. Recurrent CNA 
hotspots are known to target well defined cancer genes. However, the average extent of 
CNA encompasses thousands of gene loci, far beyond the involvement of a limited set of 
strong “cancer driver” genes. To explore indications for a non-neutral selection for CNA 
regions, we analyzed a possible relationship  between CNA occurrence and local gene 
density across the genome. We performed a genome-wide analysis of 606,318 somatic 
CNAs from 16,264 cancer samples, classified into 62 diagnostic groups. We observed a 
significant enrichment for small and extended localized CNA in gene-rich regions, both in 
terms of gene numbers and coding regions. The 1,212,636 DNA breakpoints that were 
associated with the CNA also showed a positive correlation with gene-rich regions. 
However, the frequency of arm-level CNA was negatively correlated with gene numbers on 
chromosome arms. Notably, when investigating cancer and platform type specific data, we 
got similar results. The landscape of cancer genomes revealed a global correlation 
between CNA and genome structure, and provides support for a non-neutral selection of 
multiple and/or extended CNA as recurring feature of cancer genome evolution.
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Introduction
Genomic DNA copy number aberrations are commonly found in solid tumors, and 
contribute to tumor genesis and development. The size of these alterations may  range 
from entire chromosome arm to less than 100 kb. The heterogeneity  of neoplasia-
associated chromosomal aberrations was comprehensively demonstrated by cytogenetic 
studies. The variable extent of CNA would tend to indicate different pathways taken by 
individual tumors during the course of their genetic evolution. Thus, the profiling of copy 
number alterations is likely to reflect a series of non-neutral selection procedures in cancer 
genome.
During the last decade, array  comparative genomic hybridization (aCGH) and SNP arrays 
have been extensively employed to detect genome-wide copy number changes in cancer. 
The value of these techniques is further illustrated by recent studies in which CNAs were 
used for tumor subtype classification and cancer gene screening. In particular, several 
studies performed large-scale aCGH data analyses on a wide range of cancer types, 
provided striking new insights into human cancers. So far, many efforts have been focused 
on detecting “driver” mutations from recurrent CNAs, which may point to tumor 
suppressors and oncogenes. However, little is known about specific gene defects that give 
rise to chromosomal alterations in tumors. CNA hotspots encompass hundreds of gene 
loci, far beyond the involvement of a limited set of strong “cancer driver” genes. Moreover, 
even such “regions of interest” are usually highly discordant in different studies of the 
same tumor type. Apart from recurrent CNAs, sporadic gains and losses can occur 
throughout the genome. As a result of genomic instability, these changes may  also have 
an effect on tumor progression, rather than just “byproducts”.
The complexity  of human genome structure is exemplified by the non-uniform distribution 
of genes, both within and between chromosomes. The clustering of genes in the genome, 
known as gene-rich region, has been taken into account in the array probe design. The 
fundamental aspects of human genome organization are likely to have important 
implications for understanding the non-neutral selection of CNA regions. However, the 
relationship  between CNAs and the pattern of gene distribution has so far not been 
systematically  investigated. The rapid accumulation of oncogenomic data resulted in the 
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development of several online resources. These data enable us to examine the above 
question in detail.
In this study, to explore the possible correlation between CNAs and local gene density 
across the genome, we collected 16,264 publicly available copy number profiles of 62 
diagnostic groups. We observed that small and extended localized CNAs were significantly 
enriched in gene-rich regions, either in terms of gene numbers or the fraction of coding 
regions. Furthermore, DNA breakpoints that occurred during chromosomal rearrangement 
also showed enrichment over gene-rich regions. Notably, these observations were free of 
bias by using data from multiple cancer types and array platforms. We propose that the 
non-neutral selection of small CNAs is a recurring feature of cancer genome evolution. 
Overall, our results present the landscape of copy number changes in cancer, as well as 
its correlation with the fundamental genome structure, promote a basic understanding of 
human cancer.
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Results
A collection of copy number profiles from 19,471 cancer genomes
Our cancer copy number profiles were obtained from arrayMap database, a repository  for 
annotated oncogenomic array  data. The 19,471 high quality arrays were collected from 3 
public resources, including NCBI Gene Expression Omnibus (GEO), EBI ArrayExpress 
and supplemental materials of publications, mostly  from GEO. For the whole data set, 
~97% samples are primary tumors, with the remainder cell lines, metastasis or relapse. 
After removing technical repeats (e.g. different platforms for one sample), a total of 16,264 
samples from 390 studies were left. Among the rest, 14,837 samples came from 28 
diagnostic groups, each represented by more than 100 specimens. The summary and 
details of input data set are listed in Supplementary Table 1 and 2, respectively. In our 
data set, we observed a total of 298,904 gains and 307,414 losses, for an average of 18 
gains and 19 losses per sample. In general, hematological malignancies showed less 
CNAs than epithelial carcinomas. The distribution of sample and CNA number across 
major cancer types are shown in Figure 1a. 
Figure 1. The distribution of somatic CNAs in cancer genomes. (a) Bar graph of input sample number 
(grey) and average number of genomic gains (red) and losses (blue) per case. Each cancer type is 
represented by more than 100 samples. The dashed line indicates the average number of the entire dataset. 
(b) Somatic CNA densities over 1-Mb non-overlapping windows across each of the 22 autosomes calculated 
by 16,264 cancer samples.
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The rearrangement structure of cancer genome based on the total of 606,318 CNAs 
revealed a number of hotspots (Figure 1b). Although these hotspots probably  point 
towards oncogenes or tumor suppressor genes, most CNAs span hundreds of kilo-bases 
containing multiple genes. Thus, a potential correlation may exist between CNA regions 
and the fundamental genome structure, which is important for tumorigenesis or the 
evolution of cancer genome.
Focal CNAs are enriched in gene-rich regions
In order to investigate the possible non-neutral selection for CNAs in cancer, we first 
divided the genome into 10 Mb non-overlapping intervals and counted the number of 
genes within each interval. We found that about 10% of the 248 genomic intervals contain 
twice as many as the average 73 genes in 10 Mb  intervals. These intervals can be 
considered as gene-rich regions. To assess whether CNA hotspots are associated with 
gene-rich regions, we determined the number of samples that exhibit CNAs in each 
interval, and considered genomic gains and losses respectively. Since many CNAs 
encompass thousands of gene loci, far beyond the size of interval, we confined ourselves 
to focal CNAs, which were defined here as being smaller than 5 Mb. We found that focal 
genomic gains were significantly  positively  correlated with gene-rich regions (R = 0.562; 
Spearman correlation). To evaluate whether the observed correlation could be obtained by 
chance, we randomly shuffled the number of genes in intervals across the genome, and 
calculated the correlation coefficient. We repeated this permutation 10,000 times and the 
P-value < 0.0001. We also observed a positive correlation between focal genomic losses 
and gene-rich regions (R = 0.342; P-value <  0.0001; Spearman correlation).
We subsequently determined the correlation at different interval sizes (5 Mb and 15 Mb) 
and CNA sizes (smaller than 2 Mb  and 10 Mb). We followed the method described above - 
i.e., we identified 5 Mb  (or 15 Mb) non-overlapping intervals tiling the genome. For each 
such interval, we counted the number of genes and samples present focal CNAs (smaller 
than 2 Mb or 10 Mb). As above, we investigated genomic gains and losses respectively. 
For each combination of these parameters, we found that focal CNAs were significantly 
enriched in gene-rich regions (Figure 2). In general, genomic losses exhibited slightly 
reduced correlation coefficients compared with genomic gains.
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Figure 2. The correlation coefficients between gene density  and focal CNA frequency across the 
genome. (a) Genomic gains. Each point represents a genomic interval. The combination of two parameters, 
interval size and definition of focal CNA, was considered for calculating Spearman correlation coefficient. 
The P-value is based on 10,000 times permutation. (b) Genomic losses.
Furthermore, genomic regions with high frequency of chromosomal aberrations are likely 
to contain “driver” mutations, also known as cancer genes. The sporadic CNA regions are 
usually called “passengers”, which represent random somatic events. To explore whether 
this positive correlation was only driven by cancer genes, we downloaded the catalogue of 
cancer gene from COSMIC  database, which so far contains 448 annotated cancer genes. 
The positive association remained even after we excluded all intervals that contain cancer 
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genes (Supplementary Figure 1). These findings suggest that the correlation between 
CNAs and gene-rich regions is probably genuine.
Since genes are in various sizes, one might expect that coding regions of each interval 
may better represent functionally important areas. We then performed our analysis based 
on coding region of intervals instead of gene numbers. The sum of genomic lengths of 
genes in each interval was calculated. Indeed, similar positive correlations were found 
between CNA occurrence and coding regions (Supplementary Figure 2). Although the 
correlation was slightly weaker than the condition of gene numbers, it provided similar 
results from a different angle.
CNA breakpoints are enriched in gene-rich regions
We obtained 1,212,636 CNA breakpoints from the 16,264 cancer genomes. In order to 
identify the genome-wide distribution of breakpoints, we again divided the genome into 1 
Mb non-overlapping intervals and counted the number of breakpoints within each interval. 
The breakpoints, like CNAs, were also organized in hotspots across the genome (Figure 
3a). We zoomed in two regions with high and low breakpoint frequencies, respectively, and 
overlaid genes and their corresponding genomic locations (Figure 3b). We found that, of 
these two regions, the breakpoint hotspot seemed to harbor more genes than the other 
breakpoint-poor region. This observation led us to investigate the correlation between 
CNA breakpoints and gene density on a genome-wide scale. We found that breakpoints 
were positively correlated with gene-rich regions. Furthermore, our observation was 
independent of the size of intervals. As most CNAs are much larger than 1 Mb, we 
performed the analysis with 3 Mb, 5Mb, 10Mb and 15Mb intervals (Figure 3c).
The correlation of CNAs, breakpoints and gene-rich regions across the whole genome was 
graphically exhibited by  a Circos map (Figure 4). The profile of focal CNAs that smaller 
than 5 Mb and histogram of breakpoints in 3 Mb  intervals were plotted. Clusters of CNAs, 
breakpoints and genes could be clearly observed in specific regions. These data indicated 
that the highly  variable genomic regions were largely correlated with gene density across 
the entire genome.
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Figure 3. The distribution of DNA breakpoints and its correlation with gene density  in cancer 
genomes. (a) DNA breakpoint densities calculated over 1-Mb  non-overlapping windows across the 22 
autosomes. Dashed lines indicate centromeres. (b) Two zoomed-in genomic regions represent that high and 
low breakpoint frequency region overlay gene-rich and gene-poor region, respectively. The colored boxes on 
x-axis illustrate genes with respect to their sizes and relative positions in the genome. (c) Spearman 
correlation coefficients between breakpoints and gene density at different genomic intervals.
Arm-level CNAs are negatively correlated with the number of genes covered
Copy number aberrations are frequently classified into “focal” and “arm-level” according to 
their lengths. Compared to focal alterations, arm-level CNAs are large events involving an 
entire chromosome arm and cover hundreds of genes. These two types of aberrations 
might arise through different mechanisms during cancer development. Arm-level CNAs are 
constantly filtered out when identifying “driver” mutations from CNA hotspots. However, the 
occurrence and number of whole chromosome arm alteration events are important in 
specific cancer subtype classification, and may reveal clinical implication. In our study, 
arm-level CNAs were defined as those with an extension longer than 80% of the 
respective chromosome arm. Consistent with previous reports, the frequency and 
distribution of arm-level CNAs identified in our data set were negatively correlated with the 
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number of genes on related arm (Figure 5). In addition, we investigated tumor type 
specificity of arm-level CNAs. We explored data from 6 tumor types that each has more 
than 650 samples. In general, the trends of negative correlation were observed in all 
studied cancer types (Supplementary Figure 3). Although the biological significance of 
this trend is unclear, one possible explanation is that these large events disturb  more 
genes and undergo additional negative selective pressure.
Figure 4. Circular representation of gene density  and genomic instability  region across the whole 
genome. Chromosome ideograms are oriented from p-arm to q-arm in a clockwise direction, while 
centromeres are shown in red (outer circle). The frequency of focal CNA that are smaller than 5 Mb  is plotted 
with gains in yellow and losses in blue (second circle; ranges from 0 to 900 samples). The enrichment 
between focal CNA and gene density is shown in gradually changing orange per 1 Mb  interval (third circle). 
The histogram of DNA breakpoints is depicted in non-overlapping 1 Mb  intervals (fourth circle; ranges from 0 
to 2000). The enrichment between breakpoints and gene density is shown in gradually changing green per 1 
Mb interval (fifth circle). Gene density across the genome is shown by gradually changing black per 1 Mb 
interval (sixth circle). The 448 COSMIC cancer genes are represented by gradually changing red per 1 Mb in 
the innermost circle. All genomic locations are based on the human reference genome UCSC build hg18.
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Figure 5. The frequency  of arm-level CNAs is negatively  correlated with chromosome size. The red 
line indicates a linear fit to the data. The correlation coefficient is based on Spearman correlation.
Control for robustness of results
In order to control the robustness of our results, we performed several robustness checks. 
First, centromeres and telomeres are often substrates for rearrangements that are 
associated with structural genomic alterations in cancer. Therefore, we excluded 1 Mb 
genomic intervals that overlap with centromeres and telomeres of each chromosome. We 
then repeated our analysis to determine whether focal CNAs and gene-rich regions were 
still positively correlated. We found that even after excluding the centromeric and telomeric 
intervals, both genomic gains and losses were significantly enriched in the gene-rich 
regions (Figure 6a,b). We performed the same method on coding region of intervals, and 
found that the remaining intervals also exhibited positive correlations (data not shown). 
Therefore, our observations are not biased by including centromeric and telomeric regions.
Moreover, centromeres and telomeres are also common outliers of CNA breakpoints. For 
breakpoint analysis, we again excluded all 1 Mb intervals that extended to centromeres 
and telomeres of each chromosome. As expected, CNA breakpoints were enriched in 
gene-rich regions at all the 4 analyzed interval sizes (data not shown).
Since our data set is composed of genomic profiles from 180 array platforms, the 
definitions of focal CNAs according to segment sizes may have potential platform biases. 
The resolution of a platform depends on the density of probes on the array. To obtain the 
distribution of segment size in different platforms, we divided these platforms into 3 groups 
according to their probe numbers and techniques (BAC/P1 and DNA/cDNA, 
oligonucleotide ≧ 200K and oligonucleotide < 200K). Figure 6c shows the density  plot of 
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segment size in each platform group, as well as our definitions of focal CNAs in above 
analysis. Among the 3 groups, “oligonucleotide ≧ 200K” showed relatively smaller size of 
alterations compared to other groups. This may be due to the higher sensitivity with 
increased probe numbers of these platforms. We repeated the correlation analysis on 
each of these platform groups, and found the same trend: the focal CNAs were 
significantly enriched in gene-rich regions (Supplementary Table 3). Therefore, our 
conclusions are not biased by the resolution of platforms.
As our somatic CNAs were derived from various cancer types, we then performed cancer 
type specific analysis. We focused on 6 clinical groups that each has more than 650 
samples in our data set. All these cancer types indicated a similar positive correlation 
between focal CNAs and gene-rich region (Supplementary Table 4). In general, genomic 
losses showed weaker correlations compared to genomic gains. Moreover, the 
significance of correlations were distinct in different cancer types. It may caused by the 
inherit features of specific cancers, such as segment size and complexity of genome-wide 
copy number profiles. Taken together, our data indicate that genomic instability regions are 
enriched in gene-rich regions across the whole genome.
Figure 6. Robustness checks of results. a-b, Correlations after removing telomere and centromere 
regions calculated by genomic gains (a) and losses (b). (c) Density plot of CNA size across 3 different 
platform groups. The dashed lines represent definitions of focal CNA that are used in the main text (2 Mb, 5 
Mb and 10 Mb).
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Discussion
Here we have presented that both genes and CNAs are often clustered into hotspots, and 
have explored the underlying correlation between gene distribution and copy number 
alteration profiles across cancer genomes. To achieve this, we collected more than 16,000 
cancer samples from 3 public resources of microarray data sets. Notably, focal CNAs were 
significantly enriched in gene-rich regions. As another manifestation of genome instability, 
DNA breakpoints also followed this trend. It provided us a global insight into the 
relationship  between cancer genome instability  and structure from a new perspective. The 
enrichment revealed that there is a non-neutral selection pressure for CNA regions across 
the genome. Due to observed heterogeneity of CNAs in cancer genomes, individual tumor 
probably follow a distinct path towards tumorigenesis. Many genes in CNAs may lose their 
functions or take on new roles to promote clone expansion. Genome instability  could 
generate enough variation on which these non-neutral selection events can operate during 
tumor evolution. A full understanding of how these events contribute to specific tumor will 
require further studies to investigate the differential expression of genes in CNA regions.
A negative correlation between arm-level CNAs and the size of arms was observed from 
the entire data set, consistent with previous studies. To further confirm the negative 
correlation with tumor specific data, we looked into arm-level CNAs of 6 cancer types. The 
underlying mechanism for this observation is unknown. It may reveal additional negative 
selective pressure on gene-rich arms, or inherent low arm-level CNA ratios of these arms.
To avoid bias, we performed cancer type and platform specific analysis across the entire 
dataset. Generally, focal CNAs in most cancers presented enrichment in gene-rich 
regions, although the extent of enrichment was a little bit different. A couple of cancers, 
such as hematological malignancies, presented an inherent low-level of copy number 
changes, especially of focal CNAs. Accordingly, these cancers showed relatively low 
correlation coefficients. Moreover, our data set was generated from 180 array platforms 
with various resolutions. Due to increased probe numbers, high resolution platforms are 
more sensitive to small copy number changes, thus usually show a substantially higher 
number of alterations. Therefore, compared to low resolution platforms, a higher proportion 
of segments that derived from high resolution arrays fitted our definitions of focal CNAs. 
For example, in the definition of 5 Mb, we got ~52% segments of BAC/P1 and DNA/cDNA 
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arrays, while this number increased to ~80% in oligonucleotide arrays that contain more 
than 200K probes. Nevertheless, this did not affect the consequence.
In conclusion, through large-scale oncogenomic array data analysis, our results revealed a 
significant positive correlation between genomic instability regions and gene distribution in 
cancer genomes. It may enable a better elucidation of mechanisms by which CNAs 
contribute to tumor development, and eventually  promote a more systematic 
understanding of human cancer.
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Methods
Data sets of cancer genome
We collected annotated human cancer genome data from arrayMap database, including 
the normalized probe intensities, segmented data and quality information. These 19,471 
arrays were generated from 390 studies from 3 publicly available data sources, including 
NCBI GEO, EBI ArrayExpress and supplemental materials of publications. In this study, all 
collected arrays were high quality genome-wide human cancer samples. In the case of 
technical repeats, such as different platforms for one sample, only one of the arrays was 
considered for analysis (preferably with the highest resolution and/or best overall quality). 
After this filtering process, 16,264 samples were left in total. These data were generated 
by 180 platforms with various techniques, resolutions and probe lengths. Detailed 
information for the input samples and classification of platforms are shown in 
Supplementary Table 2.
Data processing
For Affymetrix arrays, the aroma.affymetrix R package was employed to generate log2 
scale probe level data from original CEL files. For non-Affymetrix arrays, available probe 
intensity files were downloaded from GEO or ArrayExpress and processed. For 
supplemental materials of publications, all the probe-level log2 ratio profiles or segmented 
data were converted to an unique format and stored into database. Segmentation was 
performed by the CBS (Circular Binary Segmentation) algorithm. The thresholds for calling 
genomic gains and losses were obtained from publication of individual study, or if it is not 
available, empirically assigned. In our study, the boundaries of CNAs were defined as 
breakpoints. The probe locations were mapped on the human reference genome (UCSC 
build hg18). The processed array profiles can be visualized and downloaded through the 
arrayMap website (www.arraymap.org).
Ensembl gene and cancer gene
We downloaded the Ensembl gene list from Biomart (release 54). This gene list was 
processed to obtain genes with unique combination of Ensembl gene identifier (Ensembl 
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id) and start/end positions in the genome. Mitochondrial and sex chromosomal genes were 
removed, and resulting in a total of 20,207 genes (Supplementary Table 5).
The catalogue of cancer gene was obtained from the COSMIC database (v61 release). 
The gene positions were converted from gene symbols by UCSC Genome Browser (397 
genes) or from Entrez gene IDs by NCBI Gene (51 genes). In total, we got 448 cancer 
genes (Supplementary Table 6). All mapped genomic locations of Ensembl and COSMIC 
cancer genes were based on UCSC build hg18.
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Supplementary Figures
Supplementary Figure 1. The correlation coefficients between gene density and 
focal CNA frequency among intervals without cancer gene. Each point represents a 
genomic interval that without COSMIC cancer gene. Genomic gains (a) and losses (b) 
were considered separately. The coefficient was calculated by Spearman correlation. The 
P-value is based on 10,000 times permutation.
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Supplementary Figure 2. The correlation coefficients between gene density and 
focal CNA frequency in terms of coding region. Each point represents a genomic 
interval. For each interval, the fraction of coding region was obtained. Genomic gains (a) 
and losses (b) were considered separately. The coefficient was calculated by Spearman 
correlation. The P-value is based on 10,000 times permutation.
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Supplementary Figure 3. The negative correlation between frequency of arm-level 
CNAs and chromosome size among different cancer types.  Each cancer type is 
represented by more than 650 samples. Red lines indicate linear fits to the data. The 
correlation coefficient is based on Spearman correlation.
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Supplementary Tables
Supplementary Table 1. Overview of input data set
Category Array-level Case-level
Total number 19471 16264
Series 390 390
Platform 184 180
Cancer type (ICD-O) 135 135
Cancer type (diagnostic group) 62 62
Source (primary) 17043 14340
Source (cell line) 2085 1604
Supplementary Table 3. Platform type specific enrichment
Gain Loss
Focal CNA size 2 Mb 5 Mb 10 Mb 2 Mb 5 Mb 10 Mb
Platform type Interval size R P R P R P R P R P R P
BAC/P1 and 
DNA/cDNA
5 Mb 0.63 < 0.0001 0.614 < 0.0001 0.566 < 0.0001 0.497 < 0.0001 0.497 < 0.0001 0.45 < 0.0001
10 Mb 0.689 < 0.0001 0.688 < 0.0001 0.659 < 0.0001 0.551 < 0.0001 0.56 < 0.0001 0.533 < 0.0001
15 Mb 0.693 < 0.0001 0.681 < 0.0001 0.657 < 0.0001 0.594 < 0.0001 0.592 < 0.0001 0.566 < 0.0001
Oligonucleotide 
< 200K
5 Mb 0.35 < 0.0001 0.351 < 0.0001 0.372 < 0.0001 0.2 < 0.0001 0.197 < 0.0001 0.108 0.0061
10 Mb 0.402 < 0.0001 0.399 < 0.0001 0.417 < 0.0001 0.222 0.0001 0.252 0.0001 0.19 0.0009
15 Mb 0.386 0.0001 0.377 < 0.0001 0.351 < 0.0001 0.285 0.0003 0.29 0.0001 0.192 0.0079
Oligonucleotide 
≥ 200K
5 Mb 0.536 < 0.0001 0.521 < 0.0001 0.498 < 0.0001 0.21 < 0.0001 0.248 < 0.0001 0.238 < 0.0001
10 Mb 0.583 < 0.0001 0.581 < 0.0001 0.572 < 0.0001 0.276 < 0.0001 0.303 < 0.0001 0.302 < 0.0001
15 Mb 0.561 < 0.0001 0.56 < 0.0001 0.551 < 0.0001 0.294 < 0.0001 0.308 < 0.0001 0.301 < 0.0001
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Supplementary Table 4. Cancer type specific enrichment
Gain Loss
Focal CNA size 2 Mb 5 Mb 10 Mb 2 Mb 5 Mb 10 Mb
Cancer type Interval size R P R P R P R P R P R P
Breast ca.
5 Mb 0.563 < 0.0001 0.534 < 0.0001 0.495 < 0.0001 0.341 < 0.0001 0.369 < 0.0001 0.376 < 0.0001
10 Mb 0.608 < 0.0001 0.592 < 0.0001 0.575 < 0.0001 0.399 < 0.0001 0.438 < 0.0001 0.453 < 0.0001
15 Mb 0.616 < 0.0001 0.599 < 0.0001 0.573 < 0.0001 0.474 < 0.0001 0.501 < 0.0001 0.504 < 0.0001
Colorectal ca.
5 Mb 0.261 < 0.0001 0.324 < 0.0001 0.376 < 0.0001 0.181 < 0.0001 0.281 < 0.0001 0.309 < 0.0001
10 Mb 0.367 < 0.0001 0.434 < 0.0001 0.48 < 0.0001 0.257 < 0.0001 0.35 < 0.0001 0.367 < 0.0001
15 Mb 0.393 < 0.0001 0.427 < 0.0001 0.47 < 0.0001 0.275 0.0005 0.358 < 0.0001 0.372 < 0.0001
AML and MDS
5 Mb 0.299 < 0.0001 0.324 < 0.0001 0.354 < 0.0001 0.057 0.102 0.002 0.477 -0.114 0.995
10 Mb 0.289 < 0.0001 0.311 < 0.0001 0.34 < 0.0001 0.072 0.072 0.042 0.25 -0.053 0.803
15 Mb 0.251 0.0001 0.236 0.0016 0.191 0.0084 0.086 0.138 0.059 0.228 -0.073 0.824
NSCLC
5 Mb 0.244 < 0.0001 0.249 < 0.0001 0.25 < 0.0001 0.163 < 0.0001 0.266 < 0.0001 0.317 < 0.0001
10 Mb 0.364 < 0.0001 0.38 < 0.0001 0.382 < 0.0001 0.306 < 0.0001 0.378 < 0.0001 0.43 < 0.0001
15 Mb 0.398 < 0.0001 0.398 < 0.0001 0.38 < 0.0001 0.277 < 0.0001 0.347 < 0.0001 0.37 < 0.0001
Gliomas
5 Mb 0.541 < 0.0001 0.516 < 0.0001 0.486 < 0.0001 0.337 < 0.0001 0.378 < 0.0001 0.376 < 0.0001
10 Mb 0.646 < 0.0001 0.636 < 0.0001 0.611 < 0.0001 0.341 < 0.0001 0.387 < 0.0001 0.411 < 0.0001
15 Mb 0.639 < 0.0001 0.623 < 0.0001 0.603 < 0.0001 0.381 < 0.0001 0.427 < 0.0001 0.417 < 0.0001
Ovarian ca.
5 Mb 0.467 < 0.0001 0.464 < 0.0001 0.449 < 0.0001 0.177 < 0.0001 0.17 < 0.0001 0.118 0.0028
10 Mb 0.517 < 0.0001 0.501 < 0.0001 0.497 < 0.0001 0.208 0.0003 0.216 0.0006 0.182 0.0029
15 Mb 0.481 < 0.0001 0.488 < 0.0001 0.48 < 0.0001 0.29 < 0.0001 0.274 0.0001 0.249 0.0009
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NSCLC, Non-small-cell lung carcinoma
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6 CHROMOTHRIPSIS: CHROMOSOME CATASTROPHES
6.1 PREFACE
Somatically acquired genomic rearrangements may result in complex patterns of regional 
copy number changes, and consequently contribute to cancer development. Analysis of 
genomic rearrangements will promote understanding of the biological mechanisms of 
oncogenesis2,3. Through the decades efforts of the cancer research community, the 
stepwise development of cancer with the gradual accumulation of multiple genetic 
alterations has been the most widely accepted model3. In this model, somatic mutations 
are classified into two categories, “driver” mutations which contribute to the tumor’s 
progression, and “passenger” mutations which do not have any effect on the clonal 
expansion. Both types of mutations may be acquired during normal cell division, reflecting 
the intrinsic mutations. During the process of cancer development, natural selection acts 
on the phenotypic diversity  and may weed out cells carrying deleterious mutations, or 
foster cells that have acquired selective advantage. Within a cancer genome, there are 
probably hundreds of somatic mutations. The procedure may take years to convert a 
normal cell to a tumor cell.
Recently, using state-of-the-art genome analysis techniques, a phenomenon termed 
“Chromothripsis” was characterized in cancer genomes, defined by the occurrence of tens 
of hundreds of clustered genomic rearrangements, supposedly having arisen in a single 
catastrophic event105. In this event, contiguous chromosomal regions are fragmented into 
many pieces via presently  unknown mechanisms105,106. Supposedly, the cell’s DNA repair 
machinery randomly  fuses these segments together to rescue the genome. Since this is a 
one-off event, it has been proposed that this procedure could provide an alternative 
oncogenetic route, in contrast to the step-by-step paradigm of cancer development.
Furthermore, chromothripsis may be a widespread mechanism in cancer progression, as 
recent researches have reported chromothripsis events in germline and non-human 
genomes118,119. This interesting observation has stimulated many following studies after 
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the initial report. Subsequently, chromothripsis was found in breast cancer, colorectal 
cancer, leukaemia, medulloblastoma, prostate cancer, and so on121-132. However, due to 
the relatively  low incidence of this phenomenon, most studies are limited to relatively small 
numbers of observed events. Larger sample numbers are required to gain further insights 
into features and mechanisms of these events in different cancers.
6.2 CHARACTERIZATION OF CHROMOTHRIPSIS
In this work, I designed a statistical model to automatically detect chromothripsis-like 
patterns from genomic array data. The input dataset is more than 22000 high quality 
arrays from arrayMap database. The previous studies have proven that the identification of 
chromothripsis patterns from genomic array data is feasible. The algorithm is based on 
scan statistics and two related features - copy number status change times and 
breakpoints clustering195. The pipeline of this project is shown in Figure 8. Applying the 
methodology to the input dataset, I detected 918 chromothripsis-like cases. With these 
data, I was able to determine the frequency and genomic distribution of chromothripsis 
events.
Figure 8. Schematic description of the chromothripsis-like patterns detection procedure. 
Raw array data of 402 GEO  series are first collected and re-analyzed, then annotated and stored 
in arrayMap database. For high quality  arrays, a scan-statistic based algorithm was employed to 
identify CTLP cases.
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First, I found that chromothripsis events exhibited an uneven distribution along the tumor 
genomes, with disease related local enrichment. Fragmentation hotspots were found to be 
located on chromosome 8, 11, 12 and 17. These chromosomal pulverization regions may 
reveal associations between tumor type related cancer associated genes and molecular 
mechanisms behind chromothripsis events. This potential correlation is exemplified by a 
recently published study that showed the prevalence of mutant TP53 in chromothriptic Li-
Fraumeni syndrome associated Sonic-Hedgehog medulloblastomas. Then, as the 
collection of array  data represents 132 cancer types, the incidences of chromothripsis in 
diverse tumor types were able to be estimated. Interestingly, soft-tissue tumors exhibited 
particularly high chromothripsis frequencies. This finding supports and improves upon a 
previous prediction of particularly  high chromothripsis rate in bone tumors. In addition, 
genomic context analysis revealed that chromothripsis rearrangements frequently 
occurred in genomes that additional harbored multiple copy  number aberrations. It is 
possible to contradict the proposed singular “shortcut” to cancer genome generation. 
Plausible and non-exclusive explanations could be that chromothripsis might frequently 
arise due to previously established errors in the maintenance of genomic stability, or that 
chromothriptic aberrations involving genomic maintenance genes may predispose to the 
acquisition of additional CNA. For those frequent cases exhibiting additional non-
chromothripsis CNA events, their possible contribution to oncogenesis has to be 
considered when modeling the role of chromothripsis in cancer development. Moreover, an 
investigation into the affected chromosomal regions showed a large proportion of arm-level 
pulverization and telomere related events, which would support breakage-fusion-bridge 
cycles as one of the potential underlying mechanisms. Finally, I evaluated clinical 
associations of chromothripsis, based on the clinical information at hand. Chromothripsis 
seemed to occur at a more advanced patient age as compared to non-chromothripsis 
samples. It mainly occurred at stage II and III, which was significantly different from the 
stage distribution of total samples. As for tumor grade, chromothripsis showed a 
predominance for grades 2 and 3. I also found that this phenomenon was overrepresented 
in cell lines compared to primary tumors. According to follow-up  information, patients with 
chromothripsis survived a significantly  shorter time than those without this phenomenon. 
Overall, this project characterized heterogeneous features of chromothripsis through a 
large-scale analysis of oncogenomic arrays data sets and provides a better understanding 
of this new paradigm in cancer development.
The manuscript is included below.
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ABSTRACT
Chromothripsis  is  a newly discovered type of genomic rearrangement, characterized by 
locally clustered copy number aberrations. It has been proposed that it may arise during a 
single genome shattering event. This could provide an alternative paradigm in cancer 
development, replacing the gradual accumulation of genomic changes with a ”one-off” 
catastrophic event. However, the underlying mechanisms and its  specific impact on 
tumorigenesis  are still poorly understood. Here, we identified chromothripsis-like genome 
patterns (CTLP) in 918 cancer samples, from a dataset of more than 22,000 oncogenomic 
arrays including 132 cancer types. Fragmentation hotspots were found to be located on 
chromosome 8, 11, 12 and 17. Among the various cancer types, soft tissue tumors 
exhibited particularly high CTLP frequencies. Genomic context analysis revealed that 
CTLP rearrangements  frequently occurred in genomes harboring multiple additional copy 
number aberrations (CNAs). An investigation into the affected chromosomal regions 
showed a large proportion of arm-level pulverization and telomere related events, which 
would support breakage-fusion-bridge cycles as one of the potential underlying 
mechanisms. We also report evidence that this  catastrophic event may be correlated with 
patient age, stage and survival rate. 
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INTRODUCTION 
One hallmark of human cancer genomes are somatically acquired genomic 
rearrangements, which sometimes may result in complex patterns  of regional copy number 
changes (Albertson et al., 2003; Hanahan and Weinberg, 2011). These alterations have 
the potential to interrupt or activate multiple genes, and consequently have been 
implicated in cancer development (Yates and Campbell, 2012). Analysis of genomic 
rearrangements is  essential for understanding the biological mechanisms of oncogenesis 
and to determine rational points of pharmacological interference (Chen et al., 2010; Chin 
and Gray, 2008; Hanahan and Weinberg, 2011). Some large-scale efforts  have been made 
to correlate genomic rearrangements  to genome architecture as well as to the progression 
dynamics of cancer genomes (Beroukhim et al., 2031; Kim et al., 2012). At the moment, 
the stepwise development of cancer with the gradual accumulation of multiple genetic 
alterations is the most widely accepted model (Stratton et al., 2009).
Recently, using state-of-the-art genome analysis  techniques, a phenomenon termed 
”Chromothripsis” was characterized in cancer genomes, defined by the occurrence of tens 
to hundreds of clustered genomic rearrangements, supposedly arising in a single 
catastrophic event (Stephens et al., 2011). In this model, contiguous chromosomal regions 
are fragmented into many pieces, through presently unknown mechanisms. Supposedly, 
these segments are then randomly fused together by the cell’s DNA repair machinery. It 
has been proposed that this ”shattering” and aberrant repair of a multitude of DNA 
fragments could provide an alternative oncogenetic route, in contrast to the step-by-step 
paradigm of cancer development (Kitada et al., 2011; Stephens et al., 2011; Stratton et al., 
2009). The initial study reported in overall 24 chromothripsis cases, with some evidence of 
a high prevalence in bone tumors (Stephens et al., 2011).
Besides human cancers, recent studies reported chromothripsis events  in germline and 
non-human genomes (Chiang et al., 2012; Deakin et al., 2012; Kloosterman et al., 2011a). 
However, due to the overall low incidence of this  phenomenon, most studies  were limited 
to relatively small numbers of observed events. For example, in a study screening 746 
multiple myelomas by SNP arrays, only 10 cases with chromothripsis were detected 
(Magrangeas et al., 2011). Larger sample numbers are required to gain further insights 
into features and mechanisms of these events in different cancers.
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The identification of chromothripsis patterns  from genomic array data has been considered 
feasible, according to the techniques applied in previous studies  (Kim et al., 2012; 
Magrangeas et al., 2011; Northcott et al., 2012; Stephens et al., 2011). Table 1 provides an 
overview of studies  which so far have reported instances of chromothripsis in human 
cancers. Here, we present a statistical model to discover chromothripsis-like (CTLP) from 
genomic array data sets. Applying our methodology to 22,347 genomic arrays from 402 
GEO (Gene Expression Omnibus) derived experimental series (Barrett et al., 2013), we 
were able to detect 918 chromothripsis-like cases, and to determine the frequency and 
genomic distribution of CTLP events in this dataset.
Our collection of oncogenomic array data represents 132 cancer types  as defined using 
the ICD-O 3 (International Classification of Diseases for Oncology) coding scheme, 
enabling us  to estimate the incidence of chromothripsis events  in diverse tumor types. 
Among the CTLP cases, varying distributions of fragmented chromosomal regions and 
large non-CTLP copy number aberrations (CNA) regions were found, and the genomic 
context of chromothripsis events was investigated. Finally, we evaluated some clinical 
associations of chromothripsis, based on the clinical information at hand. Overall, this 
study characterized heterogeneous features of chromothripsis through a large-scale 
analysis of oncogenomic arrays data sets and provides a better understanding of this new 
paradigm in cancer development.
RESULTS
Detection of chromothripsis-like patterns from oncogenomic arrays
We collected 402 GEO series, including 22,347 high quality genomic arrays of human 
cancer samples. The annotated information of arrays, including normalized probe intensity, 
segmentation data and quality evaluation, was obtained from our arrayMap database (Cai 
et al., 2012) (see Methods for array processing pipeline). After removing technical repeats 
(e.g. multiple platforms for one sample), a total of 18,394 cases represent 132 cancer 
types remained. The input data is  summarized, at array and case-level, respectively, in 
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Supplemental Tables  1 and 2. The segmentation data and array profiling can be accessed 
and visualized through the arrayMap website (www.arraymap.org).
Table 1 Summary of chromothripsis-like cases identified in previous and current studies
Studya
Chromothripsis
-like casesb Sample size Techniques Cancer/sample types
Stephens et al., 2011 24 776 paired-end sequencing, SNP array 55 cancer typesd
Kloosterman et al., 2011 1 3c mate-pair sequencing germline, congenital defects
Le et al., 2011 1 21 aCGH chordoma
Magrangeas et al., 2011 10 764 SNP array multiple myeloma
Bass et al., 2011 3 9 whole-genome sequencing colorectal adenocarcinoma
Kloosterman et al., 2011 4 4 mate-pair sequencing, SNP array colorectal cancer
Zhang et al., 2012 3 12 whole-genome sequencing acute lymphoblastic leukaemia
Kitada et al., 2012 5 150 aCGH na
Poaty et al., 2012 1 14 aCGH gestational choriocarcinoma
Rausch et al., 2012 52 605 whole-genome sequencing, SNP array 7 cancer types
Jiang et al., 2012 1 4 paired-end sequencing hepatocellular carcinoma
Molenaar et al., 2012 16 87 paired-end sequencing, SNP array neuroblastoma
Chiang et al., 2012 2 52 whole-genome sequencing, aCGH germline
Lapuk et al., 2012 1 6 whole-genome/transcriptome sequencing, aCGH neuroendocrine prostate cancer
Berger et al., 2012 2 25 whole-genome sequencing melanoma
Natrajan et al., 2012 1 2 whole-genome sequencing breast cancer
Nik-Zainal et al., 2012 3 21 whole-genome sequencing breast cancer
Kloosterman et al., 2012 10 10 mate-pair sequencing, SNP array congenital disease
Wu et al., 2012 3 3 paired-end sequencing, aCGH prostate cancer
Northcott et al., 2012 na 1087 SNP array, whole-genome sequencing medulloblastoma
Jones et al., 2012 2 3 whole-genome sequencing medulloblastoma
Kroef et al., 2012 1 61 SNP array multiple myeloma
Govindan et al., 2012 1 17 whole-genome sequencing non-small cell lung cancer
Kim et al., 2012 124 8227 aCGH, SNP array 30 cancer types
Zehentner et al., 2012 1 28 aCGH plasma cell neoplasia
Current study 918 18394 aCGH, SNP array 132 cancer typese
a Data up to 21st December, 2012; b na, not available; c Family trio: father, mother, child; d According to site and histology; e Classified by ICD-O code
According to previous studies, segmental copy number status changes and significant 
breakpoint clustering are two relevant features of chromothripsis (Rausch et al., 2012; 
Stephens et al., 2011). For an automatic identification of CTLP, we developed a scan-
statistic based algorithm (Naus, 1965). We employed a maximum likelihood ratio score, 
which is  commonly used to detect clusters of events in time and/or space and to determine 
their statistical significance (Kulldorff, 1997) (see Methods). For each chromosome, the 
algorithm uses a series of sliding windows to identify the genomic region with the highest 
likelihood ratio as CTLP candidate. In order to test the performance of the algorithm, 23 
published chromothripsis  cases with available raw array data were collected and used as  a 
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training set. This  data contained 31 chromothriptic and 475 non-chromothriptic 
chromosomes that acted as positive and negative controls, respectively (Supplemental 
Table 3). Comparison of copy number status change times and likelihood ratios showed 
that chromothriptic chromosomes could reliably be distinguished from non-chromothriptic 
ones (Supplemental Fig. 1). We generated a receiver operating characteristic (ROC) curve 
from the training set results, and selected optimal cutoff values based on this curve (copy 
number status switch times ≥ 20 and log10 of likelihood ratio ≥ 8) (Fig. 1B). Furthermore, 
the sliding window scan statistic accurately identified the involved genomic regions 
(Supplemental Fig. 2). Applying this algorithm to the complete input data set, a total of 
1,269 chromosomes from 918 cases passed our thresholds and were marked as CTLP 
events (Supplemental Fig. 3; Supplemental Table 4).
Figure 1 The ROC curve of the training set and selected thresholds. Two predictors were tested, copy 
number status change times and the likelihood ratio. Both predictors were integrated into the combined 
threshold.
Chromothripsis-like patterns across diverse tumor types
When evaluating the 1,269 CTLP events, we found a pronounced preference for some 
chromosomes; this  preference showed only limited association with chromosome size 
(Fig. 2A). CTLP occurred more frequently in chromosome 17 than in any other 
chromosome. This observation is  in accordance with data reporting an association 
between chromothripsis and TP53 mutation in Sonic-Hedgehog medulloblastoma and 
acute myeloid leukemia (Rausch et al., 2012). TP53 is  located in the p arm of 
chromosome 17, and is involved in cell cycle control, genome maintenance and apoptosis 
(Forbes et al., 2011; Vogelstein and Levine, 2000). Our dataset showed TP53 losses in 
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438 out of 918 (∼48%) CTLP cases, compared to 3,274 out of 17,476 (∼19%) cases in the 
non-CTLP group (P < 2.2×10
-16
; two-tailed Fisher’s exact test; Supplemental Table 2). 45 
of the 438 TP53 deletions were part of a CTLP. Apart from its frequent involvement in 
different cancer types, TP53 mutation seems to be a recurring and possibly associated 
event in chromothripsis formation. Other chromosomes with relatively high incidences of 
CTLP included chromosome 8, 11 and 12.
Figure 2 Frequency and coverage length distribution of CTLP in the genome. (a) Red and blue bars indicate 
CTLP frequency and chromosome size, respectively. (b) Distribution of CTLP regions among diagnostic 
groups. Each row represents a cancer type and each column represents a chromosome. We use a black-to-
yellow gradient for representing CTLP frequencies ranging from lowest to highest, respectively, normalized 
for each row. The numbers in brackets indicate the number of cases. Groups with at least 5 CTLP cases are 
shown. (c) Sample derived fraction of genome involved in CTLP events. Density plots for common cancer 
types are shown.
In our study, genomic projection of regional CTLP frequencies revealed their 
heterogeneous distribution in different cancer types (Fig. 2B). The total length of 
fragmented genomic regions (CNA level and interspersed normal segments) accounted for 
1%-14% of the corresponding genomes (Fig. 2C). The extent of our input data set with 
resulting high number of CTLP cases permitted an investigation of the frequency and 
genomic distribution of these patterns in different cancer types. Our input samples 
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represented 65 ”diagnostic groups”, as  defined by combining ICD-O morphology and 
topography codes. The majority of samples (18,238) came from 50 diagnostic groups, 
each represented by more than 25 arrays. We observed in total of 918 CTLP events 
across all 18,394 cases, representing an overall ∼5% prevalence. The 17 diagnostic 
groups represented by at least 45 cases, and having frequencies higher than 4% (CTLP 
high) are listed in Table 2 (full list in Supplemental Table 5).
Table 2 Frequency of chromothripsis-like patterns among cancer types
Chromothripsis-like cases
Cancer type Oligo > 200K Oligo ≤ 200K BAC or cDNA Total Input cases Frequency  (95%confidence interval)
Soft tissue tumors: lipoid 49 12 0 61 114 53.5% (44%-62.8%)
Soft tissue tumors: fibroid tumors 14 0 0 14 59 23.7% (14%-36.9%)
Soft tissue tumors: sarcomas, other 9 0 2 11 48 22.9% (12.5%-37.7%)
Carcinomas: breast ca. 247 99 58 404 3652 11.1% (10.1%-12.1%)
Carcinomas: esophagus ca. 13 0 0 13 135 9.6% (5.4%-16.2%)
Carcinomas: bronchoalveolar, NSCLC 78 29 2 109 1164 9.4% (7.8%-11.2%)
Soft tissue tumors: bone tumors 7 3 0 10 123 8.1% (4.2%-14.8%)
Carcinomas: bronchoalveolar, SCLC 3 3 0 6 90 6.7% (2.7%-14.5%)
Carcinomas: prostate adenoca. 1 40 0 41 653 6.3% (4.6%-8.5%)
CNS: CNS PNET 4 0 0 4 65 6.2% (2%-15.8%)
Carcinomas: melanocytic neoplasias 31 1 6 38 621 6.1% (4.4%-8.4%)
Soft tissue tumors: myoepithelial 3 0 2 5 85 5.9% (2.2%-13.8%)
Carcinomas: ovarian ca. 31 5 1 37 801 4.6% (3.3%-6.4%)
Carcinomas: gastric ca. 1 5 1 7 160 4.4% (1.9%-9.2%)
CNS: gliomas 14 13 0 27 669 4% (2.7%-5.9%)
Soft tissue tumors: stromal tumors 5 1 0 6 151 4% (1.6%-8.8%)
CNS: medulloblastomas 13 4 0 17 430 4% (2.4%-6.4%)
Only cancer types with input cases ≥ 45 and frequency ≥ 4% are shown
The original study hypothesized that chromothripsis has a high incidence in bone tumors 
(Stephens et al., 2011). Notably, several soft tissue tumor types appeared in our ”CTLP 
high” frequency set (6 out of 17), including the 3 types with the highest scores. Moreover, 
the high prevalence of CTLP in soft tissue tumors was reflected in the ICD-O specific 
frequencies (Supplemental Table 6). The genesis and/or effect of multiple localized 
chromosomal breakage-fusion events may be related to specific molecular mechanisms in 
those tumor types. Notably, gene fusions are well-documented recurring events in 
sarcomas (Mitelman et al., 2007), in contrast to most other solid tumors. So far, more than 
40 fusion genes have been recognized in sarcomas and treated as potential diagnostic 
and prognostic markers (Mitelman et al., 2007). Possibly, the double-strand breaks and 
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random fragment stitching events  in chromothripsis are liable to generate oncogenic fusion 
genes (Stephens et al., 2011). Further sequencing-based efforts will be needed to identify 
the true extent of fusion gene generation and to elucidate their functional impact in 
chromothripsis cases.
Genomic context of chromothripsis-like events
It has  been hypothesized that chromothripsis is  a one-off cellular crisis generating a 
malignant clone in a very short time (Maher and Wilson, 2012; Stephens et al., 2011). In 
many of the CTLP samples in our study, highly fragmented chromosomal regions were 
embedded in larger CNA regions showing variations  in patterns and overall extent (Fig. 
3A). To test whether chromothripsis events  are associated with overall genomic instability, 
we examined the extent of all copy number imbalances detected in our dataset. 
Comparing the 918 CTLP positive arrays with the remainder of 17,476 CTLP negative 
arrays, we found that CTLP samples tended to have higher proportions of CNA extent in 
their genomes (P < 2.2×10
-16
; Kolmogorov-Smirnov test) (Fig. 3B,C). This indicated that 
chromothripsis events  frequently co-occur with other types of copy number aberrations. 
Plausible and non-exclusive explanations could be that chromothripsis might frequently 
arise due to previously established errors in the maintenance of genomic stability, or that 
chromothriptic aberrations involving genomic maintenance genes may predispose to the 
acquisition of additional CNA. For those frequent cases exhibiting additional non-
chromothripsis CNA events, their possible contribution to oncogenesis  has to be 
considered when modeling the role of chromothripsis in cancer development.
Potential mechanisms for chromosome shattering
While the mechanism(s) responsible for the generation of chromothripsis remain elusive, a 
number of studies have proposed hypotheses including ionizing radiation (Stephens et al., 
2011), DNA replication stress (Liu et al., 2011), breakage-fusion-bridge cycles (Rausch et 
al., 2012; Stephens et al., 2011), premature chromosome compaction (Meyerson and 
Pellman, 2011), failed apoptosis (Fullwood et al., 2011; Tubio, 2011) and micronuclei 
formation (Crasta et al., 2012). In our dataset, although most (76%) CTLP cases 
presented single chromosome CTLP events, in approximately 24% CTLP cases  affected 
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at least 2 chromosomes (Fig. 4A). For certain candidate mechanisms, e.g. micro-nucleus 
formation due to mitotic delay, this observation would imply more than one event whereas 
the observation is appears compatible with an aborted apoptosis process.
Figure 3 Examples for the genomic  context of CTLP events. (a) Copy number profiles of the relevant 
chromosomes identified to have changes suggestive of chromothripsis. Chromosomal fragmentation events 
are embedded in other types of copy number aberrations, and exhibit different combination patterns. The x-
axis indicates genomic  locations in Mb, and the y-axis is the log2 value of probe signal intensity. Yellow and 
blue lines represent genomic gains and losses respectively. (b) Distribution of CNAs account for the 
percentage of the genome between CTLP and non-CTLP cases. CT, chromothripsis. (c) Total length of CNAs 
per sample. Each point represents one sample. For the non-CTLP group, 918 samples were randomly 
chosen from the total sample of 17,476 cases to generate an equally sized comparison. P-value, indicating 
significant difference between the genome fraction distributions of two groups, is based on Kolmogorov-
Smirnov test.
In order to gain insight into the potential mechanisms, we subsequently normalized the 
size of the detected CTLP regions relative to their respective chromosomes. The affected 
regions were classified into the categories ”arm-level” (≥ 90% arm length ), ”chromosome-
level” (≥ 80% chromosome length) or ”localized” (Fig. 4B). Arm-level CTLP events  were 
observed with a relatively high frequency (~19%). In the arm-level patterns, the CTLP 
rearrangements were concentrated in one chromosome arm with the other arm of the 
same chromosome remaining normal or showing isolated CNA. Notably, one model that 
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closely conforms to this pattern involves breakage-fusion-bridge cycles  (Artandi and 
Depinho, 2010; Holland and Cleveland, 2012; McClintock, 1938, 1941; Meyerson and 
Pellman, 2011; Rausch et al., 2012; Stephens et al., 2011). In general, such cycles start 
with telomere loss and end-to-end chromosome fusions. When the dicentric chromosomes 
are formed and pulled to opposite poles during anaphase, a double-strand DNA breakage 
occurs and acts as a starting point for the next cycle. Chromosomal rearrangements would 
gradually accumulate during the additional cycles, and should be concentrated in one 
chromosome arm. To explore this hypothesis, we investigated the proportion of CTLP 
regions extending to telomeres. Here, up to 44% of all CTLP chromosomes involved 
telomere regions. We performed simulations to explore whether this telomere region 
enrichment could be explained by chance. In brief, for each sample, we retained the 
location of CTLP region in the genome and shuffled the telomere position of each 
chromosome while keeping the length of each chromosome constant. In contrast to the 
actual observations, our simulation did not result in telomeric CTLP enrichment (P < 
0.0001; 10,000 simulations; see Methods). Hence, we require an explanation for the high 
proportion of arm-level pulverization and statistically significant telomere enrichment. 
CTLP generation through breakage-fusion-bridge cycles would be a viable candidate 
hypothesis.
Figure 4 The distribution of CTLP regions in terms of chromosome number and length. (a) The number of 
chromosomes affected by CTLP per sample. The numbers outside and inside the brackets are number and 
percentage of CTLP samples respectively. (b) Length distribution of CTLP regions normalized to 
chromosome or chromosome arm lengths. For each chromosome, regions restricted on a single arm were 
normalized to arm lengths (red bars), otherwise were normalized to chromosome lengths (blue bars).
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Clinical implications
Based on analyses of the clinical impact of chromothripsis patterns (Forment et al., 2012; 
Magrangeas et al., 2011; Molenaar et al., 2012), it has been claimed that these events 
may correlate with a poor outcome in the context of the respective tumor type. In our meta-
analysis, we explored a general association of CTLP with clinical parameters, across  the 
wide range of cancer entities reflected in our input data set. Clinical data was collected 
from GEO and from the publications of the respective series (Supplemental Tables  2, 7) 
and only parameters  available for at least 1,000 cases were considered. From our dataset, 
CTLP seemed to occur at a more advanced patient age as compared to non-CTLP 
samples (Fig. 5A). CTLP mainly occurred at stage II and III (70%), which was significantly 
different from the stage distribution of total samples (55.2%) (P = 0.0149; Chi-square test) 
(Fig. 5B). No difference of grade distribution was observed in our dataset (P = 0.425; Chi-
square test) where CTLP samples showed a predominance for grades 2 and 3, similar to 
the bulk of all samples  (∼80%). We also found that CTLP was overrepresented in cell lines 
compared to primary tumors  (P < 2.2×10
-16
; two-tailed Fisher’s exact test). For a subset of 
1,203 patients, we were able to determine basic follow up parameters (time and death/
survival). 72 of these individuals showed CTLP in their tumor genomes. Notably, patients 
with CTLP survived a significantly shorter time than those without this  phenomenon (P = 
0.0039; log-rank test; Fig. 5C). Note that this analysis was  based on a sample of 
convenience averaged over cancer and stage, etc. If we break down this dataset by 
cancer type, the numbers are not large enough to provide statistical confidence 
(Supplemental Fig. 4). While the cancer type independent association of CTLP patterns 
and poor outcome is intriguing, potential clinical effects of chromothripsis induced genome 
disruption should be evaluated in large and clinically more homogeneous data sets.
Sensitivity of array platforms for chromothripsis detection 
Chromothripsis  patterns have been reported from genomic datasets  generated through 
different array and sequencing based techniques. We performed an analysis of the 
platform distribution of our CTLP samples, to estimate the possibility of platform 
associated detection bias. As the resolution of a platform depends both on type and 
density of the probes on an array, we divided the platforms into 4 groups according to their 
probe numbers and techniques (BAC/P1, DNA/cDNA, oligonucleotide ≤ 200K and 
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oligonucleotide > 200K). Although CTLP patterns were detected by all types of genomic 
arrays, a higher fraction of CTLP samples was found using data from high resolution 
oligonucleotide arrays (Fig. 6), possibly due to increased sensitivity related to higher probe 
density. Indeed, when performing platform simulations, the sensitivity of CTLP detection 
improved with increasing probe numbers (Supplemental Figs. 5, 6; see Methods). 
According to these simulations, array platforms consisting of more than 250k probes 
should be preferred when screening for chromothripsis-like events. Since our analysis 
relied on a variety of array platforms, we assume that the overall prevalence of CTLP 
patterns in cancer is higher than our reported 5% of samples.
Figure 5 Clinical  perspective on chromothripsis events. (a) Distribution of CTLP percentage versus patient 
age. (b) Distribution of sample stage, grade and source between CTLP and input dataset or non-CTLP 
cases. P-values are derived from Chi-square test (stage and grade) or two tailed Fisher’s exact test (source). 
P, primary tumor; C, cell line. (c) Kaplan-Meier survival curves for CTLP versus non-CTLP cases. The P-
value is based on log-rank test.
Figure 6 Platform distribution based on different resolutions and technology types. Different analysis groups 
are shown, including the whole input dataset, inferred CTLP cases and three cancer types. Oligo, 
oligonucleotide; NSCLC, Non-small cell lung cancer.
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DISCUSSION
Chromothripsis  has been characterized as a type of focally clustered genomic aberration 
events, occurring in a small subset of cancer genomes. In this study, we have identified 
918 chromothripsis-like genome profiles, based on an analysis of copy number aberration 
patterns from 22,347 oncogenomic arrays, representing 132 cancer types. Despite the 
inherent limitations of such a meta-analysis approach, we were able to provide several 
new insights regarding the distribution of chromothripsis-like patterns and to produce a 
comprehensive estimate of CTLP incidence in a large range of cancer entities.
In our analysis, CTLP exhibited an uneven distribution along the tumor genomes, with 
disease related local enrichment. These ”CTLP dense” chromosomal regions may reveal 
associations between tumor type related cancer associated genes and molecular 
mechanisms behind chromothripsis events. This potential correlation is exemplified by the 
prevalence of mutant TP53 in chromothriptic Li-Fraumeni syndrome associated Sonic-
Hedgehog medulloblastomas (Rausch et al., 2012). As the extent of CTLP related 
deletions of the TP53 locus indicates, chromothripsis based gene dosage changes may 
predispose to double-hit effects on specific tumor suppressors. In contrast, we found 
regional enrichment for CTLP with pre-dominant copy number gains on chromosomes 8, 
11 and 12. In the initial study, chromosome 8 shattering was found in a small cell lung 
cancer cell line (Stephens  et al., 2011). This event contained the MYC oncogene, which 
had be shown to be amplified in 10-20% of small cell lung cancers (Md and Md, 2008). 
Moreover, strong overexpression of MYC involved in a chromothripsis region was also 
detected in a neuroblastoma sample (Molenaar et al., 2012). In a study of colorectal 
tumors, chromosomes 8 and 11 were involved in concurrent pulverization events with 
generation of fusion genes, involving e.g. SAPS3 and ZFP91 (Bass et al., 2011). In a study 
on hepatocellular carcinoma, CCND1 amplification was embedded within a chromothriptic 
event on chromosome 11 (Jiang et al., 2012). Therefore, the overall uneven distribution of 
CTLP may point to specific driver mutations that contribute to these events or to a class of 
chromothripsis derived cancer promoting mutations. 
Among cancer types, we observed a high CTLP prevalence in a limited set of entities, 
particularly in among soft tissue tumors. This  finding supports  and improves upon a 
previous prediction of particularly high chromothripsis rate in bone tumors  (Stephens et al., 
89
2011). Also, the uneven distribution of CTLP is a strong indicator for a disease related 
selection of specific genomic aberrations, supporting their involvement in the oncogenetic 
process.
In the initial study, the authors stated that chromothripsis could be a one-off cataclysmic 
event that generates multiple concurrent mutations and rearrangements (Stephens et al., 
2011). Strikingly and in possible contradiction to this proposed singular ”shortcut” to cancer 
genome generation, we observed in the majority of CTLP samples additional, complex 
non-CTLP genome re-arrangements. Further efforts  are needed to investigate the 
temporal order of chromothripsis and non-chromothripsis  events observed in genomically 
complex samples.
Although the precise mechanisms that cause chromothripsis are unclear, several 
hypotheses have been put forward which might explain the phenomenon. Based on our 
observations, the number and uneven distribution of affected chromosomes in CTLP 
suggests that more than one mechanisms may be responsible for this catastrophic event. 
Furthermore, the normalized spatial distribution of shattered chromosomal regions, as well 
as the observed significant overlap between telomere and pulverized regions could be 
supportive of breakage-fusion-bridge cycles  as one of the mechanisms behind this 
process.
We found that CTLP were related to overall advanced tumor stages and overall worse 
prognosis compared to non-CTLP cases. One possible explanation is that the numerous 
concurrent genetic alterations  induced by chromothripsis events disturb a large number of 
genes and contribute to aggressive tumor phenotypes. By themselves, these observations 
do not explain if chromothripsis is an early event promoting aggressive tumor behavior 
with fast growth rates and reduced response rates  to therapeutic interventions; or if this 
observation relates to underlying primary mutations predisposing to genomic instability, 
aggressive clinical behavior and CTLP as an epiphenomenon. Interestingly, the high rate 
of TP53 involvement by itself would support both possibilities for this gene, i.e. 
chromothripsis as  result of TP53 mutation as well as  chromothriptic events with TP53 
locus involvement promoting an aggressive clinical behavior.
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In conclusion, CTLP represent a striking feature occurring in a limited set of cancer 
genomes, and can reliably be detected using biostatistical methods. The observed 
patterns may reflect on heterogenous biological phenomena beyond a single class of 
”chromothripsis” events, and probably vary in their specific impact on oncogenesis. 
Fragmentation hotspots derived from our large-scale data set may promote the detection 
of markers involved in chromothriptic rearrangements, or may be used for assigning 
disease related effects to a CTLP induced genomic events.
Methods
Genome-wide microarrays and data preparation
In this study, we screened 402 GEO series (Barrett et al., 2013), including 22,347 high 
quality genomic arrays (Supplemental Table 2). All selected arrays were human cancer 
samples hybridized onto genome wide array platforms. The normalized probe intensities, 
segmented data and quality information were obtained from the arrayMap database, which 
is  a publicly available reference database for copy number profiling data (Cai et al., 2012). 
In brief, the annotated data was  obtained by the following processing pipeline: for 
Affymetrix arrays, the aroma.affymetrix R package was  employed to generate log2 scale 
probe level data (Bengtsson et al., 2008); for non-Affymetrix arrays, available probe 
intensity files were processed; CBS (Circular Binary Segmentation) algorithm (Olshen et 
al., 2004) was performed to obtain segmented copy number data. The probe locations 
were mapped on the human reference genome (UCSC build hg18). In the case of 
technical repeats  (e.g. one sample was hybridized on multiple platforms), only one of the 
arrays was considered for analysis (preferably with the highest resolution and/or best 
overall quality). The array profiling can be visualized through the arrayMap website.
Scan-statistic based chromothripsis pattern detection algorithm
To detect chromothripsis-like cases, we formulated an algorithm identifying clustering of 
copy number status changes in the genome. Several parameters were considered to 
define the alteration of copy number status:
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i) The thresholds of log2 ratio for calling genomic gains and losses. These values were 
array specific and stored in arrayMap database. For each array, the thresholds were 
obtained from related publications or empirically assigned based on the log2 ratio 
distribution.
ii) The intensity distance between adjacent segments. Due to local correlation effects 
between probes or the existence of background noise, the segmentation profiles 
occasionally exhibit subtle striation patterns. This pattern is constituted with a large 
number of small segments, which is  unlikely to be a biological phenomenon. To reduce 
artificial copy number status change, the distance of signal intensity between adjacent 
segments was used as a threshold, and defined here as the sum of the absolute values to 
call gains and losses. If the distance of two adjacent segments differed by less  than this 
threshold, the copy number status change was not considered.
iii) Segment size. The resolution of a platform depends  on the density of probes on the 
array. One of the platforms with the highest density in our dataset is  Affymetrix SNP6, 
which contains 1.8 million polymorphic and non-polymorphic markers with the mean inter-
marker distance of 1.7 kb. It provides a practical resolution of 10 to 20 kb. Therefore, in 
this study, segments smaller than 10 kb were removed.
In order to identify clustering of copy number status changes, a scan-statistic likelihood 
ratio based on the Poisson model was employed (Kulldorff, 1997). In our implementation, 
a fixed-size window was moved along the genome and for each window the likelihood ratio 
was computed from observed and expected copy number status change times. Let G be 
the genome represented linearly, and W is  a window with fixed size. As the window W 
moves over G, it defines a collection of zones Z, where Z ⊂ G. Let nW denotes  the 
observed copy number status change times in window W, and nG the total number of 
observed status change in G. µW is  the expected status change times  in window W, and is 
calculated as W/G×nG. The likelihood function is expressed as
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This function detects the zone that is most likely to be a cluster.
Due to lack of a prior knowledge about the size of W, we predefined a series  of window 
sizes from 30 Mb to 247 Mb (Supplemental Table 8), which were based on chromosome 
sizes. The scanning process was repeated for the series of window sizes for each sample. 
When W moved over G, the step length was set to 5 Mb, and there was no overlap 
between different chromosomes in window W. In this way, for each genome, the collection 
of Z contained 4,414 windows in various sizes. The window that maximized the likelihood 
ratio defined the most probable CTLP region. Thus it can detect both the location and the 
size of the cluster. When analyzing the complete input dataset, the window with the 
highest likelihood ratio was selected as a candidate of chromothripsis for each 
chromosome of the 22,347 arrays. The R script for detecting CTLP cases can be provided 
upon request.
Analysis of fragment enrichment in telomere region
Telomere positions were simulated to test the DNA fragment enrichment. For each case, 
the CTLP region was kept at its location in the genome. Locations of chromosome 
terminals  were randomly selected while the length of each chromosome was kept. A 
genomic interval of 5 Mb from the chromosome terminal was considered as the telomere 
region. The simulation was performed 10,000 times.
Simulation of platform resolution
The 15 Affymetrix SNP6 CTLP chromosomes in the training set were used for simulation. 
For each genome, a certain number of probes were randomly chosen from the original 
probe set. These probes generally represented the profile that the same sample was 
hybridized on a platform with corresponding resolution. Then the CTLP pattern detection 
in window W, and is calculated asW/G⇥nG. The likelihood function is expressed as
  =
8>><>>:
⇣
nW
µW
⌘nW ⇣nG nW
nG µW
⌘nG nW
if nWµW >
nG nW
nG µW
1 otherwise
This function detects the zone that is most likely to be a cluster.
Due to lac a prior knowledge about the siz ofW, we predefined a seri s of window sizes from
30 Mb to 247 Mb (Supplemental Table 8), which were based on chromosome sizes. The scanning
process was repeated for the series of window sizes for each sample. When W moved over G, the
step le gth was set to 5 Mb, and there was no overlap bet een diff rent chromosomes in window
W. In this way, for each genome, the collection of Z contained 4,414 windows in various sizes. The
window that maximized the likelihood ratio defined the most probable CTLP region. Thus it can
detect both the location and the size of the cluster. When analyzing the complete input dataset, the
window with the highest likelihood ratio was selected as a candidate of chromothripsis for each
chromosome of the 22,347 arrays. The R script for detecting CTLP cases can be provided upon
request.
Analysis of fragment enrichment in telomere region
Telomere positio s ere simulated to test the DNA fragment enrichment. F r each case, the CTLP
region was kept at its location in the genome. Locations of chromosome terminals were randomly
selected while the length of each chromosome was kept. A genomic interval of 5Mb from the chro-
mosome terminal was considered as the telomere region. The simulation was performed 10,000
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algorithm was applied on the simulated arrays, and the number of cases that passed the 
thresholds were recorded.
Statistical testing
The significance in the number of CTLP cases with TP53 loss in comparison to those in 
non-CTLP cases was assessed using two-tailed Fisher’s exact test. We performed a 
Kolmogorov-Smirnov test to compare the distributions of copy number aberration 
proportions in the genome between CTLP and the other cases. The Chi-square test was 
used to assess the significance in the distribution of both patient stage and grade in CTLP 
and the whole input dataset. The associations between the number of cell lines  in CTLP 
and non-CTLP cases were tested by two-tailed Fisher’s exact test. The difference in the 
survival curve between two subgroups was evaluated by log-rank test.
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Supplementary Figure 1. Scatter plot of the training set. Copy number status change 
times compared to the likelihood ratio. Each point represents the window with the highest 
LR for each chromosome. The dashed lines indicate the selected thresholds. CN, copy 
number; LR, likelihood ratio.
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Supplementary Figure 2. The positive training set and CTLP detection algorithm 
performances. The red rectangles are chromothripsis-like regions identified by scan-
statistic. For each plot, the parameters and corresponding values are shown in orange 
boxes. The schema of the chromosome is the same as in Figure 2.
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Supplementary Figure 3. Scatter plot of CTLP candidates. For each chromosome of the 
input dataset, the window with the highest likelihood ratio was considered as a CTLP 
candidate. The selected thresholds are indicated with dashed lines. The candidates falling 
in the upper right area are inferred CTLP cases.
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Supplementary Figure 4. Kaplan-Meier survival curves for CTLP versus non-CTLP cases 
in specific cancer types.
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Supplementary Figure 5. An example of the platform resolution based simulation from 
Affymetrix SNP6 array (1.8M). Chromosome 16 of GSM681794 is a reported 
chromothripsis event in multiple myeloma. The number above each plot represents the 
number of probes randomly selected from the original probe set. In this sample, the CTLP 
pattern is detectable starting at 250k probes.
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Supplementary Figure 6. CTLP detection sensitivity of simulated platform resolutions. All 
the 15 chromothripsis chromosomes are from the positive training set analyzed using 
Affymetrix SNP6 platform.
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Supplementary Table 1. Overview of input dataset
Category Array-level Case-level
Total number 22347 18394
Series 402 397
Platform 190 185
Cancer type (ICD-O) 132 132
Cancer type (diagnostic group) 65 65
Source (primary) 19623 16309
Source (cell line) 2309 1714
Source (relapse) 75 75
Source (metastasis) 340 296
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Supplementary Table 7. Demographic and clinicopathologic characteristics of input 
and CTLP samples
Variable Name Sample Number Mean±SD/Median or %
Input set
      Male 1088 49.7%
      Age(year) 2740 47.5 ± 25.7/55
      AJCC Stage
            I 270 21.1%
            II 331 25.9%
            III 374 29.3%
            IV 303 23.7%
      Grade
1 204 19.5%
2 435 41.7%
3 405 38.8%
      Tumor recurrence 198 44.0%
      Follow up (month) 1203 36.5 ± 34.6/26
      Event
            Deceased 553 46.0%
            Censored 650 54.0%
CTLP
      Male 46 32.6%
      Age(year) 259 54.1 ± 20.7/59
      AJCC Stage
            I 14 14.3%
            II 36 36.7%
            III 34 34.7%
            IV 14 14.3%
      Grade
1 16 14.4%
2 49 44.1%
3 46 41.5%
      Tumor recurrence 18 47.4%
      Follow up (month) 72 32.9 ± 35.2/17.6
      Event
            Deceased 46 63.9%
            Censored 26 36.1%
† All information is based on the available clinical data
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Supplementary Table 8. Sizes of sliding windows for the scan-statistic based 
algorithm
Size ID Size (Mb) Corresponding chromosome
1 247.249 Chromosome 1
2 242.951 Chromosome 2
3 199.501 Chromosome 3
4 191.273 Chromosome 4
5 180.857 Chromosome 5
6 170.899 Chromosome 6
7 158.821 Chromosome 7
8 146.274 Chromosome 8
9 140.273 Chromosome 9
10 135.374 Chromosome 10
11 134.452 Chromosome 11
12 132.349 Chromosome 12
13 114.142 Chromosome 13
14 106.368 Chromosome 14
15 100.338 Chromosome 15
16 88.827 Chromosome 16
17 78.774 Chromosome 17
18 76.117 Chromosome 18
19 63.811 Chromosome 19
20 62.435 Chromosome 20
21 46.944 Chromosome 21
22 49.691 Chromosome 22
23 40 NA
24 30 NA
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7 DISCUSSION
7.1 COPY NUMBER ABERRATION DATA IN HUMAN CANCER
Two databases for genomic copy number aberration in human cancer were launched and 
maintained by our group  - arrayMap23 and Progenetix169. They are developed to facilitate 
the progress of oncogenomic research. To this end, besides high-quality  genomic arrays, a 
set of online tools are also provided for accessing and analyzing CNA data. The user 
friendly  web interface contains search options for CNA features and patient information 
(Figure 9). In our implementation, raw array data with various platforms and techniques 
were processed into platform independent segmentation files. Importantly, the direct 
access to pre-computed probe level data plots supports a rapid evaluation of experiments 
for features of interest. Since clinical information is of importance when performing the 
following CNA data analysis, standardized annotation schemes were used, such as ICD 
classification of morphology and topography. In this way, large-scale CNA data analysis for 
thousands of arrays can be done efficiently and effectively.
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Figure 9. Overview of the basic structure of arrayMap. In the database, the two main models 
are query and output engines. Several types of information can be used by  the query  engine to 
search the interested CNA data. Then, matched records are combined and grouped by  the output 
engine to perform statistical analysis, and displayed on the result page. In addition, the returned 
CNA data can be downloaded for further investigations.
Although both arrayMap  and Progenetix provide copy number profiling data in cancer, they 
are not the same in many respects (Table 5). For data source, entities in arrayMap  were 
obtained with in-house pipeline ran on the raw array data, whereas data in Progenetix 
were manually  extracted from main text or supplementary files of publications. For 
techniques, Progenetix contains both chromosome and array CGH data, whereas 
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arrayMap focuses on array CGH data only. In terms of data visualization, arrayMap 
provides query and illustration options for probe-level intensity  data, as well as the ability 
to zoom in specific region for a target gene investigation. Progenetix focuses on using 
statistical methods for describing and analyzing segment-level data. Note that, for the data 
re-analysis in arrayMap, we employed aroma.affymetrix R package196 for processing 
Affymetrix arrays, and CBS (Circular Binary Segmentation)191 algorithm for segmentation. 
There are several other tools available to implement these processes. Thus, the 
interpretation of the data can vary due to different low level (e.g. signal/background 
correction) and higher level (e.g. segmentation algorithms, regional or size based filtering) 
procedures. However, for Progenetix, we rely on the authors to ensure that the data they 
provided in their articles is well annotated, as usually only  the segmentation data was 
extracted from publications. Furthermore, we are able to perform array quality assessment 
and filtering for arrayMap based on the probe-level data. But this process is not available 
for Progenetix. Finally, the data is organized in array and case-level in arrayMap and 
Progenetix respectively. Although the two databases are designed on different emphasis of 
their purpose of annotating the CNA data, we attempt to make them easy to use and serve 
as the valuable reference databases for the research community.
Table 5. A comparison between Progenetix and arrayMap
Features Progenetix arrayMap
Techniques cCGH, aCGH aCGH
Scope case-level array-level
Raw data presentation no yes; CEL file, log2, segmentation
Raw data re-analysis no; supervised result yes; re-segmentation, thresholding
Final data annotated CN status for GP and 
cytogenetic regions
unsupervised CN status for GP and 
cytogenetic regions
Data from arrayMap and Progenetix can be used on different levels, i.e. locus centric and 
for entity profiling. Obviously, systematic analysis will help  researchers to discover features 
which are indiscernible in individual studies, and thus bring new insights for understanding 
of disease pathology and the development of new therapeutic approaches. Since both 
databases support batch data download, researchers are able to integrate these data with 
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their own analysis efforts, e.g. to increase sample size or for result verification purposes. I 
believe these two databases will promote further evolution of microarray data meta-
analysis. Furthermore, arrayMap includes more than 3000 normal samples from healthy 
individuals or from normal tissues of cancer patients. These normal control samples are of 
vital importance for genomic imbalances studies. They could be integrated as reference 
dataset, e.g. to account for copy number variation data superimposed on the tumor 
profiling results, or to act as the “base line” in some CNA calling algorithms.
During the raw data processing procedure, I encountered a large number of individual data 
sets with insufficient or limited probe quality  in both GEO and ArrayExpress. This may be 
due to the lack of quality control step for GEO and ArrayExpress, since they aim at storing 
raw experimental data. These poor quality  arrays may lead to erroneous analysis results, 
especially  in certain quality  sensitive study such as chromothripsis pattern identification. 
Currently, the representative genomic array quality control methods are NUSE 
(Normalized Unscaled Standard Error) and RLE (Relative Log Expression). They were 
developed from fitted statistical models of probe level data. NUSE provides a measure of 
relative array quality  derived from the residuals from the Robust Multichip Analysis (RMA) 
model. RLE is an absolute metric that measures by summarizing the distribution of relative 
log expressions within a set of arrays against a reference set. They provide a better basis 
for judging quality compared to standard methods like SNP Call Rate. However, NUSE can 
only be used to assess the relative quality  of arrays within a dataset, whereas the results 
obtained from RLE will be influenced by different batches of experiments. In general, they 
have a limited accuracy for detection of arrays with inadequate probe-level data. Currently, 
the most viable strategy for quality assessment of processed, heterogeneous copy  number 
arrays is the visual inspection of probe plotting and segmentation results through an 
experienced researcher. I generated a quality classification system for arrayMap. Each 
array in the database was classified into four categories based on inspections of genome-
wide array plots. Depending on the intended research purpose this basic classification 
system can be used for a pre-analysis triage of copy number data. In addition, these 
quality  tags can also be used as the “gold standard” for further quality  control algorithm 
design. A platform independent quality  assessment system for genomic arrays is under 
development at the moment.
Through the data collection and annotation efforts, it is able to provide an estimation of 
content and trends for the platform usage. In the last two decades, the most widely 
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available array CGH platforms are either based on large insert clones (BAC/P1 arrays) or 
based on shorter single-stranded DNA molecules (oligonucleotide arrays), which may or 
may not include single-nucleotide polymorphism specific probe sequences (SNP arrays). 
Also, although designed for gene expression profiling, cDNA arrays were used by several 
laboratories for measuring genomic copy number changes. In reviewing the technical 
platform composition, two related trends were observed. Originally  developed in groups 
with expertise in molecular cytogenetics and cancer genome analysis, printed large insert 
clone arrays (BAC/P1) were the first whole genome CNA screening tools with a spatial 
resolution surpassing that of chromosomal CGH. However, over the last years the 
overwhelming use of various industrially produced oligonucleotide array  platforms can be 
observed. These SNP arrays contain a probe density  at 1-3 orders of magnitude higher 
than common for BAC/P1 arrays. Therefore in the near future, the very high resolution 
CNA data may accumulate rapidly. It will become possible to integrate these data with 
next-generation sequencing data and/or high density  DNA methylation array data by 
systems biology methods to elucidate effects of genomic instability, and describe the 
results from more perspectives. Envisioned examples would be, e.g. the identification of 
genes that are involved in metastasis and treatment response; identification of 
chromosomal breakpoints distribution in cancer; and modeling functional networks in 
cancer by systems biology approaches.
7.2 ORIENTATION OF GENOME INSTABILITY
In the project described in Chapter 5, I have presented that both genes and CNAs are 
often clustered into hotspots, and have explored the underlying correlation between gene 
distribution and copy number alteration profiles across cancer genomes. To achieve this, 
we collected more than 16,000 cancer samples from 3 public resources of microarray data 
sets. Notably, focal CNAs were significantly enriched in gene-rich regions. As another 
manifestation of genome instability, DNA breakpoints also followed this trend. It provides 
us a global insight into the relationship between cancer genome instability and structure 
from a new perspective. The enrichment reveals that there is a non-neutral selection 
pressure for CNA regions across the genome. Due to observed heterogeneity  of CNAs in 
cancer genomes, individual tumor probably follows a distinct path towards tumorigenesis. 
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Many genes in CNAs may lose their functions or take on new roles to promote clone 
expansion. Genome instability  could generate enough variation, on which these non-
neutral selection events can operate during tumor evolution. A full understanding of how 
these events contribute to specific tumor will require further studies to investigate the 
differential expression of genes in CNA regions.
A negative correlation between arm-level CNAs and the size of arms is observed from the 
entire data set, consistent with previous studies47. To further confirm the negative 
correlation with tumor specific data, I looked into arm-level CNAs of 6 cancer types. The 
underlying mechanism for this observation is unknown. It may reveal additional negative 
selective pressure on gene-rich arms, or inherent low arm-level CNA ratios of these arms.
To avoid bias, I performed cancer type and platform specific analysis across the entire 
dataset. Generally, focal CNAs in most cancers present an enrichment in gene-rich 
regions, although the extent of enrichment is a little bit different. A couple of cancers, such 
as hematological malignancies, present an inherent low-level of copy  number changes, 
especially  of focal CNAs. Accordingly, these cancers show relatively  low correlation 
coefficients. Moreover, our data set is generated from 180 array platforms with various 
resolutions. Due to increased probe numbers, high resolution platforms are more sensitive 
to small copy number changes, thus usually show a substantially  higher number of 
alterations. Therefore, compared to low resolution platforms, a higher proportion of 
segments that derived from high resolution arrays fit our definitions of focal CNAs.
In summary, the observed significant positive correlation between genomic instability 
regions and gene distribution in cancer genomes may enable a better elucidation of 
mechanisms by  which CNAs contribute to tumor development, and eventually promote a 
more systematic understanding of human cancer.
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7.3 CHROMOSOME SHATTERING AND CELL FATE
Since the initial report of chromothripsis over two years ago, many following studies have 
been performed and provided several hypotheses of this phenomenon. Now it has been 
characterized as a type of focally  clustered genomic aberration events, occurring in a small 
subset of cancer genomes. Our recent work described in Chapter 6 identified 918 
chromothripsis-like genome profiles, based on an analysis of copy number aberration 
patterns from 22,347 oncogenomic arrays, representing 132 cancer types. Despite the 
inherent limitations of such a meta-analysis approach, this project is able to provide 
several new insights regarding the distribution of chromothripsis-like patterns and to 
produce a comprehensive estimate of chromothripsis incidence in a large range of cancer 
entities. This work partly overcomes the limitation of individual research resulting from the 
relatively small number of chromothripsis samples available.
To automatically identify chromothripsis pattern, I developed a scan-statistic based 
algorithm196. A maximum likelihood ratio score was employed, which is commonly used to 
detect clusters of events in time and/or space and to determine their statistical 
significance. According to previous studies, segmental copy  number status changes and 
significant breakpoint clustering are two relevant features of chromothripsis. According to 
these features, in our implementation, the algorithm used a series of sliding windows to 
identify the chromosome region with the highest likelihood ratio as the chromothripsis 
candidate. Note that there is another algorithm in a recent published study can be used to 
detect chromothripsis event. In that study, authors identified chromosomes with at least 10 
copy number alterations, and breakpoints have to be randomly distributed over the 
chromosome. They also requested the sizes of neighboring segments to be roughly the 
same or the same order of magnitude. Indeed, this model effectively  detected 
chrompthripsis-like cases. However, the model is not able to distinguish the exact spot on 
which chromosome smashed. These pulverization regions are important for examining 
associations between tumor type related cancer associated genes and molecular 
mechanisms behind chromothripsis events. For example, in our dataset, chromothripsis 
occurs more frequently in chromosome 17 than in any other chromosome. This 
observation is in accordance with data reporting an association between chromothripsis 
and TP53 mutations in Sonic-Hedgehog medulloblastoma and acute myeloid leukemia125. 
TP53 is located on the p  arm of chromosome 17, and is involved in cell cycle control, 
genome maintenance and apoptosis. Based on the observation, we hypothesize that TP53 
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mutation is a recurring and possibly associated event in chromothripsis formation. 
Therefore, the accurate identification of chromosome shattering region may point to 
specific driver mutations that contribute to chromothripsis events or to a class of 
chromothripsis derived cancer promoting mutations.
In order to test the performance of our algorithm, 23 previously published chromothripsis 
cases with available raw array data were collected and used as a training set. I generated 
a receiver operating characteristic (ROC) curve from the training set results, and selected 
optimal cutoff values based on this curve. Not many published studies provide raw array 
data to allow us to perform re-analysis. Furthermore, until now, a lot of chromothripsis 
related research are based on whole-genome sequencing data. These data provide 
additional information that can not be obtained by microarray, such as the class of 
rearrangements involved in the chromosome shattering region. The type of breakpoint 
junctions, such as nonhomologous end joining or microhomology-mediated end joining, 
may reveal break repair pathways, which are important for understanding mechanisms 
underlying chromothripsis129. Moreover, inter-chromosomal or intra-chromosomal 
breakpoint junctions are also only able to be detected by genome sequencing. According 
to previous research, at least two mechanisms driving formation of genomic 
rearrangements may contribute to the occurrence of chromothripsis: double-strand DNA 
breaks and template-switching during DNA replication. In our dataset, about one-fourth of 
chromothripsis cases affected at least two chromosomes, which, from another point of 
view, confirmed that more than one mechanisms may be responsible for this catastrophic 
event. For certain candidate mechanisms, e.g. micro-nucleus formation due to mitotic 
delay, this observation would imply  more than one event whereas the observation appears 
compatible with an aborted apoptosis process.
In the initial study, the authors stated that chromothripsis could be a one-off cataclysmic 
event that generates multiple concurrent mutations and rearrangements105. Strikingly, and 
in possible contradiction to this proposed singular “shortcut” to cancer genome generation, 
we observed in the majority  of chromothripsis samples additional, complex non-CTLP 
genome re-arrangements. Plausible and non-exclusive explanations could be that 
chromothripsis might frequently  arise due to previously established errors in the 
maintenance of genomic stability, or that chromothriptic aberrations involving genomic 
maintenance genes may predispose to the acquisition of additional CNA. For those 
frequent cases exhibiting additional non-chromothripsis CNA events, their possible 
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contribution to oncogenesis has to be considered when modeling the role of 
chromothripsis in cancer development. Further efforts are needed to investigate the 
temporal order of chromothripsis and non-chromothripsis events observed in genomically 
complex samples.
At last, our dataset revealed that chromothripsis are related to overall more advanced 
tumor stages and overall worse prognosis, when compared to non-chromothripsis cases. 
One possible explanation is that the numerous concurrent genetic alterations induced by 
chromothripsis events disturb  a larger number of genes and contribute to more aggressive 
tumor phenotypes. By themselves, these observations do not differentiate whether 
chromothripsis is an early event promoting aggressive tumor behavior with fast growth 
rates and reduced response rates to therapeutic interventions; or whether this observation 
relates to underlying primary mutations predisposing to genomic instability, aggressive 
clinical behavior and chromothripsis as an epiphenomenon. Interestingly, the high rate of 
TP53 involvement by itself would support both possibilities for this gene, i.e. 
chromothripsis as result of TP53 mutation as well as chromothriptic events with TP53 
locus involvement promoting an aggressive clinical behavior122.
In conclusion, chromothripsis represents a striking feature occurring in a limited set of 
cancer genomes, and can reliably  be detected using biostatistical methods. The observed 
patterns may reflect on heterogenous biological phenomena beyond a single class of 
“chromothripsis” events, and probably  vary in their specific impact on oncogenesis. 
Fragmentation hotspots derived from our large-scale data set may promote the detection 
of markers involved in chromothriptic rearrangements, or may be used for assigning 
disease related effects to a chromothripsis induced genomic events.
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8 PERSPECTIVES
8.1 EXPANSION OF CANCER GENOME PROFILES IN THE FUTURE
Thanks to the widespread implementation of array  comparative genomic hybridization and 
SNP arrays to detect genome-wide copy number changes in cancer, the last decade have 
witnessed a significant increase in oncogenomic array data. For example, during the last 
12 years, the size of our Progenetix database has been grown almost 60 times, with 
included cancer samples increasing from 490 to more than 30 000. The advantage of 
making use of the vast amount of genomic array data is exemplified by recent studies that 
performed large-scale aCGH data analyses on a wide range of cancer types, provided 
striking new insights into human cancers. In the future, one can imagine the continued 
expansion of this resource. Note that, there are thousands of cancer samples in our 
database with detailed clinical information and outcome of patients. Data mining of these 
records can provide valuable insight into the complicated process of tumorigenesis. To this 
end, further online tools may be developed and provided to the research community. The 
main purpose is to try to find aberrations that correlate with a specific diagnostic, 
prognostic or therapeutic trait, such as poor prognosis or drug resistance. In the 
meanwhile, new visualization options and components may also be added to make the 
website more powerful and easier to use.
In the first version of arrayMap, I generated a pipeline for determining the genomic 
positions for the tens to hundreds of thousands array probes with reference to a common 
genome Golden Path edition. For each array platform, the genome positions of probes 
were remapped to the current commonly used version of the human reference genome 
assembly (UCSC HG18). This information and procedure, presented in Chapter 4, can be 
updated. At the moment the latest version of the genome assembly is UCSC HG19. The 
accurate physical coordinates of probes are important for analyzing gene-specific copy 
numbers and facilitating the integration of data measured with different array platforms. In 
previous work, specific mapping procedures were employed for different types of probes. 
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In average, about 96% probes were successfully remapped (Table 6). This percentage 
may be improved by the up-to-date UCSC Genome annotation database.
Table 6. Percentage of remapped probes classified by platform types
Platform Type Average Mapping Rate Number of Arrays Number of Platforms
Original HG18 NA 1583 40
in situ oligonucleotide 99% 21678 55
BAC/P1 98% 5464 55
spotted DNA/cDNA 91% 2365 82
So far only  human cancer genome data is collected for the database. However, 
information of other species can be added as an extension. Although both databases are 
not user driven repository, several user submitted data series are already included in 
arrayMap. Accordingly, the website provides an interface for user data processing. Users 
are able to upload private data in a number of formats, and to obtain summary reports and 
to visualize their data. At present, the Zebrafish (Danio rerio) genome is integrated into 
Progenetix, which enables researchers to analyze Zebrafish data with the benefit of online 
tools.
8.2 “SNIPING” CANCER GENES
As discussed in Chapter 5, arm-level genomic aberrations often involve entire 
chromosomes or chromosomal arms. These patterns are typically tumor type specific and 
have been used to distinguish cancer subtypes. Since arm-level CNAs spread over 
thousands of genes, focal CNAs may be more useful to narrow the list of candidate 
targets. With the progress of microarray technology, current arrays contain as many as 1.8 
million probes that tile the reference human genome. They enable the sensitive and 
reliable detection of very small (~10 kb) CNAs. Such high resolution arrays can readily 
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detect CNAs spanning several genes or even single gene. Therefore, the identification of 
candidate cancer genes by focal CNAs is possible. Many oncogenes and tumor 
suppressors have been identified from copy number profiles of cancer genomes. For 
example, GISTIC (Genomic Identification of Significant Targets in Cancer)50 is an algorithm 
designed to identify significantly  altered genomic regions. The detected peak regions 
frequently  contain target genes. Based on our large-scale datasets, focal CNAs can be a 
valuable resource in identifying novel cancer genes.
Besides focal CNAs, breakpoints are also potential resources for screening driver genes. 
For instance, DNA strand break may occur within a gene and result in dysfunctional 
protein production. If breaks occur within two distinct genes to create a fusion gene, it may 
encode either a defective protein or a protein with novel functions. In addition, breakpoints 
may disturb regulatory elements of genes, so that change the expression of the involved 
gene. Note that, the ability to detect target genes by breakpoints will be limited by 
resolution of arrays, the higher resolution, the more accurate localization of breakpoints 
can be obtained. Moreover, CNVs may also influence the results and cause false 
positives. A recent study developed an algorithm, GFD (Genomic Fusion Detection)197, to 
detect fusion genes based on the segmentation data from Affymetrix SNP6 array. In this 
tool, breakpoints are defined by segments of DNA. Subsequently, simulated and real 
cancer data were used to train and test this algorithm. GFD is able to detect non-
functional, silenced and novel fusions. In general, many useful tools are available to be 
applied to our datasets. They are supposed to provide further valuable data.
8.3 DIGGING DEEPER INTO THE MECHANISMS OF CHROMOTHRIPSIS
In the work described in Chapter 6, we identified 1,269 chromothripsis chromosomes from 
918 cases among more than 100 cancer types. This dataset gives us a good opportunity 
to further explore the mechanism(s) responsible for the generation of chromothripsis. In 
our analysis, although most (76%) chromothripsis cases presented single chromosome 
shattering events, in approximately 24% chromothripsis cases affected at least 2 
chromosomes (Figure 10A). According to this observation, we hypothesize that more than 
one mechanism may be responsible for this catastrophic event.
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Figure 10. Evidence of different  potential mechanisms underlying chromothripsis. (A) The 
number of chromosomes affected by  chromothripsis per sample. The numbers outside and inside 
the brackets are number and percentage of CTLP samples respectively. (B) An example of 
chromothripsis that may  result from DNA double-strand break. (C) An example of chromothripsis 
that may be caused by replicative processes.
Interestingly, the distinctive patterns of copy number states give some clues for the 
mechanisms underlying these events. Chromothripsis cases in our dataset can be 
classified into two basic categories, based on their copy number states of the pulverized 
genomic regions105,198. In the first category, the copy number changes alternate between 
two or three states: gain, loss and/or normal (Figure 10B). It implies that these breakpoints 
may result from DNA double-strand break while the chromosomes are condensed for 
mitosis105,107. This hypothesis is supported by the initial report of chromothripsis 
phenomenon. The second category comprises of cases which exhibit more than three 
copy number states in the chromosome shattered regions35,41,144 (Figure 10C). These 
features may be attributed to long-distance template-switching by FoSTeS42 (Fork Stalling 
and Template Switching) or MMBIR36,39 (Microhomology-Mediated Break-Induced 
Replication). The evidence in support of this hypothesis comes from a recently published 
study that revealed the replicative processes involved in chromothripsis by breakpoint 
sequencing. To further elucidate these potential mechanisms, the cancer-related genes 
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and pathways in chromothripsis regions can be investigated. They may provide insight into 
the difference between both mechanisms. Furthermore, the measurement of the 
enrichment with respect to GO (Gene Ontology)199 categories can be performed to 
facilitate biological interpretation and hypothesis testing. Since the chromosome-shattering 
was observed in a wide variety of tumors, the underlying mechanism is likely to reflect 
unknown general features of human cancer.
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Abstract
Background: Regional genomic copy number alterations (CNA) are observed in the vast majority of cancers. Besides
specifically targeting well-known, canonical oncogenes, CNAs may also play more subtle roles in terms of modulating
genetic potential and broad gene expression patterns of developing tumors. Any significant differences in the overall CNA
patterns between different cancer types may thus point towards specific biological mechanisms acting in those cancers. In
addition, differences among CNA profiles may prove valuable for cancer classifications beyond existing annotation systems.
Principal Findings: We have analyzed molecular-cytogenetic data from 25579 tumors samples, which were classified into
160 cancer types according to the International Classification of Disease (ICD) coding system. When correcting for
differences in the overall CNA frequencies between cancer types, related cancers were often found to cluster together
according to similarities in their CNA profiles. Based on a randomization approach, distance measures from the cluster
dendrograms were used to identify those specific genomic regions that contributed significantly to this signal. This
approach identified 43 non-neutral genomic regions whose propensity for the occurrence of copy number alterations
varied with the type of cancer at hand. Only a subset of these identified loci overlapped with previously implied, highly
recurrent (hot-spot) cytogenetic imbalance regions.
Conclusions: Thus, for many genomic regions, a simple null-hypothesis of independence between cancer type and relative
copy number alteration frequency can be rejected. Since a subset of these regions display relatively low overall CNA
frequencies, they may point towards second-tier genomic targets that are adaptively relevant but not necessarily essential
for cancer development.
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Introduction
Genetic changes such as point mutations, regional copy number
alterations/aberrations (CNA) and structural changes (e.g. gene
fusion events) are all hallmarks of cancer. CNAs arise as somatic
changes in the tumor cell genome through a variety of mechanisms
and can be observed in virtually all types of cancer, to a varying
extent. So far, the most widely used methods for the detection of
CNAs have been chromosomal and array-based Comparative
Genomic Hybridization (CGH) techniques [1–4]. Localized,
recurring CNAs (hot-spots) have been shown to target canonical
oncogenes (e.g. duplications/amplifications of the MYC, MYCN,
REL loci) or tumor suppressor genes (e.g. deletions of the
CDKN2A/B, TP53, ATM loci). Some regional CNAs such as
gains on 8q and losses on 3p are present across multiple cancer
types, whereas other imbalances may be largely restricted to a
limited number of cancer entities [5].
Datasets integrated across multiple cancer types have previously
been analyzed, to report regional ‘‘hot-spots’’ of frequent CNAs
[5,6]. In a given set of individual tumor samples, the number and
distribution of CNAs varies considerably [5] and this genetic
heterogeneity has been used to detect and report co-occurring
CNAs [7].
In principle, specific patterns and similarities in the individual
and/or disease specific CNA profiles might point to distinct
oncogenomic mechanisms acting in different cancer types and
specimens, given a sufficiently large number of data points.
Indeed, clustering of CNA patterns has been used to identify
oncogenomic similarities [5,8–11]. The adaptation of clustering
techniques to the analysis of CNA patterns has been subject of
previous studies [12–14]. With a few exceptions [5,14], however,
sample-based clustering has been the main focus of such studies so
far. In contrast, we here explore the clustering of cancer types, not
of individual cancer samples.
Both descriptive and clustering-based analyses of CNA across
multiple cancer types suffer from a bias towards the more
frequently occurring events. Due to the heterogeneity of the
overall CNA signal, with greatly varying average frequencies of
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CNAs per cancer type (Figure 1a), clustering results may be
distorted depending on the disease entities analyzed. This
variation in overall CNA occurrence frequencies across cancer
types may simply be owed to differences in the average time points
of clinical detection or in different progression characteristics, and
should be corrected for prior to clustering analyses. To the best of
our knowledge, so far no implementation has been reported for a
comprehensive, very large-scale clustering analysis of frequency-
normalized cancer CNA profiles.
Here, we focus on the identification of genomic regions that
contribute meaningfully to the clustering of cancer types. From
hereon we will refer to those as ‘‘non-neutral’’ regions. As the
starting point of our analysis, we use hierarchical clustering to
arrange cancer types on the basis of their CNA frequency profiles.
We then employ a permutation approach to estimate the relative
contribution of individual genomic regions to the quality of the
clustering and to the derived relationship tree. The clustering
quality is inferred from an intrinsic measure (summed branch
lengths: tree height statistics), and genomic regions that reject the
null hypothesis are termed non-neutral. Identified regions are
compared to canonical CNA hot-spots (i.e. those that occur most
frequently across the entire dataset).
Our current analysis is based on data from a total of 25579
samples, which are classified into 160 different cancer entities
(table S1) according to the International Classification of Disease
in Oncology (ICD-O 3). Our approach is unique in that it a)
focuses less on the clustering as such but more on the individual
genomic regions that best support the clustering, b) uses an
intrinsic quality measure coupled to a permutation strategy for
validation, c) performs CNA frequency normalization prior to
analysis, and d) is based on a very large data set, processed in a
standardized setup. We aim for the identification of potential
cancer-specific driver/modulator regions, which may not have
been detected in earlier, largely hot-spot-focused approaches. All
of the underlying cancer data is available through our Progenetix
repository (www.progenetix.org; [15]).
Results
The average overall frequency of CNAs across the entire
genome varies among different cancer types (Figure 1a). Since the
relative weight of CNAs at individual genomic regions in a given
cancer type depends on the observed overall genome-wide
frequency, we aggregated all patient samples by cancer type and
normalized the frequencies of CNAs for each cancer type to the
overall mean observed across the entire data set (Figure 1b, Figure
S1). The normalized CNA frequency profiles were then clustered
using hierarchical clustering.
To evaluate the quality and the biological signal in the
clustering, we labeled each cancer type with its ‘‘root’’ cell type
(i.e., an undifferentiated cell type from which the tumor likely
originated). We expected cancers of the same root cell type to
cluster together; this was used as an external proxy for the
expected biological relationships between cancer entities. The
Random Index [16] was used to compute this external cluster
quality measure. Tumors of the same cell type indeed often
clustered together, usually in 2–3 small groups (Figure 2). The
consistency of this grouping was significantly higher than expected
Figure 1. The overall frequency of genomic copy number alterations (CNA) differs among cancer types. Boxplots show the CNA
frequency distributions among tumor samples in 10 randomly selected cancer types. The boxplot delineations mark the percentiles 5%, 25%, 75%
and 95%. The red lines indicate the mean frequency for each cancer type, whereas the blue line represents the overall mean frequency across all 160
cancer types analyzed here. Frequency values are defined as the ratio of number of samples showing a CNA for a genomic region (i.e., cytogenetic
bands) over total number of samples in that cancer type. a) Before normalization b) After normalization. In b) the nominal frequency distribution for
each cancer type is re-scaled so that its mean matches the overall mean across all cancer types. (NOS – ‘‘not otherwise specified’’: high-order
classifications, not further assigned to more detailed levels).
doi:10.1371/journal.pone.0043689.g001
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at random, pointing towards biologically meaningful differences in
CNA profiles between tumors of distinct origins. Cutting the tree
at several heights always led to an observed quality of clustering
that was better than the expected random value (Figure 2), except
for the cut at the highest level, which resulted in only three
clusters. This strongly argues against a completely neutral
occurrence pattern of CNAs in the genome, and supports a
correlation between biologically meaningful groups of cancer
entities and their CNA profiles.
Randomizations of the entire frequency matrix lead to a
complete loss of the signal present in the clustering tree (Figure S2),
and also strongly reduced the summed branch lengths tree-height
statistic.
Non-neutral CNAs
The normalized and clustered frequency matrix encompassing
160 large-scale genomic regions and 160 cancer types is shown in
Figure 3. To determine how much each individual genomic region
contributes to the overall signal, we individually randomized its
profile across cancer types, while keeping the rest of the data
unchanged. We then examined the concomitant reduction in the
tree length statistics (TLS) of the clustering dendrogram, upon
100000 independent randomizations, to determine the statistical
significance of that region’s contribution. The resulting cancer-
diverging CNA regions are important as they cannot be fully
neutral and have the potential to define relationships among
cancer types. Indeed, 43 out of the 160 genomic regions (table S1)
were observed to have a non-neutral contribution (Bonferroni-
corrected p-value ƒ0:016) in the aggregated cancer CNA data.
Note that gain and loss events were treated independently, and no
preferential bias towards gains or losses was observed among the
detected non-neutral regions (22 gains and 21 losses). The CNA
occurrence frequencies of the non-neutral genomic regions spread
thorough the entire frequency spectrum (Figure 4). Only 13 (8
gains and 5 losses) of the non-neutral regions were found altered
overall more often than average (Figure 5, intersection of black
and grey rectangle), indicating that subset of frequently altered
hotspot regions carry a detectable signal to distinguish cancer types
(the number of frequently altered regions stands at 59; Bonferroni-
corrected p-valueƒ0:016, table S1). This observation emphasizes
our key point that not only the frequent CNA regions should be
used to cluster and annotate cancer types.
22 genomic intervals across 12 chromosomes were found to be
informative when specifically considering duplications/gains only
(Table 1 and Figure 5). All three genomic segments of
chromosome 18 (18p1, 18p2, 18q2) exhibited a signal. For other
chromosomes such as chromosome 1 (1q2,1q3,1q4,1p2), chromo-
some 3 (3q1, 3q2, 3p1), chromosome 12 (12q1,12q2) and
chromosome 21 (21p1, 21q1) more than 50% of genomic regions
were informative as gains, suggesting simultaneous involvement of
multiple loci from these chromosomes. Changes on chromosome
1(1p2), chromosome 3 (3p1, 3q1), chromosome 5 (5q2, 5q3),
chromosome 9 (9p1), chromosome 11 (11p1), chromosome 12
(12q1, 12q2), chromosome 18 (18p1, 18q1, 18q2) and chromo-
some 21 (21p1, 21q1) were selectively informative only as gains. In
terms of deletions/losses, 10 chromosomes encompassing 21
genomic regions were found to be non-neutral. Like for
chromosome 18 gains, the complete chromosome 7 (7p1, 7p2,
7q1, 7q2, 7q3) was found to be informative when lost (Table 1).
Informative regions on chromosome 1 (1p1,1q1, 1q2, 1q3, 1q4)
and chromosome 9 (9q1, 9q3, 9p2) covered more than 50% of
genomic segments present on these chromosomes. Selective losses
were observed on chromosome 1 (1p1, 1q1), chromosome 6 (6q2),
7 (7q1, 7q2, 7q3, 7p2), 8 (8q1, 8q2), 9 (9p2, 9q1, 9q3), 12 (12p1),
16 (16q1). CNAs involving chromosome 1 (1q2, 1q3, 1q4),
chromosome 3 (3q2), chromosome 7 (7p1), chromosome 19 (19p1)
and chromosome 22 (22q1) were informative both as gain and loss
events. This represents a small proportion (16%) of non-neutral
CNA. Involvement of a region both as gain and loss may point
towards multiple adaptively relevant loci, and/or towards a
generally unstable nature of these regions.
Cancer Diverging Nature of Non-neutral CNA
To provide few examples of cancer classifying behavior of non-
neutral changes, we selected a few of the enriched changes and
analyzed them for their specific occurrence in different cancers.
An example include cancer entities showing predominant losses
versus gains on 7q. Preferential losses involving 7q were observed
in germ cell, myeloid and myeloproliferative tumors (Figure 3)
whereas neuroepithelial brain tumors (among other entities)
preferentially displayed gains on 7q. Losses involving 7q are
common in myeloid and myeloproliferative tumors [17–20] and
are associated with advanced age and resistance to therapies
[21,22]. However, here we show that 7q losses are quite specific to
myeloid tumors and promote their selective divergence from other
cancer types. 7q losses in germ cell tumors had not been explored
in detail [23,24]. With the accumulation of 7q losses virtually
restricted to myeloid/myeloproliferative neoplasias and germ cell
tumors and in contrast to chromosome 7(q) gains observed in e.g.
neuroepithelial brain tumors, it is tempting to propose involve-
ment of at least one common oncogenetic mechanism acting in
these clinically unrelated malignancies.
Chromosome 8q gains can be observed in the majority of
cancer entities [5,6]. However, in our analysis 8q losses were
enriched as non-neutral events. Preferential losses involving 8q
were present in some brain tumors (e.g. medulloblastoma,
Figure 3), separating them from other epithelial tumors. Differ-
ences in preferential losses involving 8q separated neuroepithelial
tumors in two categories with both having gains on 7q but only
one (mainly meduloblastomas) having preferential losses on 8q
(Figure S3). Losses involving chromosome 8q across medulloblas-
tomas have been reported by a few [25] studies before. Our
analysis shows that 8q losses are selected for in some medullo-
blastomas and therefore could be important for cancer develop-
ment/progression. Preferential losses of 8q were also observed in
germ cell tumors separating them from other epithelial neoplasias
(Figure S4).
As another example of restricted CNA types we also looked for
cancers showing gains involving chromosome 18. Follicular
lymphomas exhibited specific gains on chromosome 18 where as
epithelial tumors prefered to loose chromosome 18 (Figure S4).
Chromosome 18 gains are very common in follicular lymphomas
and are supposed to provide an alternative mechanism for BCL2
activation [26,27]. However, here we show that this CNA event
statistically separates them from other cancer types.
Discussion
Our current study represents the largest analysis performed to
date on cancer CNA data, with the aim of detecting oncogenomic
features that may be specifically associated or enriched in certain
subsets of cancer entities. In contrast to gene-centric approaches,
our analysis assesses the complete information space of genomic
copy number imbalances from whole genome profiling experi-
ments.
Overall, the frequency of CNAs across genomic intervals varied
between between 0.01% to 23% (Figure 4). Clustering of cancer
types on the basis of their frequency profiles helped to identify a
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Figure 2. The tissue type of a cancer has a strong influence on its CNA likelihood pattern. a) examples of individual chromosome
segments, showing their observed CNA frequencies stratified by cell type. Each dot summarizes all samples classified under one particular ICD type,
color-coded by root cell type. In the left panel, three chromosome segments are shown that exhibit strong differences between cell types; on the
right, three negative examples without such a signal. All p-values were corrected for multiple testing according to Benjamini-Hochberg. b) the
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class of underlying molecular signals that is orthogonal to
histological classifications or clinical categories (the latter are
predominantly driven by the affected organ/tissue). Cancer types
vary from each other in their CNA abundance, CNA size
spectrum and degree of genomic instability. With respect to
genomic coverage, large CNAs are generally frequent in cancer
[6] and should not be excluded from statistical analyses of cancer
genome patterns. While comparing CNA profiles of cancer types,
their complexity and variation in frequencies have to be
considered. When correcting for these parameters, regional CNAs
defining the divergence of the overall profiles can be delineated.
We performed an analysis of a global cancer CNA dataset,
identifying 43 genomic regions on 15 chromosomes as significant
for CNA profile divergence in cancer types. Obviously, these
changes do not cover the entire spectrum of CNA events in cancer,
but define a subset of genomic regions that may have a possibly
adaptive link to the distinct biology of various cancer types. These
regions overlap rather poorly with hot-spot regions observed in
many cancers. This suggests that hot-spot regions, though
frequently associated with canonical oncogenes, may not always
be very useful in aiding data-driven evaluation of cancer (sub-)
types.
Disease specific studies have the potential to detect a
representative spectrum of oncogenomic aberrations in the given
entities. It can be expected that the cancer type specific regions
highlighted with our approach had been discussed in the context
of the respective publications. However, with our current study,
we aim to provide a new, generalized approach at identifying
genomic elements relevant in the genesis of individual cancer
entities. Although here showcasing a ‘‘global’’ approach without
entity pre-selection, our methodology may prove valuable when
targeting relevant genomic separators in limited, biologically
related entity sets.
Since the current analysis is based primarily on molecular-
cytogenetic data from chromosomal CGH experiments with a
spatial resolution of several megabases, only inferred information
about the causal genes present in the non-neutral regions could be
obtained. With upcoming high-resolution genomic array and/or
sequencing data, similar analyses will more specifically define the
non-neutral CNAs and can be valuable starting points for an
integration of the results with functional pathway frameworks. We
have recently announced the creation and public availability of a
reference resource for oncogenomic array data (www.arraymap.
org [28]), which will serve as starting point for such approaches
dendrogram (tree) has been obtained using hierarchical Ward clustering on the global frequency-normalized CNA profiles across all 160 genomic
regions. Cancer types are again color-coded according to the cell type of origin, with the same legend as in a). Partitioning the tree by cutting at
different heights produces multiple clusters; validation of those clusters based on the cancer origin (metric: Random Index) shows that the clustering
works significantly better than expected at random.
doi:10.1371/journal.pone.0043689.g002
Figure 3. Examples for non-neutral CNA regions. a) Heatmap of CNA profiles on genomic regions (same clustering as in Figure 2). Genomic
locations are represented with orange color when considering duplications/gains, and in blue when considering deletions/losses. Color intensity
shows relative CNA frequencies; the most-affected region in each row is arbitrarily set the to brightest color (1.0) for display purposes. b) Small
regions (black rectangles on the heatmap) are zoomed in to show how non-neutral CNAs can differentiate between cancer types. The example shows
that 7q is preferentially gained in brain tumors (red labels) whereas it is preferentially lost in germ cell (black labels), myeloid and myeloproliferative
cancer types (blue labels). c) Small regions (red rectangles on the heatmap) are zoomed in to show how 8q is preferentially lost in medullublastomas
(green labels) and is preferentially gained in epithelial tumors (pink labels). Some chromosomes consist entirely of non-neutral regions (such as
chromosomes 18 and 7). Note that the spatial resolution of the CNA data on the chromosome is limited (roughly corresponding to cytogenetic band
resolution).
doi:10.1371/journal.pone.0043689.g003
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both from our side as well as from interested members of the
research community. Also, although we have focused our current
analysis solely on a CNA dataset, our methodology should prove
particularly valuable when combined with other sets of related
diagnostics (for example point mutation data), whereby the
assignment of possible driver genes in the non-neutral regions
might become feasible.
Figure 4. Not only CNA ‘‘hotspots’’ are informative in cancer classification. Genomic regions (bands) are sorted according to their overall
frequency of CNAs observed. Those regions that are informative with respect to cancer type clustering are marked with arrows. a) Considering
duplications (gains) b) Considering deletions (losses).
doi:10.1371/journal.pone.0043689.g004
Figure 5. Comparison of non-neutral vs. hot-spot CNA. Genomic regions affected by CNAs, either more frequently than average (black
rectangle), or non-neutrally with respect to cancer-type classifications (grey rectangle). The intersection defines regions that are affected both
frequently and non-neutrally. Changes are color-coded (gains in orange and losses in blue).
doi:10.1371/journal.pone.0043689.g005
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Materials and Methods
Data
Our study is based on well annotated cancer CNA data from
the Progenetix project [5], including a total of 25579 samples
analyzed by chromosomal (cCGH; 18708) and array CGH
(aCGH; 6871) experiments. The clinical samples had been
classified into 160 distinct cancer entities according to the
International Classification of Disease codes (ICD). At the time
of writing, the Progenetix collection represents the largest resource
for annotated, whole genome CNA profiling data in cancer.
For our analysis, regional CNA information across all cancer
types was reduced to 80 genomic intervals covering the entire
genome with the exception of the sex chromosomes. Gain and loss
events were considered separately for the analysis, resulting in a
matrix of dimensions nXm, where n is the number of samples and
m is the number of genomic intervals (i.e. 160).
Cancer Clustering
The frequency of CNA changes across all genomic intervals was
computed for each ICD type, and the entire frequency matrix was
then normalized (Figure S1). The frequency matrix was ordered
using hierarchical Ward clustering. The aggregated separation
distance between cancer entities obtained using hierarchical
clustering can be analyzed by parsing the clustering tree
(dendrogram). The tree represents the relatedness among groups
present in the same clade (similar to phylogenetic trees).
Randomized data disrupts the tree completely (Figure S2), and
the overall tree height statistic is reduced 3-fold, reflecting the
complete loss of ordering information present in the original tree.
Method to Compare Tree Height
We used the tree height as an intrinsic measure to compare
cancer associations obtained using clustering and to gauge the
information present in the tree; this was used to define non-neutral
CNAs. This has advantages over traditional clustering evaluation
techniques, as it a) does not require external gold standard
information, and b) does not require cutting the tree at an
arbitrary distance. The overall tree height is defined as the sum of
all direct parent-child relation path lengths in the tree. Tree
distances (branch lengths) generally reflect the CNA profile
discrepancies between two cancers (or groups of cancers). For
any node i, the tree height between this node and its immediate
parent j can be measured as THj{THi. The overall tree height of
a tree with n nodes is than obtained as OTH =Pi~n,j~n
i~1,j~1 THj{THi (figure S3).
Tree length statistics (TLS). To identify genomic regions
that are non-neutrally affected by CNA we have developed the
following permutation strategy:
1. Normalized frequencies of CNA across all genomic intervals
are computed across all cancer types.
2. The cancer classification tree is obtained using hierarchical
Ward clustering.
3. The observed over all tree height (OTHo) is calculated as
mentioned above (Figure S5).
Table 1. Number of non-neutral regions per chromosome.
Chromosome No. No. genomic locations Non-neutral gains Non-neutral losses
1 7 4 5
2 5 – –
3 4 3 1
4 4 – –
5 4 2 –
6 4 – 1
7 5 1 5
8 4 – 2
9 5 1 3
10 3 – –
11 3 1 –
12 3 2 1
13 4 1 –
14 4 – –
15 3 – –
16 3 – 1
17 3 – –
18 3 3 –
19 2 1 –
20 2 – –
21 3 2 –
22 2 1 –
Some chromosomes consist entirely of non-neutral regions (such as choromosomes 18 and 7). Note that the spatial resolution of the CNA data on the chromosome is
limited (it roughly corresponds to the cytogenetic banding patterns).
doi:10.1371/journal.pone.0043689.t001
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4. A counter C is set to zero for every genomic interval in
consideration.
5. For any genomic interval i, its status values are shuffled among
all samples keeping its over all frequency the same (ni).
6. The frequency of CNA at genomic interval i is re-calculated
after randomization across all cancer types. The shuffling in the
previous step changes the frequency of interval i across all
cancer types keeping the normalized frequency distribution of
all other genomic intervals.
7. The frequencies for interval i in the normalized frequency
matrix from step one are replaced with permuted frequencies
for this interval and the permuted overall tree heigh (OTHi,p) is
computed.
8. If OTHi,p§OTHo, C is incremented as C=C+1.
9. p-value for genomic location i, at the end of N (100’000)
permutations is computed as pi~C=N.
10. p-values across all bands are corrected for false discovery
rate using Bonferroni correction.
Frequency Based Enrichment (FBE)
Frequently observed CNA regions (‘‘hot-spots’’) are genomic
changes that occur more often than expected under a fully random
null model. Such hot-spot CNAs can be identified using the
binomial probability function [29]. Let’s suppose genomic interval
i shows a CNA across ni samples out of N samples. The
background CNA frequency (nb) can be represented as the mean
frequency change across all intervals. The p value that the
frequency of CNA ni, is more than any frequency x (ni§x) is
obtained using the binomial probability function.
p(ni DN,nb)~
N
ni
! "
n
ni
b (1{nb)
N{ni
pi~
XN
n~x
p(ni DN,nb)
Genomic intervals showing a large deviation from the mean will
be assigned low p-values. All p-values are corrected for false
discovery rate using Bonferroni correction.
Supporting Information
Figure S1 Method for CNA frequency normalization
across cancer types. All the frequencies among cancer types
were normalized to the mean frequency of CAN changes across
across the 160 cancer types. This normalization was achieved by
multiplying the cancer-type-specific frequencies with an index An,
whose value was calculated as shown.
(PNG)
Figure S2 Dendrogram of a permuted frequency ma-
trix. For this clustering, the frequencies among cancer types were
permuted and then normalized. Hierarchial Ward clustering was
then performed and the dendrogram tree shown was obtained.
The tree height is severely affected by the permutation. In this
randomized clustering, similar cancer types no longer clustered
together.
(PDF)
Figure S3 Small regions from heatmap in main Figure 3
are shown here. These regions represent gains and losses on 7q
and 8q. 8q changes differentiate between two categories of brain
tumors, with a subset showing preferential losses on 8q (green
labels) and other rarely showing involvement of 8q locus (red
label). Thus depending on 8q involvement neuroepithelial tumors
can be divided in to two different categories. Both of them show 7q
gains.
(PDF)
Figure S4 Examples for non-neutral CNA regions. a)
Heatmap of CNA profiles on genomic regions (same as in
Figure 3). b) Small regions (red rectangles on the heatmap) are
zoomed in to show how 8q is preferentially lost in in germ cell
(black labels) tumors and is preferentially gained in epithelial
cancer types (pink labels). c) Small regions (black rectangles on the
heatmap) are zoomed in to show how 18q is preferentially gained
in medullublastomas (brown labels) and is preferentially lost in
epithelial tumors (pink labels). The examples here show that how
two different non-neutral changes differential epithelial tumors
from germ cell tumors and follicular lymphomas.
(PDF)
Figure S5 Calculation of over all tree height. Schematic
representation of the summed branch-length tree height statistic.
Overall tree height is computed by summing up the distance
between all parents and child nodes. Note that the branch lengths
of terminal branches (‘‘leafs’’) are not considered. Overall tree
height = HA{CzHBDzHABzHE .
(PDF)
Table S1 Table with information about cancer types
used in the analysis, non-neutral and hot-spot p values.
The table giving details about all cancer types used in this analysis
with the corresponding numbers of samples in them and the root
cell type of each cancer. The table also has information about the
non-neutral and hot-spot p-values obtained for all genomic bands
in analysis.
(ODS)
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Abstract Little is known about frequency, association
with clinical characteristics, and prognostic impact of DNA
copy number alterations (CNA) on survival in central
primitive neuroectodermal tumors (CNS-PNET) and
tumors of the pineal region. Searches of MEDLINE, Pub-
med, and EMBASE—after the original description of
comparative genomic hybridization in 1992 and July
2010—identified 15 case series of patients with CNS-
PNET and tumors of the pineal region whose tumors were
investigated for genome-wide CNA. One additional case
study was identified from contact with experts. Individual
patient data were extracted from publications or obtained
from investigators, and CNAs were converted to a digitized
format suitable for data mining and subgroup identification.
Summary profiles for genomic imbalances were generated
from case-specific data. Overall survival (OS) was esti-
mated using the Kaplan–Meier method, and by univariable
and multivariable Cox regression models. In their overall
CNA profiles, low grade tumors of the pineal region clearly
diverged from CNS-PNET and pineoblastoma. At a median
follow-up of 89 months, 7-year OS rates of CNS-PNET,
pineoblastoma, and low grade tumors of the pineal region
were 22.9 ± 6, 0 ± 0, and 87.5 ± 12 %, respectively.
Multivariable analysis revealed that histology (CNS-
PNET), age (B2.5 years), and possibly recurrent CNAs
were associated with unfavorable OS. DNA copy number
profiling suggests a close relationship between CNS-PNET
and pineoblastoma. Low grade tumors of the pineal region
differed from CNS-PNET and pineoblastoma. Due to their
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high biological and clinical variability, a coordinated
prospective validation in future studies is necessary to
establish robust risk factors.
Keywords Chromosomal imbalances ! Prognostic
markers ! Comparative genomic hybridization !
Brain tumor
Introduction
Central nervous system primitive neuroectodermal tumors
(CNS-PNET) are a heterogeneous group of WHO grade IV
lesions (Supplementary Table 1). They comprise 3–7 % of
brain tumors in children and young adults [1, 2] and are
associated with a dismal prognosis [3, 4]. Histologically,
these highly proliferative lesions are currently divided into
CNS-PNET or supratentorial PNET, respectively (syno-
nym PNET not otherwise specified, PNET NOS), CNS
neuroblastoma, CNS ganglioneuroblastoma, medulloepi-
thelioma, and ependymoblastoma [5]. CNS-PNET and
medulloblastoma share a similar histology and are often
solely distinguishable by their supratentorial versus infra-
tentorial location. Further, pineoblastoma, a WHO grade
IV tumor of the pineal gland [5], is filed in some studies as
CNS-PNET although pineoblastoma forms a group of
neoplasms of the pineal region together with pineocytoma,
pineal parenchymal tumor of intermediate differentiation,
and papillary tumor of the pineal region [5]. The classifi-
cation of malignancies within the group of embryonal
tumors has changed considerably in the last four editions
of the WHO classification of tumors of the CNS (Supple-
mentary Table 1). Tumor classification systems are
increasingly complemented by molecular genetic profiling
data, especially in hematologic neoplasias [6]. However,
for the various subtypes of CNS-PNET, such data are still
scarce and large series are missing. Profiling of regional
copy number abnormalities (CNA) by genomic hybridiza-
tion techniques is a robust methodology for whole genome
data analysis. Principal techniques include the different
variants of chromosomal and array-based comparative
genomic hybridization (cCGH/aCGH; [7–10]) and single-
color oligonucleotide array technologies [e.g., genomic
single nucleotide polymorphism (SNP) arrays].
In contrast to data from gene expression measurements,
CGH data is easily adaptable across multiple datasets to per-
form a meta-analysis. Methods to assess genomic CNAs are
standardized and reproducible as demonstrated in previous
reports (e.g., [11, 12]). Some earlier reviews have reported on
specific types of aberrations orwere focusedon thedescriptive
analysis of certain classes of malignancies [13, 14].
Due to the low incidence of CNS-PNET and pineo-
blastoma, only a few CGH studies have been reported in
these tumors [2, 15–17]. So far, results have suggested that
CNS-PNET are genetically heterogeneous with frequent
and diverse CNAs and that CNA patterns are distinct from
those observed in medulloblastoma [2, 15–17].
For the present study, we performed an individual
patient data (IPD) meta-analysis—a specific method of
systematic review [18] offering advantages for meta-anal-
ysis [19, 20]—of genomic imbalances in CNS-PNET and
tumors of the pineal region. The collected data are made
available through the ‘‘Progenetix’’ molecular-cytogenetic
database (www.progenetix.org: [14, 21, 22]).
Methods
Search strategy, and selection criteria
Wedid amodification of theCochraneHighly Sensitive Search
Strategy for prognostic studies [20] combined with predefined
search terms in MEDLINE, Pubmed, and EMBASE without
language restriction [23, 24]. The process of the study retrieval,
in- and exclusion of studies/patients is displayed in the flow
chart (Supplementary Fig. 1) according to the PRISMA (pre-
ferred reporting items for systematic reviews and meta-analy-
ses) statement.The searchwas limited toarticlespublishedafter
the original description of CGH [7] until July 2010. Key words
were: ‘‘medullo(-)blastoma(s)’’, ‘‘primitive neuroectodermal
tumo(u)r(s)’’, ‘‘neuroectodermal tumo(u)r(s) primitive’’ ‘‘pnet
(s)’’, ‘‘medullo(-)epithelioma(s)’’, ‘‘ependymoblastoma(s)’’,
‘‘ganglioneuroblastoma(s)’’, ‘‘pinealoma’’, ‘‘pineocytoma(s)’’,
‘‘pineoblastoma(s)’’, ‘‘pineal tumo(u)r(s)’’, ‘‘pineal parenchy-
mal tumo(u)r(s)’’, ‘‘mixed transitional pineal tumo(u)r(s)’’,
‘‘mixed transitional pineal tumo(u)r(s)’’, ‘‘atypical teratoid
rhabdoid tumo(u)r(s)’’, ‘‘rhabdoid tumo(u)r(s)’’, ‘‘AT(/)RT’’
and ‘‘rhabdoid’’, ‘‘supratentorial neoplasm(s)’’ or ‘‘neuroblas-
toma(s)’’ and ‘‘central nervous system neoplasm(s)’’; and
‘‘cgh’’ or ‘‘comparative genomic hybridization’’ or ‘‘snp’’ or
‘‘SNP’’ or ‘‘genomic array(s)’’ or ‘‘copy number’’ or ‘‘dna
microarray(s)’’ or ‘‘amplification’’. Additionally to the search
queries, we followed references from the selected articles and
assessed each abstract.Minimal requirements for inclusion of a
patient to the study were the availability of case-specific
genomic copy number data with whole genome coverage, the
unambiguous diagnostic classification of CNS-PNET/tumor of
the pineal region, and matching available or inferred locus
information.
Fig. 1 Delineation of 3 distinct clinicogenetic subgroups. a Regional
copy number imbalances for individual cases were plotted separately
by overall diagnostic assignment [yellow gain, blue loss, blue tumors
of the pineal region except pineoblastoma, light blue pineoblastoma,
pink central primitive neuroectodermal tumors (CNS-PNET)]. Indi-
vidual profiles were arranged by hierarchical clustering inside their
groups. b Histograms of genomic gain and loss frequencies (color
legend corresponding to (a))
c
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Clinical and CNA data collection, data extraction,
quality assessment, conversion of CNA data,
and data synthesis
For CGH results specified in cytogenetic annotation for-
mats, data were standardized to ISCN 1995 (International
System for Human Cytogenetic Nomenclature, 1995) ‘‘re-
vish’’ format based on an 862-bands karyotype and
checked for semantically correct annotation using dedi-
cated software. For genomic array data without annotated
gain/loss information, clone specific data files were seg-
mented using Progenetix website tools. Normalized data
were converted to Golden Path mapped copy number status
information by software implemented in the Perl scripting
language [14].
In a first step, clinical and genomic data were extracted
from publications by two reviewers (A.O.V.B. and M.B.).
Subsequently, the original data, in particular in case of
incomplete data (genomic and clinical data), for each par-
ticipant were obtained and updated directly from the
researcher responsible for each included study [25]. To
prevent duplicate inclusions, authors were asked to indicate
whether a patient had been analyzed within different studies.
In addition, copy number profiles were clustered for simi-
larity and reviewed for the occurrence of profile pairs, in
order to avoid duplicate cases due to republished data. Data
of three unpublished CNS-PNET patients were provided by
two authors (S.P. and O.D.). Generally, two approaches to
perform IPD meta-analyses are used. First, IPD meta-anal-
yses can be performed directly, as if all data belong to a
single trial/study, termed the ‘‘one-stage’’ approach [26].
Second, a ‘‘two-stage’’ approach can also be used. Each trial/
study is analyzed separately using its raw data before the
summary results from each trial/study are pooled and ana-
lyzed using conventional meta-analyses techniques [26].
Due to the small patient numbers of each individual case
series, the ‘‘one-stage’’ approach was used here.
Exploratory data mining and statistical analysis
For the evaluation of regional copy number changes, non-
overlapping genomic segments were generated based on
the complete CNA data from all cases. For each of these
intervals, case-specific involvement was evaluated and
gain/loss frequencies determined. For visualization and
ordering of case-specific CNA data, data matrices were
produced containing imbalance status (gain, or loss) map-
ped to a variety of genomic intervals (from chromosomal
arm level down to 1 Mb). Cases were ordered by hierar-
chical clustering of gain/loss matrices (unsupervised,
complete linkage), and the derived case order was used
for re-plotting of the original CNA annotations. CNA
complexity, a relatively resolution-independent surrogate
marker of genomic instability, was determined for each
case by evaluating the occurrence of gain and loss events
per chromosome arm, with a maximum score of 2 per arm
(i.e. occurrence of one or more of each gain and loss;
modified from [27]).
To evaluate imbalance distribution in relation to diag-
nostic assignment, for each of the entities in our dataset, gain/
loss frequencies were calculated mapped to genomic inter-
vals on a 5-Mb level. Copy number profiles were compared
by generating a heatmap of gain/loss distributions.
Cases with clinical follow-up were evaluated with
respect to correlation of clinical factors and regional CNA
status to OS. OS was defined as date of diagnosis to death
of any cause or to the date of last visit. Cut-off values of
age and CNA complexity were determined by recursive
partitioning [28]. Univariable and multivariable survival
analyses were performed. OS was estimated by the Kap-
lan–Meier method, and the log-rank test was used for
comparisons of survival in different groups [29]. Univari-
able analyses to investigate the effect of age (continuous),
and CNA complexity (continuous) on OS was done with
univariable Cox regression analysis. Multivariable analyses
were performed using Cox’s proportional hazards model.
All statistical analyses are intended to be rather exploratory
than confirmatory. p values are considered statistically
significant when p\ 0.05. No adjustment for multiple
testing was carried out. Statistical analyses were performed
using SAS (v.9.2 for Windows; SAS Institute, Cary,
NC, USA), and PASW Statistics 18 for Windows (SPSS,
Chicago, IL, USA).
Results
Supplementary Figure 1 illustrates the process of evaluat-
ing articles for inclusion in the IPD meta-analysis. We
identified 1,220 papers by the search terms. The number of
papers was reduced to 840 after removing of duplicates (by
titles and abstracts). Title and abstract review resulted in
the exclusion of 710 papers. Three case-specific data (one
case series) were provided by two authors. We reviewed
131 papers in full, from which 15 studies, and 1 unpub-
lished case series (n = 3), met inclusion criteria for this
study (Supplementary Fig. 1).
Study characteristics and quality assessment
The 16 studies included here comprised 107 patients in
total, after exclusion of 4 cases with ambiguous CNA
profiles. From 61 patients, information about OS was
available (clinical characteristics are shown in Table 1). Of
those, 38 patients were profiled using aCGH and 23
patients using cCGH. The median follow-up time for
418 J Neurooncol (2012) 109:415–423
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survivors was 75 months, and the median follow-up time
across all patients was 89 months. Fifteen children were
aged B2.5 years and 46 patients were aged[2.5 years. The
cohort compromised all tumor entities classified as CNS-
PNET in the current WHO classification when taking into
account the update of earlier WHO classification in which
some of these tumors were partly classified as different
subgroups of embryonal tumors [5, 30] (n = 46), and
tumors of the pineal region (n = 15) which included pin-
eocytoma (n = 4), pineal parenchymal tumor of interme-
diate differentiation (n = 3), papillary tumor of the pineal
region (n = 5), and pineoblastoma (n = 3). Mean CNA
complexity was 9.4 (range, 0.00–30.00). For the purpose of
statistical analysis, CNS-PNET were considered as one
group and tumors of the pineal region were considered as
another group.
Overall genomic imbalance patterns in central nervous
system primitive neuroectodermal tumors and tumors
of the pineal region
In order to evaluate the overall patterns of genomic
imbalances in bona fide CNS-PNET and tumors of the
pineal region, we visualized the case-specific CNAs of all
tumors clustered for their overall imbalance similarities
(Fig. 1a). In CNS-PNET (n = 88), frequent gains of
chromosomes 1q4 [n = 31 (35 %)], 2p2 [n = 27 (31 %)],
and 7q3 [n = 16 (18 %)] as well as losses involving
chromosome 13q2 [n = 21 (24 %)], and 6q [n = 18
(20 %)] could be observed among other less frequent
changes (Fig. 1b). In contrast, low grade tumors of the
pineal region were characterized by gains of chromosomes
4q2 [n = 6 (46 %)], and 12 [n = 5 [38 %)] as well as
losses of chromosomes 10 [n = 4 (31 %)), and 22 [n = 5
(38 %)]. Interestingly, pineoblastoma (n = 6) displayed a
pattern of genomic imbalances unrelated to the changes
observed in the group of low grade tumors of the pineal
region. Supplementary Figs. 2–4 illustrate gains and losses
of the different disease entities.
We observed frequent gains involving chromosome 2
and losses involving chromosome 6 in ependymoblastoma
as well as in medulloepithelioma (Supplementary Fig. 3b,
c). Losses of chromosome 6 and 13 were typical for
ependymoblastoma.
Embryonal tumor with abundant neuropil and true
rosettes (ETANTR) was first described by Eberhart et al.
[31], but is so far not listed as a distinct tumor entity in the
2007 WHO classification [5] and represents a CNS-PNET
with ‘‘ependymoblastic’’ rosettes [32]. Recently, Korshu-
nov et al. [33] demonstrated in a series of 21 ependymo-
blastoma and 20 ETANTR that 95 % of ETANTRs and
90 % of ependymoblastoma have the unique focal ampli-
fication at 19q13.42.
Therefore, the term embryonal tumor with multilayered
rosette (ETMR) has been suggested for ependymoblastoma
and ETANTR, a new entity with multilayered rosettes for
which amplification at 19q13.42 represents a rather sensi-
tive and specific marker [32].
In our cohort, we identified 9 tumors with such an
amplification. As described previously by Li et al. [2],
cases with such an amplification predominantly (8/9) also
displayed gains of the whole or the major part of chro-
mosome 2. For some additional cases with gain of chro-
mosome 2 identified by cCGH, no high-resolution data
were available. Therefore, we may not rule out an addi-
tional amplification at 19q13.42 in these cases.
Univariable and multivariable survival analysis
of clinical factors and CNA complexity
To assess which parameters contribute to prognosis, we
evaluated each clinical variable by univariable Kaplan–
Meier analysis. Tested variables were: gender, age, histol-
ogy (CNS-PNET vs. tumors of the pineal region), metastatic
stage (no metastases vs. metastases), extent of postoperative
residual disease (complete/gross total resection vs. residual
disease C1.5 cm2), radiotherapy (no radiotherapy/local
radiotherapy vs. cranio-spinal radiotherapy), chemotherapy
(no chemotherapy vs. chemotherapy), CNA complexity
(\11 vs C11 as defined by recursive partitioning), tumor
Table 1 Demographics and disease characteristics of 61 patients
with central primitive neuroectodermal tumors (CNS-PNET) and
tumors of the pineal region
Characteristics Number of patients
(complete follow-up;
n = 61)
Sex
Male 13 (21 %)
Female 17 (28 %)
N/A 31 (51 %)
Age
Median age at diagnosis
(range; years)
4.2 (0.6–66)
Histology
CNS-PNET 46 (75 %)
Tumors of the pineal region 15 (25 %)
Tumor samples source
Primary tumors 59 (97 %)
Relapses 2 (3 %)
Metastatic stage
Metastases 8 (13 %)
No metastases 21 (35 %)
N/A 32 (52 %)
N/A information not available
J Neurooncol (2012) 109:415–423 419
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sample source (primary tumor vs. relapse), and technique
(aCGH vs. cCGH). Supplementary Table 2 illustrates the
factors (histology, CNA complexity, and age) showing dif-
ferences as assessed by univariable analysis. Patients with
tumors of the pineal region had a more favorable OS when
compared to patients with CNS-PNET (7-year OS:
64.7 ± 15 vs. 22.9 ± 6 %, p = 0.007). Of note, all three
patients with a pineoblastoma and available follow-up were
dead 33 months after diagnosis, whereas all other patients
with low grade tumors of the pineal region had excellent
outcome (7-year OS: 87.5 ± 12 %). Patients aged
B2.5 years had unfavorable OS when compared to patients
aged [2.5 years (7-year OS: 0 ± 0 vs. 41.3 ± 8 %,
p = 0.001). OS rates were similar in CNS-PNET patients
with and without the amplification at 19q13.42. Univariable
cox regression analysis confirmed that increasing age
(continuous variable) is denoting a more favorable OS
[hazard ratio, 0.967 (per year); 95 % confidence interval,
0.939–0.996; p = 0.0282] and increasing CNA complexity
(continuous variable) a less favorable OS [hazard ratio,
1.063 (per unit); 95 % confidence interval, 1.012–1.117;
p = 0.0153]. Multivariable analysis of clinical factors and
CNA complexity revealed that histology (tumors of the
pineal region), age (older than 2.5 years) and CNA com-
plexity\11 are favorable prognostic factors (Table 2).
Multivariable survival analysis of chromosomal
aberrations, CNA complexity, and clinical factors
To identify which of the chromosomal aberrations might
have an impact on OS, multivariable survival analyses were
applied to all 61 patients incorporating the significant clinical
factors (histology and age), CNA complexity, as well as 75
different chromosomal gains and 75 different chromosomal
losses in a stepwise approach, respectively. These analyses
finally revealed that young age (B2.5 years), histology
(CNS-PNET), and recurrent gains of 3p1 (n = 3; 5 %), 13q1
(n = 5; 8.2 %), and 15q2 (n = 8; 13.1 %) are associated
with an increased risk for unfavorable OS (Table 3).
Discussion
Over recent years, whole genome/transcriptome molecular
analysis has led to the identification of divergent biological
characteristics in what were considered single cancer types.
In the field of pediatric neuro-oncology, medulloblastoma
are now considered as a group of biologically differing
entities consisting of at least 4 molecular subgroups,
loosely connected through their topography (cerebellum)
and partially overlapping histological appearance [34–42].
Molecular studies in rare tumor entities are severely
limited due to the low number of cases included in single
series, as well as conceptual and technical heterogeneity of
the studies. To our knowledge, our study is the first IPD
meta-analysis assessing the genomic and clinical features
in CNS-PNET and tumors of the pineal region and their
impact on OS. In this study, we show that CNS-PNET and
pineoblastoma are divergent in their CNA profiles when
compared with low grade tumors of the pineal region. For
the cases analyzed here, recurring CNA observed only in
low grade tumors of the pineal region were, e.g., gains on
Table 2 Multivariable
analyses of clinical prognostic
factors (n = 61) for overall
survival (OS)
CNS-PNET Central primitive
neuroectodermal tumor, Non
CNS-PNET tumors of the pineal
region, CNA copy number
aberrations, HR OS Hazard ratio
overall survival
Parameter Comparison Sample
size
HR OS 95 % Confidence
interval
P value
Histology Non CNS-PNET 15 0.312 0.109–0.891 0.0296
CNS-PNET 46
Age group (years) [2.5 46 0.386 0.197–0.757 0.0056
B2.5 15
CNA complexity C11 CNA 23 1.790 0.943–3.400 0.0752
\11 CNA 38
Table 3 Multivariable
analyses of clinical factors and
recurrent chromosomal
aberrations (forward stepwise
selection; n = 61) for overall
survival
Parameter Sample
size
Hazard ratio
overall survival
95 % Confidence
interval
P value
Age (C2.5 years) 46 0.295 0.141–0.619 0.0012
Histology (tumor of the
pineal region)
15 0.120 0.029–0.498 0.0035
seg3p1_gain 3 8.759 1.778–43.159 0.0077
seg13q1_gain 5 4.128 1.192–14.303 0.0253
seg15q2_gain 8 4.338 1.614–11.665 0.0036
420 J Neurooncol (2012) 109:415–423
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4q2, 9p, 12p, and 8q2 as well as deletions of chromosome
10. In contrast, recurring CNA only found in pineoblas-
toma were deletions on 4q, chromosome 9, and 1p3. Based
on our results, CGH analysis might be of help—in addition
to neuroradiological and histopathological evaluation—to
differentiate between CNS-PNET, pineoblastoma, and
lower WHO grade tumors of the pineal region. While
detection of the listed aberrations may be indicative for
assignment to one of the diagnostic groups, development of
a CNA-based classifier will ideally require larger numbers
of genome profiles.
We found evidence that younger age at time of diag-
nosis is a negative prognostic factor for OS, confirming
several previous studies reporting on poor outcome of
young children with CNS-PNET/pineoblastoma [3, 43].
Timmermann et al. [3] reported on OS and progression-free
survival rates after 3 years of 17.2 and 14.9 %, respec-
tively. Administration of radiotherapy was the only sig-
nificant prognostic marker (15 out of 29 patients were not
irradiated) in this study [3] suggesting that omitting the
radiotherapy in young children—with the goal to reduce
neurologic sequelae—might at least explain partly the
extremely poor outcome of young children with CNS-
PNET/pineoblastoma.
In our cohorts, CNS-PNET and pineoblastoma shared an
unfavorable prognosis. Small numbers of pineoblastoma (3
out of 61 patients) may limit the comparison of those two
tumor entities. Based on the literature, there is some evi-
dence that patients with pineoblastoma may do better than
patients with CNS-PNET [44, 45]. Patients with low grade
tumors of the pineal region had a favorable outcome (7-
year OS: 87.5 ± 12 %) confirming that those tumor enti-
ties need a less aggressive treatment than CNS-PNET/
pineoblastoma.
CNS-PNET and tumors of the pineal region share a
complex karyotype with frequent CNAs [46]. In our series
of 107 patients, low grade tumors of the pineal region
showed relative frequently absence of CNAs (4/13), less
frequently in pineoblastoma (1/6), and CNS-PNET (2/88).
Recently, a new entity of CNS-PNET termed ETMR has
been suggested for a subgroup of CNS-PNET (ependy-
moblastoma and ETANTR) for which amplification at
19q13.42 represents a rather sensitive and specific marker
[32]. Korshunov et al. [33] identified in the great majority
of ependymoblastoma and ETANTR the focal amplifica-
tion at 19q13.42 whereas such an amplification was not
observed in a large series of other pediatric brain tumors
[32]. As we report about cCGH and aCGH data, the fre-
quency of tumors with amplification at 19q13.42 (Supple-
mentary Fig. 6) should be interpreted with caution as
detection of the amplification at 19q13.42 might be missed
when tumors are profiled by conventional cCGH, which
has a spatial resolution limited of several megabases.
Patients with 19q13.42 amplified tumors had a relatively
poor OS (6/7 patients with available follow-up died of
disease). Of note, the analysis of the prognostic impact of
the amplification at 19q13.42 is limited in our cohort,
because—as mentioned above—this amplification might be
missed in tumors analyzed with cCGH.
Our results provide evidence that high CNA complexity
is an unfavorable prognostic marker in our cohort. Because
of high frequencies of genomic imbalances as well as
heterogeneous patterns and frequencies of CNAs, CNA
complexity appears to be a good measure for overall
genomic instability which may reflect aggressiveness of a
certain tumor. In light of this, specific recurrent genomic
imbalances which have been identified as CNAs with
potential impact on OS in our analyses [e.g., in the 61
patients: gain of seg3p1 (n = 3), seg13q1 (n = 5), seg15q2
(n = 8)], need to be validated—ideally in large future
studies—for their prognostic value.
After the search cut-off date imposed by the IPD meta-
analysis criteria, another study was published recently
focusing on CNS-PNET/pineoblastoma only in pediatric
patients [17]. By evaluating the genomic array datawhich are
available from NCBI’s Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/; accession numberGSE12370),
we were able to generate CNA profiles for 38 patients (8 of
whom had pineoblastoma, and 30 had a CNS-PNET; CGH
data from 35 CNS-PNET cases were listed, 5 recurrent
tumors were paired with a primary sample from the same
patient) and 1CNS-PNET cell line. Here, as in our IPDmeta-
analysis, pineoblastoma exhibited CNA profiles roughly
comparable to subsets of cases identified as CNS-PNET as
shown in the Supplementary Fig. 5 a, b.
The approach of an IPD meta-analysis—a specific
method of systematic review based on a systematic
search—is in our opinion both necessary and efficient to
increase the patient number in rare tumor diseases. By
using IPD, we may overcome many of the limitations of
systematic reviews (e.g., poor quality of data can be
improved by updating the information). We used common
inclusion and exclusion criteria for each individual case. In
addition, we have performed a quality assessment of
genomic data by reassessment of each individual case by
two researchers (M.B. and H.C.). Methods to assess
genomic CNAs are standardized and reproducible as
demonstrated in previous reports (e.g., [11, 12]). Moreover,
by including unpublished data [25], we aimed to reduce the
risk for publication bias [20]. Of course, the inclusion of a
larger number of unpublished cases would have been
desirable, and a ‘‘pooling’’ of such data has an exceptional
value for rare diseases. Of note, IPD meta-analyses usually
take longer than conventional systematic review, and
obtaining IPD is time-consuming [20]. Therefore, it is not
possible to include all very recent studies, and many IPD
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meta-analyses are conducted on a cyclical basis with data
collection, quality assessment, analyses, and dissemination
of results taking place every few years [18], because by the
time of the final analysis of the pooled data new cases are
already available. We acknowledge some limitations of our
study which is based on original data produced over a time
period of several years. As shown in Supplementary
Table 1, the WHO classification of tumors of the CNS has
changed during this period. Moreover, in recent years, the
staging has improved, as have surgical procedures and non-
surgical treatment options of patients with CNS-PNET and
tumors of the pineal region. Regarding genomic analysis
methods, high-resolution profiling by genomic copy num-
ber arrays or whole genome sequencing could provide a
higher sensitivity for the detection of hitherto undetected
CNA. However, the main limitations in identifying robust
CNA markers with prognostic value are in the limited
number of samples and associated clinical datasets avail-
able for such analyses.
In summary, CNS-PNET and low grade tumors of the
pineal region are characterized by differences in CNA
profiles. In this respect, pineoblastoma fit readily into the
genomically heterogeneous group of CNS-PNET with a
complex karyotype. Although not necessarily displayed by
each individual case, typical CNA profiles underline the
differing biological background of these entities. Our
results provide evidence that young age, high CNA com-
plexity, and potentially also several specific CNAs may
have an impact on OS.
Acknowledgments The authors’ are indebted to the authors of
articles, who provided the data to this study that otherwise would not
have been accessible. In particular, the authors would like to thank the
following researcher/clinicians for their help: Milo Puhan, Carolyn
Russo, Wolfram Scheurlen, Barbara Schu¨tz, Christine Haberler,
Martin McCabe, and Hans-Hermann Dubben. The author would like
to thank Klaus-Dieter Papke for assisting the literature search. The
authors acknowledge the following sources of funding: German
Children‘s Cancer Foundation/Deutsche Kinderkrebsstiftung (to
A.O.V.B., S.R.). Haoyang Cai is supported through a grant from the
China Scholarship Council.
Conflict of interest None.
References
1. Gaffney CC, Sloane JP, Bradley NJ, Bloom HJ (1985) Primitive
neuroectodermal tumours of the cerebrum. Pathology and treat-
ment. J Neurooncol 3:23–33
2. Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP,
Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang
ML, Scherer SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC,
Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A (2009)
Frequent amplification of a chr19q13.41 microRNA polycistron
in aggressive primitive neuroectodermal brain tumors. Cancer
Cell 16:533–546
3. Timmermann B, Kortmann RD, Kuhl J, Rutkowski S, Meisner C,
Pietsch T, Deinlein F, Urban C, Warmuth-Metz M, Bamberg M
(2006) Role of radiotherapy in supratentorial primitive neuroec-
todermal tumor in young children: results of the German HIT-
SKK87 and HIT-SKK92 trials. J Clin Oncol 24:1554–1560
4. Fangusaro J, Massimino M, Rutkowski S, Gururangan S (2010)
Non-cerebellar primitive neuroectodermal tumors (PNET): sum-
mary of the Milan consensus and state of the art workshop on
marrow ablative chemotherapy with hematopoietic cell rescue for
malignant brain tumors of childhood and adolescents. Pediatr
Blood Cancer 54:638–640
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO
classification of tumours of the central nervous system. IARC,
Lyon
6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ,
Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E,
Tefferi A, Bloomfield CD (2009) The 2008 revision of the World
Health Organization (WHO) classification of myeloid neoplasms
and acute leukemia: rationale and important changes. Blood
114:937–951
7. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW,
Waldman F, Pinkel D (1992) Comparative genomic hybridization
for molecular cytogenetic analysis of solid tumors. Science
258:818–821
8. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du
Manoir S, Lichter P (1995) Mapping of chromosomal gains and
losses in prostate cancer by comparative genomic hybridization.
Genes Chromosom Cancer 14:267–276
9. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner
A, Dohner H, Cremer T, Lichter P (1997) Matrix-based com-
parative genomic hybridization: biochips to screen for genomic
imbalances. Genes Chromosom Cancer 20:399–407
10. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamen-
schikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO
(1999) Genome-wide analysis of DNA copy-number changes
using cDNA microarrays. Nat Genet 23:41–46
11. Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD,
Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen
H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR,
Vandesompele J, Van Roy N (1999) Gain of chromosome arm
17q and adverse outcome in patients with neuroblastoma. N Engl
J Med 340:1954–1961
12. Zenz T, Mertens D, Dohner H, Stilgenbauer S (2008) Molecular
diagnostics in chronic lymphocytic leukemia—pathogenetic and
clinical implications. Leuk Lymphoma 49:864–873
13. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P (2005)
Chromosome alterations in human hepatocellular carcinomas
correlate with aetiology and histological grade–results of an
explorative CGH meta-analysis. Br J Cancer 92:935–941
14. Baudis M (2007) Genomic imbalances in 5918 malignant epi-
thelial tumors: an explorative meta-analysis of chromosomal
CGH data. BMC Cancer 7:226
15. Russo C, Pellarin M, Tingby O, Bollen AW, Lamborn KR,
Mohapatra G, Collins VP, Feuerstein BG (1999) Comparative
genomic hybridization in patients with supratentorial and infra-
tentorial primitive neuroectodermal tumors. Cancer 86:331–339
16. Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F,
Wittmann A, Devens F, von Hoff K, Rutkowski S, Kulozik A,
Radlwimmer B, Scheurlen W, Lichter P, Korshunov A (2007)
Supratentorial primitive neuroectodermal tumors of the central
nervous system frequently harbor deletions of the CDKN2A
locus and other genomic aberrations distinct from medulloblas-
tomas. Genes Chromosom Cancer 46:839–851
17. Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M,
Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brun-
dler MA, Lowe J, Coyle B, Grundy RG (2011) Genome-wide
422 J Neurooncol (2012) 109:415–423
123
molecular characterization of central nervous system primitive
neuroectodermal tumor and pineoblastoma. Neuro Oncol 13:866–
879
18. Clarke M, Godwin J (1998) Systematic reviews using individual
patient data: a map for the minefields? Ann Oncol 9:827–833
19. Riley RD, Sauerbrei W, Altman DG (2009) Prognostic markers in
cancer: the evolution of evidence from single studies to meta-
analysis, and beyond. Br J Cancer 100:1219–1229
20. Altman DG (2001) Systematic reviews of evaluations of prog-
nostic variables. BMJ 323:224–228
21. BaudisM,ClearyML(2001)Progenetix.net: anonline repository for
molecular cytogenetic aberration data. Bioinformatics 17:1228–
1229
22. Baudis M (2006) Online database and bioinformatics toolbox to
support data mining in cancer cytogenetics. Biotechniques
40:269–270, 272
23. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D
(2007) Presentation of childhood CNS tumours: a systematic
review and meta-analysis. Lancet Oncol 8:685–695
24. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement. PLoS Med 6:e1000097
25. Stewart LA, Tierney JF (2002) To IPD or not to IPD? Advantages
and disadvantages of systematic reviews using individual patient
data. Eval Health Prof 25:76–97
26. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ,
Thompson SG (2005) Meta-analysis of individual patient data
from randomized trials: a review of methods used in practice.
Clin Trials 2:209–217
27. Boerma EG, Siebert R, Kluin PM, Baudis M (2009) Transloca-
tions involving 8q24 in Burkitt lymphoma and other malignant
lymphomas: a historical review of cytogenetics in the light of
todays knowledge. Leukemia 23:225–234
28. LeBlanc M, Crowley J (1992) Relative risk trees for censored
survival data. Biometrics 48:411–425
29. Kaplan EL, Meier P (1958) Nonparametric estimation from
incomplete observations. J Am Stat Assoc 53:457–481
30. Kleihues P, Cavenee WK (2000) World Health Organization
classification of tumours. Pathology and genetics of tumours of
the nervous system. IARC, Lyon
31. Eberhart CG, Brat DJ, Cohen KJ, Burger PC (2000) Pediatric
neuroblastic brain tumors containing abundant neuropil and true
rosettes. Pediatr Dev Pathol 3:346–352
32. Paulus W, Kleihues P (2010) Genetic profiling of CNS tumors
extends histological classification. Acta Neuropathol 120:269–
270
33. Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt
H, Tobias V, Buccoliero AM, Sardi I, Gardiman MP, Bonnin J,
Scheithauer B, Kulozik AE, Witt O, Mork S, von Deimling A,
Wiestler OD, Giangaspero F, Rosenblum M, Pietsch T, Lichter P,
Pfister SM (2010) Focal genomic amplification at 19q13.42
comprises a powerful diagnostic marker for embryonal tumors
with ependymoblastic rosettes. Acta Neuropathol 120:253–260
34. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M,
Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ,
Ellison DW, Bailey S, Clifford SC (2011) Rapid diagnosis of
medulloblastoma molecular subgroups. Clin Cancer Res 17:1883–
1894
35. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau
CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor
MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics iden-
tifies medulloblastoma subgroups that are enriched for specific
genetic alterations. J Clin Oncol 24:1924–1931
36. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P,
Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B,
Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC,
Versteeg R (2008) Integrated genomics identifies five medullo-
blastoma subtypes with distinct genetic profiles, pathway signa-
tures and clinicopathological features. PLoS One 3:e3088
37. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich
H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau
CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M,
Ligon K, Meyerson M, Mesirov JP, Pomeroy SL (2011) Inte-
grative genomic analysis of medulloblastoma identifies a
molecular subgroup that drives poor clinical outcome. J Clin
Oncol 29:1424–1430
38. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG,
Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka
JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four
distinct molecular variants. J Clin Oncol 29:1408–1414
39. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M,
Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A,
Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Kor-
shunov A (2011) Adult medulloblastoma comprises three major
molecular variants. J Clin Oncol 29:2717–2723
40. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S,
Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D,
Witt H, Haag D, Toedt G, Wittmann A, Schottler A, von Bueren
AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE,
Taylor MD, Lichter P, Pfister SM (2011) FSTL5 is a marker of
poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin
Oncol 29:3852–3861
41. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ,
Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A,
Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M,
Pfister SM (2012) Molecular subgroups of medulloblastoma: the
current consensus. Acta Neuropathol 123:465–472
42. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M,
Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van
Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S,
McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F,
Delattre O, Doz F, Ellison DW,Gilbertson RJ, Pomeroy SL, Taylor
MD, Lichter P, Pfister SM (2012) Molecular subgroups of
medulloblastoma: an international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3, and
Group 4 medulloblastomas. Acta Neuropathol 123:473–484
43. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger
D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA,
Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D,
Radcliffe J, Tao ML, Shiminski-Maher T (2005) Multiagent
chemotherapy and deferred radiotherapy in infants with malig-
nant brain tumors: a report from the Children’s Cancer Group.
J Clin Oncol 23:7621–7631
44. Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J,
Saran F, Lashford LS, Tait D, Lucraft H, Walker DA, Bailey CC,
Taylor RE (2006) Analysis of patients with supratentorial prim-
itive neuro-ectodermal tumours entered into the SIOP/UKCCSG
PNET 3 study. Eur J Cancer 42:1120–1128
45. Timmermann B, Kortmann RD, Kuhl J, Meisner C, Dieckmann
K, Pietsch T, Bamberg M (2002) Role of radiotherapy in the
treatment of supratentorial primitive neuroectodermal tumors in
childhood: results of the prospective German brain tumor trials
HIT 88/89 and 91. J Clin Oncol 20:842–849
46. Li MH, Bouffet E, Hawkins CE, Squire JA, Huang A (2005)
Molecular genetics of supratentorial primitive neuroectodermal
tumors and pineoblastoma. Neurosurg Focus 19:E3
J Neurooncol (2012) 109:415–423 423
123

BIBLIOGRAPHY
[1] American Cancer Society. Global Cancer Facts & Figures 2nd Edition. Atlanta: 
American Cancer Society; 2011.
[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 
4;144(5):646-74.
[3] Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr 
9;458(7239):719-24.
[4] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, et al. Cancer genome 
landscapes. Science. 2013 Mar 29;339(6127):1546-58.
[5] von Hansemann, D. Ueber asymmetrische Zelltheilung in epithel Krebsen und deren 
biologische Bedeutung. Virchows Arch. Path. Anat. 1890; 119, 299.
[6] Boveri, T. Zur Frage der Entstehung Maligner Tumoren. Gustav Fischer 1914; 1–64.
[7] Avery, O. T., MacLeod, C. M. and McCarty, M. Studies on the chemical nature of the 
substance inducing transformation of Pneumococcal types: Induction of transformation 
by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. J. Exp. Med. 
1944; 79, 137–158.
[8] Watson, J. D. and Crick, F. H. Molecular structure of nucleic acids; a structure for 
deoxyribose nucleic acid. Nature. 1953; 171, 737–738.
[9] Nowell, P. and Hungerford, D. A minute chromosome in human granulocytic leukemia. 
Science. 1960; 132, 1497.
[10] Rowley, J. A new consistent chromosomal abnormality in chronic myelogenous 
leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 
243, 290–293.
[11] Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, et al. Comparative genomic 
hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992 Oct 
30;258(5083):818-21.
[12] Joos S, Scherthan H, Speicher MR, Schlegel J, et al. Detection of amplified DNA 
sequences by reverse chromosome painting using genomic tumor DNA as probe. 
Hum Genet. 1993 Feb;90(6):584-9.
161
[13] du Manoir S, Speicher MR, Joos S, Schröck E, et al. Detection of complete and partial 
chromosome gains and losses by comparative genomic in situ hybridization. Hum 
Genet. 1993 Feb;90(6):590-610.
[14] Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer 
therapy. Nat Rev Cancer. 2013 Feb;13(2):83-96.
[15] Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical 
interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011 Jun 
24;11(7):512-22.
[16] Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology 
meets molecular pathology. Nat Rev Cancer. 2006 Sep;6(9):702-13.
[17] Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev 
Cancer. 2005 Jan;5(1):65-72.
[18] Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 
2012 Mar 22;12(4):265-77.
[19] Ataman OU, Sambrook SJ, Wilks C, Lloyd A, et al. The clinical development of 
molecularly  targeted agents in combination with radiation therapy: a pharmaceutical 
perspective. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e447-54.
[20] Wang LC, Wang L, Kwauk S, Woo JA, et al. Analysis on the clinical features of 22 
basaloid squamous cell carcinoma of the lung. J Cardiothorac Surg. 2011 Jan 
26;6:10.
[21] Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 
2007 Feb 10;25(5):561-70.
[22] Ferlay  J, Shin HR, Bray F, Forman D, Mathers C  and Parkin DM. GLOBOCAN 2008 
v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
[23] Cai H, Kumar N, Baudis M. arrayMap: a reference resource for genomic copy number 
imbalances in human malignancies. PLoS One. 2012;7(5):e36944.
[24] A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D.M. Parkin et al. ICD-O-3. 
2000; WHO, Geneva, Switzerland.
[25] National Cancer Institute. Cancer staging. 2013 Jan.
[26] Barrett T, Wilhite SE, Ledoux P, Evangelista C, et al. NCBI GEO: archive for functional 
genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database 
issue):D991-5.
[27] Rustici G, Kolesnikov N, Brandizi M, Burdett T, et al. ArrayExpress update--trends in 
database growth and links to data analysis tools. Nucleic Acids Res. 2013 Jan;
41(Database issue):D987-90.
162
[28] Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. 
Genes Dev. 2011 Mar 15;25(6):534-55.
[29] Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to 
personalized medicine. Nat Med. 2011 Mar;17(3):297-303.
[30] Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, et al. The UCSC Genome Browser 
database: extensions and updates 2013. Nucleic Acids Res. 2013 Jan;41(Database 
issue):D64-9.
[31] Ou SH. Lung cancer in never-smokers. Does smoking history matter in the era of 
molecular diagnostics and targeted therapy? J Clin Pathol. 2013 May 9.
[32] Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis. 2012 Nov;16(4):
839-50.
[33] Marrot L, Meunier JR. Skin DNA photodamage and its biological consequences. J Am 
Acad Dermatol. 2008 May;58(5 Suppl 2):S139-48.
[34] Bracht JR, Fang W, Goldman AD, Dolzhenko E, et al. Genomes on the edge: 
programmed genome instability in ciliates. Cell. 2013 Jan 31;152(3):406-16.
[35] Liu P, Carvalho CM, Hastings PJ, Lupski JR. Mechanisms for recurrent and complex 
human genomic rearrangements. Curr Opin Genet Dev. 2012 Jun;22(3):211-20.
[36] Chen JM, Cooper DN, Férec C, Kehrer-Sawatzki H, Patrinos GP. Genomic 
rearrangements in inherited disease and cancer. Semin Cancer Biol. 2010 Aug;20(4):
222-33.
[37] Malkova A, Haber JE. Mutations arising during repair of chromosome breaks. Annu 
Rev Genet. 2012;46:455-73.
[38] Bordeianu G, Zugun-Eloae F, Rusu MG. The role of DNA repair by homologous 
recombination in oncogenesis. Rev Med Chir Soc Med Nat Iasi. 2011 Oct-Dec;
115(4):1189-94.
[39] Hastings PJ, Ira G, Lupski JR. A microhomology-mediated break-induced replication 
model for the origin of human copy number variation. PLoS Genet. 2009 Jan;
5(1):e1000327.
[40] Chen JM, Chuzhanova N, Stenson PD, Férec C, Cooper DN. Intrachromosomal serial 
replication slippage in trans gives rise to diverse genomic rearrangements involving 
inversions. Hum Mutat. 2005 Oct;26(4):362-73.
[41] Zhang F, Carvalho CM, Lupski JR. Complex human chromosomal and genomic 
rearrangements. Trends Genet. 2009 Jul;25(7):298-307.
163
[42] Colnaghi R, Carpenter G, Volker M, O'Driscoll M. The consequences of structural 
genomic alterations in humans: genomic disorders, genomic instability and cancer. 
Semin Cell Dev Biol. 2011 Oct;22(8):875-85.
[43] Cheung KJ, Rogic S, Ben-Neriah S, Boyle M, et al. SNP analysis of minimally  evolved 
t(14;18)(q32;q21)-positive follicular lymphomas reveals a common copy-neutral loss 
of heterozygosity pattern. Cytogenet Genome Res. 2012;136(1):38-43.
[44] González JR, Rodríguez-Santiago B, Cáceres A, Pique-Regi R, et al. A fast and 
accurate method to detect allelic genomic imbalances underlying mosaic 
rearrangements using SNP array data. BMC Bioinformatics. 2011 May 17;12:166.
[45] Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 
2004 Aug;10(8):789-99.
[46] Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, et al. Genomic architecture 
characterizes tumor progression paths and fate in breast cancer patients. Sci Transl 
Med. 2010 Jun 30;2(38):38ra47.
[47] Stephens PJ, Tarpey PS, Davies H, Van Loo P, et al. The landscape of cancer genes 
and mutational processes in breast cancer. Nature. 2012 May 16;486(7403):400-4.
[48] Nik-Zainal S, Alexandrov  LB, Wedge DC, Van Loo P, et al. Mutational processes 
molding the genomes of 21 breast cancers. Cell. 2012 May 25;149(5):979-93.
[49] Yuan X, Yu G, Hou X, Shih IeM, et al. Genome-wide identification of significant 
aberrations in cancer genome. BMC Genomics. 2012 Jul 27;13:342.
[50] Beroukhim R, Getz G, Nghiemphu L, Barretina J, et al. Assessing the significance of 
chromosomal aberrations in cancer: methodology and application to glioma. Proc 
Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. Epub 2007 Dec 6.
[51] Yuan Y, Savage RS, Markowetz F. Patient-specific data fusion defines prognostic 
cancer subtypes. PLoS Comput Biol. 2011 Oct;7(10):e1002227.
[52] Tang YC, Amon A. Gene copy-number alterations: a cost-benefit analysis. Cell. 2013 
Jan 31;152(3):394-405.
[53] Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions 
on cancer causation. Nat Rev Cancer. 2007 Apr;7(4):233-45. Epub 2007 Mar 15.
[54] Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate 
cancer. Nat Rev Cancer. 2008 Jul;8(7):497-511.
[55] Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, et al. Matrix-based 
comparative genomic hybridization: biochips to screen for genomic imbalances. 
Genes Chromosomes Cancer. 1997 Dec;20(4):399-407.
164
[56] Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in 
genetic medicine. Am J Hum Genet. 2009 Aug;85(2):142-54.
[57] Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb 
Perspect Biol. 2012 Dec 1;4(12). pii: a009829.
[58] Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung 
cancer. J Clin Oncol. 2013 Mar 10;31(8):1097-104.
[59] Croce CM. Oncogenes and cancer. N Engl J Med. 2008 Jan 31;358(5):502-11.
[60] Todd R, Wong DT. Oncogenes. Anticancer Res. 1999 Nov-Dec;19(6A):4729-46.
[61] Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 
2009 Jul;9(7):501-7.
[62] Zhang Y, Xia J, Zhang Y, Qin Y, et al. Pitfalls in experimental designs for 
characterizing the transcriptional, methylational and copy number changes of 
oncogenes and tumor suppressor genes. PLoS One. 2013;8(3):e58163.
[63] Forbes SA, Bindal N, Bamford S, Cole C, et al. COSMIC: mining complete cancer 
genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011 
Jan;39(Database issue):D945-50.
[64] Duffy MJ, Crown J. Companion Biomarkers: Paving the Pathway to Personalized 
Treatment for Cancer. Clin Chem. 2013 May 8.
[65] Dang CV. MYC on the path to cancer. Cell. 2012 Mar 30;149(1):22-35.
[66] Ohno S, Yazaki A. Simple construction of human c-myc gene implicated in B-cell 
neoplasmas and its relationship with avian v-myc and human lymphokines. Scand J 
Immunol. 1983 Nov;18(5):373-88.
[67] Dalla-Favera R, Bregni M, Erikson J, Patterson D, et al. Human c-myc onc gene is 
located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. 
Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7.
[68] Taub R, Kirsch I, Morton C, Lenoir G, et al. Translocation of the c-myc gene into the 
immunoglobulin heavy chain locus in human Burkitt lymphoma and murine 
plasmacytoma cells. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41.
[69] Mitchell KF, Battey J, Hollis GF, Moulding C, et al. The effect of translocations on the 
cellular myc gene in Burkitt lymphomas. J Cell Physiol Suppl. 1984;3:171-7.
[70] Paulson KG, Lemos BD, Feng B, Jaimes N, et al. Array-CGH reveals recurrent 
genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest 
Dermatol. 2009 Jun;129(6):1547-55.
165
[71] Wu R, Lin L, Beer DG, Ellenson LH, et al. Amplification and overexpression of the L-
MYC proto-oncogene in ovarian carcinomas. Am J Pathol. 2003 May;162(5):1603-10.
[72] Lv  XH, Chen JW, Zhao G, Feng ZZ, et al. N-myc downstream-regulated gene 1/
Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin 
Oncol. 2012 Oct;138(10):1703-15. Epub 2012 Jun 8.
[73] Buechner J, Einvik C. N-myc and noncoding RNAs in neuroblastoma. Mol Cancer 
Res. 2012 Oct;10(10):1243-53.
[74] Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. 
Cancer Lett. 2003 Jul 18;197(1-2):125-30.
[75] Lin CY, Lovén J, Rahl PB, Paranal RM, et al. Transcriptional amplification in tumor 
cells with elevated c-Myc. Cell. 2012 Sep 28;151(1):56-67.
[76] Liu H, Radisky DC, Yang D, Xu R, et al. MYC suppresses cancer metastasis by  direct 
transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol. 2012 May 
13;14(6):567-74.
[77] Brooks TA, Hurley  LH. The role of supercoiling in transcriptional control of MYC and its 
importance in molecular therapeutics. Nat Rev Cancer. 2009 Dec;9(12):849-61.
[78] Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? 
Nat Rev Cancer. 2003 Oct;3(10):756-67.
[79] Delbridge AR, Valente LJ, Strasser A. The role of the apoptotic machinery in tumor 
suppression. Cold Spring Harb Perspect Biol. 2012 Nov 1;4(11). pii: a008789.
[80] Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl 
Acad Sci U S A. 1971 Apr;68(4):820-3.
[81] MacPherson D, Dyer MA. Retinoblastoma: from the two-hit hypothesis to targeted 
chemotherapy. Cancer Res. 2007 Aug 15;67(16):7547-50.
[82] Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. 
Nature. 2011 Aug 10;476(7359):163-9.
[83] O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel 
chromosomal lesion in myeloid malignancies. Blood. 2010 Apr 8;115(14):2731-9.
[84] Thiagalingam S, Foy  RL, Cheng KH, Lee HJ, et al. Loss of heterozygosity as a 
predictor to map  tumor suppressor genes in cancer: molecular basis of its 
occurrence. Curr Opin Oncol. 2002 Jan;14(1):65-72.
[85] Jahromi MS, Putnam AR, Druzgal C, Wright J, et al. Molecular inversion probe 
analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet. 
2012 Jul-Aug;205(7-8):391-404.
166
[86] Jasmine F, Rahaman R, Dodsworth C, Roy S, et al. A genome-wide study of 
cytogenetic changes in colorectal cancer using SNP microarrays: opportunities for 
future personalized treatment. PLoS One. 2012;7(2):e31968.
[87] Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for 
investigating human mutagenesis. Genes Chromosomes Cancer. 1992 Jan;4(1):
1-15.
[88] Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical 
outcome. Nat Rev Cancer. 2001 Dec;1(3):233-40.
[89] Maddocks OD, Berkers CR, Mason SM, Zheng L, et al. Serine starvation induces 
stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013 Jan 
24;493(7433):542-6.
[90] Junttila MR, Karnezis AN, Garcia D, Madriles F, et al. Selective activation of p53-
mediated tumour suppression in high-grade tumours. Nature. 2010 Nov 
25;468(7323):567-71.
[91] Laurie NA, Donovan SL, Shih CS, Zhang J, et al. Inactivation of the p53 pathway in 
retinoblastoma. Nature. 2006 Nov 2;444(7115):61-6.
[92] Vassilev LT, Vu BT, Graves B, Carvajal D, et al. In vivo activation of the p53 pathway 
by small-molecule antagonists of MDM2. Science. 2004 Feb  6;303(5659):844-8. 
Epub 2004 Jan 2.
[93] Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. 
Trends Cell Biol. 2010 Jan;20(1):14-24.
[94] Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 
mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 
2010 Jan;22(1):64-9.
[95] Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a 
mutated p53 gene in a cancer-prone family  with Li-Fraumeni syndrome. Nature. 1990 
Dec 20-27;348(6303):747-9.
[96] Masciari S, Dillon DA, Rath M, Robson M, et al. Breast cancer phenotype in women 
with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast 
Cancer Res Treat. 2012 Jun;133(3):1125-30.
[97] Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013 Jan;15(1):2-8.
[98] Beroukhim R, Mermel CH, Porter D, Wei G, et al. The landscape of somatic copy-
number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905.
[99] Grasso CS, Wu YM, Robinson DR, Cao X, et al. The mutational landscape of lethal 
castration-resistant prostate cancer. Nature. 2012 Jul 12;487(7406):239-43.
167
[100] Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, et al. The patterns and dynamics 
of genomic instability in metastatic pancreatic cancer. Nature. 2010 Oct 
28;467(7319):1109-13.
[101] Shen MM. Chromoplexy: a new category of complex rearrangements in the cancer 
genome. Cancer Cell. 2013 May 13;23(5):567-9.
[102] Roche B, Hochberg ME, Caulin AF, Maley CC, et al. Natural resistance to cancers: a 
Darwinian hypothesis to explain Peto's paradox. BMC Cancer. 2012 Sep 3;12:387.
[103] Torkamani A, Verkhivker G, Schork NJ. Cancer driver mutations in protein kinase 
genes. Cancer Lett. 2009 Aug 28;281(2):117-27.
[104] Bashashati A, Haffari G, Ding J, Ha G, et al. DriverNet: uncovering the impact of 
somatic driver mutations on transcriptional networks in cancer. Genome Biol. 2012 
Dec 22;13(12):R124.
[105] Stephens PJ, Greenman CD, Fu B, Yang F, et al. Massive genomic rearrangement 
acquired in a single catastrophic event during cancer development. Cell. 2011 Jan 
7;144(1):27-40.
[106] Maher CA, Wilson RK. Chromothripsis and human disease: piecing together the 
shattering process. Cell. 2012 Jan 20;148(1-2):29-32.
[107] Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single 
chromosomes. Cell. 2011 Jan 7;144(1):9-10.
[108] Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, et al. High detection rate 
of clinically  relevant genomic abnormalities in plasma cells enriched from patients 
with multiple myeloma. Genes Chromosomes Cancer. 2012 Nov;51(11):997-1006.
[109] Bass AJ, Lawrence MS, Brace LE, Ramos AH, et al. Genomic sequencing of 
colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 
2011 Sep 4;43(10):964-8.
[110] Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, et al. Chromothripsis is 
a common mechanism driving genomic rearrangements in primary and metastatic 
colorectal cancer. Genome Biol. 2011 Oct 19;12(10):R103.
[111] Zhang J, Ding L, Holmfeldt L, Wu G, et al. The genetic basis of early T-cell precursor 
acute lymphoblastic leukaemia. Nature. 2012 Jan 11;481(7380):157-63.
[112] Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, et al. The effects of hepatitis B virus 
integration into the genomes of hepatocellular carcinoma patients. Genome Res. 
2012 Apr;22(4):593-601.
168
[113] Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, et al. Sequencing of 
neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. 
Nature. 2012 Feb 22;483(7391):589-93.
[114] Natrajan R, Mackay A, Lambros MB, Weigelt B, et al. A whole-genome massively 
parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -
positive breast cancers. J Pathol. 2012 May;227(1):29-41.
[115] Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, et al. The life history of 21 
breast cancers. Cell. 2012 May 25;149(5):994-1007.
[116] Northcott PA, Shih DJ, Peacock J, Garzia L, et al. Subgroup-specific structural 
variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 2;488(7409):
49-56.
[117] Jones DT, Jäger N, Kool M, Zichner T, et al. Dissecting the genomic complexity 
underlying medulloblastoma. Nature. 2012 Aug 2;488(7409):100-5.
[118] Kloosterman WP, Guryev V, van Roosmalen M, Duran KJ, et al. Chromothripsis as a 
mechanism driving complex de novo structural rearrangements in the germline. 
Hum Mol Genet. 2011 May 15;20(10):1916-24.
[119] Chiang C, Jacobsen JC, Ernst C, Hanscom C, et al. Complex reorganization and 
predominant non-homologous repair following chromosomal breakage in 
karyotypically balanced germline rearrangements and transgenic integration. Nat 
Genet. 2012 Mar 4;44(4):390-7, S1.
[120] Deakin JE, Bender HS, Pearse AM, Rens W, et al. Genomic restructuring in the 
Tasmanian devil facial tumour: chromosome painting and gene mapping provide 
clues to evolution of a transmissible tumour. PLoS Genet. 2012;8(2):e1002483.
[121] Le LP, Nielsen GP, Rosenberg AE, Thomas D, et al. Recurrent chromosomal copy 
number alterations in sporadic chordomas. PLoS One. 2011;6(5):e18846.
[122] Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a 
rare and aggressive entity  among newly  diagnosed multiple myeloma patients. 
Blood. 2011 Jul 21;118(3):675-8.
[123] Kitada K, Taima A, Ogasawara K, Metsugi S, Aikawa S. Chromosome-specific 
segmentation revealed by  structural analysis of individually  isolated chromosomes. 
Genes Chromosomes Cancer. 2011 Apr;50(4):217-27.
[124] Poaty H, Coullin P, Peko JF, Dessen P, et al. Genome-wide high-resolution aCGH 
analysis of gestational choriocarcinomas. PLoS One. 2012;7(1):e29426.
[125] Rausch T, Jones DT, Zapatka M, Stütz AM, et al. Genome sequencing of pediatric 
medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 
2012 Jan 20;148(1-2):59-71.
169
[126] Wu C, Wyatt AW, McPherson A, Lin D, et al. Poly-gene fusion transcripts and 
chromothripsis in prostate cancer. Genes Chromosomes Cancer. 2012 Dec;51(12):
1144-53.
[127] Lapuk AV, Wu C, Wyatt AW, McPherson A, et al. From sequence to molecular 
pathology, and a mechanism driving the neuroendocrine phenotype in prostate 
cancer. J Pathol. 2012 Jul;227(3):286-97.
[128] Berger MF, Hodis E, Heffernan TP, Deribe YL, et al. Melanoma genome sequencing 
reveals frequent PREX2 mutations. Nature. 2012 May 9;485(7399):502-6.
[129] Kloosterman WP, Tavakoli-Yaraki M, van Roosmalen MJ, van Binsbergen E, et al. 
Constitutional chromothripsis rearrangements involve clustered double-stranded 
DNA breaks and nonhomologous repair mechanisms. Cell Rep. 2012 Jun 28;1(6):
648-55.
[130] Govindan R, Ding L, Griffith M, Subramanian J, et al. Genomic landscape of non-
small cell lung cancer in smokers and never-smokers. Cell. 2012 Sep 14;150(6):
1121-34.
[131] Kim TM, Xi R, Luquette LJ, Park RW, et al. Functional genomic analysis of 
chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res. 
2013 Feb;23(2):217-27.
[132] Zehentner BK, Hartmann L, Johnson KR, Stephenson CF, et al. Array-based 
karyotyping in plasma cell neoplasia after plasma cell enrichment increases 
detection of genomic aberrations. Am J Clin Pathol. 2012 Oct;138(4):579-89.
[133] Liu P, Erez A, Nagamani SC, Dhar SU, et al. Chromosome catastrophes involve 
replication mechanisms generating complex genomic rearrangements. Cell. 2011 
Sep 16;146(6):889-903.
[134] Fullwood MJ, Lee J, Lin L, Li G, et al. Next-generation sequencing of apoptotic DNA 
breakpoints reveals association with actively transcribed genes and gene 
translocations. PLoS One. 2011;6(11):e26054.
[135] Tubio JM, Estivill X. Cancer: When catastrophe strikes a cell. Nature. 2011 Feb 
24;470(7335):476-7.
[136] Crasta K, Ganem NJ, Dagher R, Lantermann AB, et al. DNA breaks and 
chromosome pulverization from errors in mitosis. Nature. 2012 Jan 18;482(7383):
53-8.
[137] Drets ME, Shaw MW. Specific banding patterns of human chromosomes. Proc Natl 
Acad Sci U S A. 1971 Sep;68(9):2073-7.
[138] Russell WO. Tissue diagnosis of cancer: changed concepts, technical advances and 
future applications. Proc Natl Cancer Conf. 1964;5:673-85.
170
[139] Bowen P. Chromosomal abnormalities. Clin Orthop  Relat Res. 1964 Mar-Apr;
33:40-58.
[140] Cancer Genome Atlas Research Network. Comprehensive genomic characterization 
defines human glioblastoma genes and core pathways. Nature. 2008 Oct 
23;455(7216):1061-8.
[141] Curtis C, Shah SP, Chin SF, Turashvili G, et al. The genomic and transcriptomic 
architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012 Apr 
18;486(7403):346-52.
[142] Langer-Safer PR, Levine M, Ward DC. Immunological method for mapping genes on 
Drosophila polytene chromosomes. Proc Natl Acad Sci U S A. 1982 Jul;79(14):
4381-5.
[143] Cagir B, Gelmann A, Park J, Fava T, et al. Guanylyl cyclase C messenger RNA is a 
biomarker for recurrent stage II colorectal cancer. Ann Intern Med. 1999 Dec 
7;131(11):805-12.
[144] Van Prooijen-Knegt AC, Van Hoek JF, Bauman JG, Van Duijn P, et al. In situ 
hybridization of DNA sequences in human metaphase chromosomes visualized by 
an indirect fluorescent immunocytochemical procedure. Exp Cell Res. 1982 Oct;
141(2):397-407.
[145] Pinkel D, Segraves R, Sudar D, Clark S, et al. High resolution analysis of DNA copy 
number variation using comparative genomic hybridization to microarrays. Nat 
Genet. 1998 Oct;20(2):207-11.
[146] Zhao X, Li C, Paez JG, Chin K, et al. An integrated view of copy number and allelic 
alterations in the cancer genome using single nucleotide polymorphism arrays. 
Cancer Res. 2004 May 1;64(9):3060-71.
[147] Nannya Y, Sanada M, Nakazaki K, Hosoya N, et al. A robust algorithm for copy 
number detection using high-density oligonucleotide single nucleotide polymorphism 
genotyping arrays. Cancer Res. 2005 Jul 15;65(14):6071-9.
[148] Hall N. Advanced sequencing technologies and their wider impact in microbiology. J 
Exp Biol. 2007 May;210(Pt 9):1518-25.
[149] Church GM. Genomes for all. Sci Am. 2006 Jan;294(1):46-54.
[150] National Academy of Sciences. Science. 1960 Nov 18;132(3438):1488-501.
[151] Bobrow M, Madan K. The effects of various banding procedures on human 
chromosomes, studied with acridine orange. Cytogenet Cell Genet. 1973;12(3):
143-56.
171
[152] Caspersson T, Zech L, Johansson C. Differential binding of alkylating fluorochromes 
in human chromosomes. Exp Cell Res. 1970 Jun;60(3):315-9.
[153] Rowley JD, Bodmer WF. Relationship of centromeric heterochromatin to fluorescent 
banding patterns of metaphase chromosomes in the mouse. Nature. 1971 Jun 
25;231(5304):503-6.
[154] Crossen PE. Giemsa banding patterns of human chromosomes. Clin Genet. 
1972;3(3):169-79.
[155] Bühler EM, Tsuchimoto T, Stalder GR. Reverse banding in the human Y 
chromosome. Lancet. 1973 May 26;1(7813):1178-9.
[156] Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with 
molecular biology. Nat Rev Genet. 2005 Oct;6(10):782-92.
[157] Daniel A, Lam-Po-Tang PR. Mechanism for the chromosome banding phenomenon. 
Nature. 1973 Aug 10;244(5415):358-9.
[158] Northcott PA, Rutka JT, Taylor MD. Genomics of medulloblastoma: from Giemsa-
banding to next-generation sequencing in 20 years. Neurosurg Focus. 2010 Jan;
28(1):E6.
[159] Cavazzini F, Ciccone M, Negrini M, Rigolin GM, Cuneo A. Clinicobiologic importance 
of cytogenetic lesions in chronic lymphocytic leukemia. Expert Rev  Hematol. 2009 
Jun;2(3):305-14.
[160] O'Connor M, Peifer M, Bender W. Construction of large DNA segments in 
Escherichia coli. Science. 1989 Jun 16;244(4910):1307-12.
[161] Shizuya H, Birren B, Kim UJ, Mancino V, et al. Cloning and stable maintenance of 
300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-
based vector. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7.
[162] Shizuya H, Kouros-Mehr H. The development and applications of the bacterial 
artificial chromosome cloning system. Keio J Med. 2001 Mar;50(1):26-30.
[163] Burke DT, Carle GF, Olson MV. Cloning of large segments of exogenous DNA into 
yeast by means of artificial chromosome vectors. Science. 1987 May 15;236(4803):
806-12.
[164] Weiss MM, Hermsen MA, Meijer GA, van Grieken NC, et al. Comparative genomic 
hybridisation. Mol Pathol. 1999 Oct;52(5):243-51.
[165] Ren H, Francis W, Boys A, Chueh AC, et al. BAC-based PCR fragment microarray: 
high-resolution detection of chromosomal deletion and duplication breakpoints. Hum 
Mutat. 2005 May;25(5):476-82.
172
[166] Bignell GR, Huang J, Greshock J, Watt S, et al. High-resolution analysis of DNA 
copy number using oligonucleotide microarrays. Genome Res. 2004 Feb;14(2):
287-95.
[167] Lockwood WW, Chari R, Chi B, Lam WL. Recent advances in array comparative 
genomic hybridization technologies and their applications in human genetics. Eur J 
Hum Genet. 2006 Feb;14(2):139-48.
[168] Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! 
or oligonucleotides: a perspective for micro array comparative genomic hybridization 
(array CGH). Nucleic Acids Res. 2006 Jan 26;34(2):445-50. Print 2006.
[169] Baudis M, Cleary  ML. Progenetix.net: an online repository  for molecular cytogenetic 
aberration data. Bioinformatics. 2001 Dec;17(12):1228-9.
[170] Cowell JK, Hawthorn L. The application of microarray technology to the analysis of 
the cancer genome. Curr Mol Med. 2007 Feb;7(1):103-20.
[171] Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, et al. A tiling resolution DNA 
microarray with complete coverage of the human genome. Nat Genet. 2004 Mar;
36(3):299-303. Epub 2004 Feb 15.
[172] Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent JM, Meltzer PS. 
Detection of gene amplification by genomic hybridization to cDNA microarrays. 
Cancer Res. 2000 Feb 15;60(4):799-802.
[173] Pollack JR, Perou CM, Alizadeh AA, Eisen MB, et al. Genome-wide analysis of DNA 
copy-number changes using cDNA microarrays. Nat Genet. 1999 Sep;23(1):41-6.
[174] Brennan C, Zhang Y, Leo C, Feng B, et al. High-resolution global profiling of genomic 
alterations with long oligonucleotide microarray. Cancer Res. 2004 Jul 15;64(14):
4744-8.
[175] Carvalho B, Ouwerkerk E, Meijer GA, Ylstra B. High resolution microarray 
comparative genomic hybridisation analysis using spotted oligonucleotides. J Clin 
Pathol. 2004 Jun;57(6):644-6.
[176] Urban AE, Korbel JO, Selzer R, Richmond T, et al. High-resolution mapping of DNA 
copy alterations in human chromosome 22 using high-density tiling oligonucleotide 
arrays. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4534-9. Epub 2006 Mar 14.
[177] Shinawi M, Cheung SW. The array  CGH and its clinical applications. Drug Discov 
Today. 2008 Sep;13(17-18):760-70.
[178] Lucito R, Healy  J, Alexander J, Reiner A, et al. Representational oligonucleotide 
microarray analysis: a high-resolution method to detect genome copy number 
variation. Genome Res. 2003 Oct;13(10):2291-305. Epub 2003 Sep 15.
173
[179] Le Scouarnec S, Gribble SM. Characterising chromosome rearrangements: recent 
technical advances in molecular cytogenetics. Heredity (Edinb). 2012 Jan;108(1):
75-85.
[180] Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications 
in cancer. Nat Genet. 2005 Jun;37 Suppl:S11-7.
[181] Gardina PJ, Lo KC, Lee W, Cowell JK, Turpaz Y. Ploidy status and copy number 
aberrations in primary glioblastomas defined by integrated analysis of allelic ratios, 
signal ratios and loss of heterozygosity using 500K SNP Mapping Arrays. BMC 
Genomics. 2008 Oct 17;9:489.
[182] Lo KC, Bailey D, Burkhardt T, Gardina P, et al. Comprehensive analysis of loss of 
heterozygosity events in glioblastoma using the 100K SNP mapping arrays and 
comparison with copy number abnormalities defined by BAC array comparative 
genomic hybridization. Genes Chromosomes Cancer. 2008 Mar;47(3):221-37.
[183] Schaaf CP, Wiszniewska J, Beaudet AL. Copy number and SNP arrays in clinical 
diagnostics. Annu Rev Genomics Hum Genet. 2011 Sep 22;12:25-51.
[184] Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic 
hybridization and its applications in human genetics. Clin Genet. 2004 Dec;66(6):
488-95.
[185] Brady PD, Vermeesch JR. Genomic microarrays: a technology overview. Prenat 
Diagn. 2012 Apr;32(4):336-43.
[186] International HapMap Consortium. A haplotype map of the human genome. Nature. 
2005 Oct 27;437(7063):1299-320.
[187] International HapMap Consortium. A second generation human haplotype map of 
over 3.1 million SNPs. Nature. 2007 Oct 18;449(7164):851-61.
[188] Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in 
disease. Annu Rev Med. 2010;61:437-55.
[189] Yau C, Holmes CC. CNV discovery using SNP genotyping arrays. Cytogenet 
Genome Res. 2008;123(1-4):307-12.
[190] Lai WR, Johnson MD, Kucherlapati R, Park PJ. Comparative analysis of algorithms 
for identifying amplifications and deletions in array CGH data. Bioinformatics. 2005 
Oct 1;21(19):3763-70. Epub 2005 Aug 4.
[191] Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for 
the analysis of array-based DNA copy number data. Biostatistics. 2004 Oct;5(4):
557-72.
174
[192] Cao Q, Zhou M, Wang X, Meyer CA, et al. CaSNP: a database for interrogating copy 
number alterations of cancer genome from SNP array data. Nucleic Acids Res. 2011 
Jan;39(Database issue):D968-74.
[193] Scheinin I, Myllykangas S, Borze I, Böhling T, et al. CanGEM: mining gene copy 
number changes in cancer. Nucleic Acids Res. 2008 Jan;36(Database 
issue):D830-5. Epub 2007 Oct 11.
[194] International Human Genome Sequencing Consortium. Finishing the euchromatic 
sequence of the human genome. Nature. 2004 Oct 21;431(7011):931-45.
[195] Kulldorff, M. A spatial scan statistic. Commun statist. 1997;26(6):1481–1496.
[196] Bengtsson, H., Simpson, K., Bullard, J., and Hansen, K. aroma.affymetrix: A  genetic 
framework in R for analyzing small to very large affymetrix data sets in bounded 
memory. 2008; Tech Report #745, Department of Statistics, University  of California, 
Berkeley.
[197] Thieme S, Groth P. Genome Fusion Detection: a novel method to detect fusion 
genes from SNP-array data. Bioinformatics. 2013 Mar 15;29(6):671-7.
[198] Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and 
consequences of chromosome shattering. Nat Rev Cancer. 2012 Oct;12(10):
663-70.
[199] Gene Ontology Consortium. The Gene Ontology project in 2008. Nucleic Acids Res. 
2008 Jan;36(Database issue):D440-4. Epub 2007 Nov 4.
175



